GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

September 29, 2004, 18:02:07; Search time 12.3745 Seconds Run on:

(without alignments)

3219.466 Million cell updates/sec

US-09-830-972-32 Title:

Perfect score: 705

1 QASGEAGVSCLRENFAVYSV.....ESEVAISEELVQKYSNSALG 141 Sequence:

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

1586107 seqs, 282547505 residues Searched:

1586107 Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

A Geneseq_29Jan04:* Database :

1: geneseqp1980s:*

2: geneseqp1990s:*

3: geneseqp2000s:*

4: geneseqp2001s:*

5: geneseqp2002s:*

6: geneseqp2003as:*

7: geneseqp2003bs:*

8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

		ક				
Result No.	Score	Query Match	Length	DB	ID	Description
1	680.5	96.5	522	3	AAY71312	Aay71312 Rat neuri
2	510	72.3	199	5	ABB81077	Abb81077 Rat neuro
3	503	71.3	118	5	ABB89192	Abb89192 Human pol
4	503	71.3	199	2	AAW53947	Aaw53947 Human NSP
5	503	71.3	199	2	AAW78313	Aaw78313 Fragment
6	503	71.3	199	2	AAY35903	Aay35903 Extended
7	503	71.3	199	3	AAB12805	Aab12805 Human NSP
8	503	71.3	199	4	AAB82348	Aab82348 Human NOG
9	503	71.3	199	5	ABG30939	Abg30939 Human Nog

10	503	71.3	199	5	ABB81080	Abb81080	Human neu
11	499.5	70.9	199	3	AAY71559	Aay71559	Rat Nogo
12	448	63.5	1178	3	AAY71311	Aay71311	Human neu
13	447	63.4	403	3	AAY71563	Aay71563	Rat Nogo
14	447	63.4	893	3	AAY95012	Aay95012	Human sec
15	447	63.4	983	6	ABU11573	Abu11573	Human MDD
16	447	63.4	1162	3	AAY71557		Rat Nogo
17	447	63.4	1163	3	AAY71310	Aay71310	Rat neuri
18	447	63.4	1163	3	AAY71384	Aay71384	Alternati
19	447	63.4	1163	5	ABB81074	Abb81074	Rat neuro
20	447	63.4	1192	3	AAY56967	Aay56967	Human MAG
21	447	63.4	1192	4	AAB82349	Aab82349	Human NOG
22	447	63.4	1192	4	AAU04591	Aau04591	Human Nog
23	447	63.4	1192	5	ABG30938	_	Human Nog
24	447	63.4	1192	5	ABP68600		Human pan
25	447	63.4	1192	5	ABB81078		Human neu
26	447	63.4	1192	6	ABR59667		Human Nog
27	443	62.8	103	4	AAE03980	Aae03980	Human gen
28	443	62.8	200	4	AAB64514	Aab64514	Human sec
29	443	62.8	359	3	AAY71558	-	Rat Nogo
30	443	62.8	360	3	AAY71383	<u>-</u>	Rat neuri
31	443	62.8	360	4	AAE03987		Human gen
32	443	62.8	360	5	ABB81076		Rat neuro
33	443	62.8	361	3	AAY71385	-	Alternati
34	443	62.8	373	3	AAY53624	-	A bone ma
35	443	62.8	373	3	AAY56969	-	Human MAG
36	443	62.8	373	3	AAB24242		Human Nog
37	443	62.8	373	4	AAB82350		Human NOG
38	443	62.8	373	5	AAM47954		Human RTN
39	443	62.8	373	5	ABG30937		Human Nog
40	443	62.8	373	5	ABP68601		Human pan
41	443	62.8	373	5	ABB81079		Human neu
42	443	62.8	379	7	ADB85283		Rat fooce
43	440	62.4	91	2	AAY12360	_	Human 5'
44	439	62.3	291	4	AAM93484		Human pol
45	410.5	58.2	642	2	AAW58383	Aaw58383	Human sec

ALIGNMENTS

```
RESULT 1
AAY71312
     AAY71312 standard; protein; 522 AA.
ID
XX
    AAY71312;
AC
XX
     02-NOV-2000 (first entry)
DT
XX
     Rat neurite growth inhibitor Nogo C.
DE
XX
     Rat; neurite growth inhibitor; Nogo C; neural cell; myelin; CNS;
KW
     central nervous system; neoplastic disease; antiproliferative; glioma;
KW
     antisense gene therapy; neuroblastoma; menagioma; retinoblastoma;
KW
     degenerative nerve disease; Alzheimer's disease; Parkinson's disease;
KW
     hyperproliferative disorder; benign dysproliferative disorder; diagnosis;
KW
     psoriasis; tissue hypertrophy; neuronal regeneration; treatment;
KW
```

```
structural plasticity; screening.
KW
XX
OS
     Rattus sp.
XX
                      Location/Qualifiers
FH
     Key
                      1. .39
FT
     Region
                      /note= "Sequence upstream to the N-terminus of Nogo C
FT
FT
                      protein"
     Misc-difference 3
FT
                      /note= "Encoded by TAG"
FT
     Region
                      11. .191
FT
                      /note= "Region specifically described in claim 16"
FT
     Misc-difference 29
FT
                      /note= "Encoded by TAA"
FT
                      40. .238
FT
     Protein
                      /label= Nogo C protein
FT
                      51. .238
FT
     Region
                      /note= "C-terminal common region found in Nogo A, B and C
FT
                      isoforms "
FT
                      239. .522
FT
     Region
                      /note= "Sequence downstream to the C-terminus of Nogo C
FT
                      protein"
FT
     Misc-difference 239
FT
                      /note= "Encoded by TGA"
FT
     Misc-difference 263
FT
                      /note= "Encoded by TGA"
FT
     Misc-difference 276
FT
                      /note= "Encoded by TAG"
FT
     Misc-difference 281
FT
                      /note= "Encoded by TGA"
FT
     Misc-difference 295
FT
                      /note= "Encoded by TAA"
FT
     Misc-difference 298
FT
                      /note= "Encoded by TAA"
FT
     Misc-difference 314
FT
                      /note= "Encoded by TGA"
FT
     Misc-difference 318
FT
                      /note= "Encoded by TGA"
FT
FT
     Misc-difference 335
                      /note= "Encoded by TAG"
FT
     Misc-difference 371
FT
                      /note= "Encoded by TGA"
FT
     Misc-difference 374
FT
                      /note= "Encoded by TAG"
FT
      Misc-difference 380
 FT
                      /note= "Encoded by TAA"
 FT
      Misc-difference 406
 FT
                       /note= "Encoded by TAA"
 FT
      Misc-difference 408
 FT
                       /note= "Encoded by TAG"
 FT
      Misc-difference 410
 FT
                       /note= "Encoded by TAA"
 FT
      Misc-difference 422
 FT
                       /note= "Encoded by TAA"
 FT
      Misc-difference 433
 FT
                       /note= "Encoded by TGA"
 FT
      Misc-difference 440
```

FT

```
/note= "Encoded by TAG"
FT
    Misc-difference 453
FT
                     /note= "Encoded by TAG"
FT
FT
    Misc-difference 465
                     /note= "Encoded by TAG"
FT
    Misc-difference 482
FT
                     /note= "Encoded by TAG"
FT
FT
    Misc-difference 513
                     /note= "Encoded by TAA"
FT
XX
PN
     WO200031235-A2.
XX
     02-JUN-2000.
PD
XX
PF
     05-NOV-1999;
                    99WO-US026160.
XX
                    98US-0107446P.
PR
     06-NOV-1998;
XX
     (SCHW/) SCHWAB M E.
PA
     (CHEN/) CHEN M S.
PΑ
XX
     Schwab ME, Chen MS;
PΙ
XX
     WPI; 2000-400052/34.
DR
     N-PSDB; AAD01175.
DR
XX
     Nogo proteins and nucleic acids useful for treating neoplastic disorders
PT
     of the central nervous system and inducing regeneration of neurons.
PT
XX
     Claim 7; Fig 14; 122pp; English.
PS
XX
     The present sequence is a rat Nogo C protein which is a potent neural
CC
     cell growth inhibitor and is free of all central nervous system (CNS)
CC
     myelin material with which it is natively associated. Nogo proteins and
CC
     fragments displaying neurite growth inhibitory activity are used in the
CC
     treatment of neoplastic disease of the CNS e.g. glioma, glioblastoma,
CC
     medulloblastoma, craniopharyngioma, ependyoma, pinealoma,
CC
     haemangioblastoma, acoustic neuroma, oligodendroglioma, menagioma,
CC
     neuroblastoma or retinoblastoma and degenerative nerve diseases e.g.
CC
     Alzheimer's and Parkinson's diseases. Therapeutics which promote Nogo
CC
     activity can be used to treat or prevent hyperproliferative or benign
CC
     dysproliferative disorders e.g. psoriasis and tissue hypertrophy.
CC
     Ribozymes or antisense Nogo nucleic acids can be used to inhibit
CC
     production of Nogo protein to induce regeneration of neurons or to
CC
     promote structural plasticity of the CNS in disorders where neurite
CC
     growth, regeneration or maintenance are deficient or desired. The animal
CC
     models can be used in diagnostic and screening methods for predisposition
CC
     to disorders and to screen for or test molecules which can treat or
CC
     prevent disorders or diseases of the CNS. Note: SEQ ID numbers 35-42 are
CC
     referred in claim 32 and SEQ ID NO: 29 in disclosure of the
CC
     specification. However the specification does not include sequences for
CC
     these SEQ ID numbers
CC
XX
     Sequence 522 AA;
SQ
                           96.5%; Score 680.5; DB 3; Length 522;
  Ouerv Match
                           98.6%; Pred. No. 2.5e-71;
  Best Local Similarity
```

```
1; Indels
                                                             1; Gaps
                                                                         1;
 Matches 138; Conservative
                               0; Mismatches
           3 SGEAGVSCLRENFAVYSVSVGMHNL-LLLEGRSWQEMDGQKKHWKDKVVDLLYWRDIKKT 61
QУ
             4 SGEAGVSCLRENFAVYSVSVGMHNLXLLLEGRSWQEMDGQKKHWKDKVVDLLYWRDIKKT 63
Db
          62 GVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIAKSDEGHPFRAYL 121
Qу
             64 GVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYL 123
Db
         122 ESEVAISEELVQKYSNSALG 141
Qу
             1111111111111111111111
         124 ESEVAISEELVQKYSNSALG 143
Db
RESULT 2
ABB81077
     ABB81077 standard; protein; 199 AA.
XX
AC
    ABB81077;
XX
     05-NOV-2002 (first entry)
DT
XX
     Rat neurotransmitter receptor protein Nogo-C.
DE
XX
     Nerve regeneration; neuroprotection; neuronal degeneration; CNS; PNS;
KW
     central nervous system; peripheral nervous system; tranquillizer; Nogo;
KW
     vulnerary; cerebroprotective; anti-tumour; antidiabetic; anticonvulsant;
KW
     nootropic; antiparkinsonian; ophthalmological; analgesic; hepatotropic;
KW
     osteopathic; vasotropic; nephrotropic; cytostatic; antigen; gene therapy;
KW
     neurotransmitter receptor; rat; receptor.
KW
XX
     Rattus norvegicus.
OS
XX
     US2002072493-A1.
ΡN
XX
     13-JUN-2002.
PD
XX
     28-JUN-2001; 2001US-00893348.
PF
XX
                   98IL-00124500.
PR
     19-MAY-1998;
                   98WO-US014715.
PR
     21-JUL-1998;
     22-DEC-1998;
                   98US-00218277.
PR
                   99US-00314161.
     19-MAY-1999;
PR
XX
     (YEDA ) YEDA RES & DEV CO LTD.
PA
XX
     Eisenbach-Schwartz M, Hauben E, Cohen IR, Beserman P, Mosonego A;
PΙ
PΙ
     Moalem G;
XX
     WPI; 2002-607255/65.
DR
DR
     N-PSDB; ABN86600.
XX
     Promoting nerve regeneration and preventing neuronal degeneration in the
 PT
     central/peripheral nervous system from injury/disease, comprises
 PT
     administering nervous system-specific activated T cells/antigen, or
 PT
     analogs/peptides.
 PT
```

```
XX
    Example 5; Page 48-49; 93pp; English.
PS
XX
    The invention relates to promoting nerve regeneration or conferring
CC
    neuroprotection and preventing or inhibiting neuronal degeneration in the
CC
    central/peripheral nervous system (NS). The method involves administering
CC
    NS-specific activated T cells, NS-specific antigen, its analogue or its
CC
    peptide, a nucleotide sequence the NS-specific antigen or its analogue or
CC
    combinations. The method is useful for promoting nerve regeneration and
CC
    preventing neuronal degeneration in central/peripheral nervous system
CC
     from injury/disease, where the injury is spinal cord injury, blunt
CC
     trauma, penetrating trauma, hemorrhagic stroke, ischaemic stroke or
CC
    damages caused by surgery such as tumour excision. The disease is not an
CC
    autoimmune disease or neoplasm. The disease results in a degenerative
CC
     process occurring in either gray or white matter or both. The disease is
CC
    diabetic neuropathy, senile dementia, Alzheimer's disease, Parkinson's
CC
    disease, facial nerve (Bell's) palsy, glaucoma, Huntington's chorea,
CC
     amyotrophic lateral sclerosis, non-arteritic optic neuropathy, and
CC
     vitamin deficiency, intervertebral disc herniation, prion diseases such
CC
     as Creutzfeldt-Jakob disease, carpal tunnel syndrome, peripheral
CC
     neuropathies associated with various diseases, including but not limited
CC
     to uremia, porphyria, hypoglycemia, Sjorgren Larsson syndrome, acute
CC
     sensory neuropathy, chronic ataxic neuropathy, biliary cirrhosis, primary
CC
     amyloidosis, obstructive lung diseases, acromegaly, malabsorption
CC
     syndromes, polycythemia vera, immunoglobulin (Ig) A- and IgG gamma-
CC
     pathies, complications of various drugs (e.g., metronidazole) and toxins
CC
     (e.g., alcohol or organophosphates), Charcot-Marie-Tooth disease, ataxia
CC
     telangectasia, Friedreich's ataxia, amyloid polyneuropathies,
CC
     adrenomyeloneuropathy, Giant axonal neuropathy, Refsum's disease, Fabry's
CC
     disease, or lipoproteinemia. The present sequence represents the rat
CC
     neurotransmitter receptor protein Nogo-C, an example of NS-specific
CC
CC
     antigen
XX
     Sequence 199 AA;
SO
                         72.3%; Score 510; DB 5; Length 199;
  Query Match
                         99.0%; Pred. No. 9.6e-52;
  Best Local Similarity
                                                 1; Indels
                                                               0; Gaps
                                0; Mismatches
  Matches 103; Conservative
           38 MDGQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 97
Qу
              1 MDGQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 60
Dh
           98 FRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
Qу
              61 FRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 104
Db
RESULT 3
ABB89192
     ABB89192 standard; protein; 118 AA.
ΙD
XX
AC
     ABB89192;
XX
DΤ
     24-MAY-2002 (first entry)
XX
     Human polypeptide SEQ ID NO 1568.
DΕ
```

```
XX
     Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
KW
     antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;
KW
     vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;
KW
     cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
KW
     neurological disease; infection; human; secreted protein.
KW
XX
     Homo sapiens.
OS
XX
PN
     WO200190304-A2.
XX
PD
     29-NOV-2001.
XX
     18-MAY-2001; 2001WO-US016450.
PF
XX
     19-MAY-2000; 2000US-0205515P.
PR
XX
     (HUMA-) HUMAN GENOME SCI INC.
PΑ
XX
PΤ
     Birse CE, Rosen CA;
XX
     WPI; 2002-122018/16.
DR
DR
     N-PSDB; ABL89601.
XX
     Novel 1405 isolated polypeptides, useful for diagnosis, treatment and
PΤ
     prevention of neural, immune system, muscular, reproductive,
PΤ
     gastrointestinal, pulmonary, cardiovascular, renal and proliferative
PT
PT
     disorders.
XX
     Claim 11; SEQ ID NO 1568; 2081pp + Sequence Listing; English.
PS
XX
     The invention relates to novel genes (ABL89449-ABL90853) and proteins
CC
     (ABB89040-ABB90444) useful for preventing, treating or ameliorating
CC
     medical conditions e.g. by protein or gene therapy. The genes are
CC
     isolated from a range of human tissues disclosed in the specification.
CC
     The nucleic acids, proteins, antibodies and (ant)agonists are useful in
CC
     the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and
CC
     ovarian cancer and other cancers of the adrenal gland, bone, bone marrow,
CC
     breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune
CC
     disorders e.g. Addison's disease, allergies, autoimmune haemolytic
CC
     anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
CC
     multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)
CC
     cardiovascular disorders such as myocardial ischaemias; (d) wound healing
CC
     ; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)
CC
     infectious diseases such as viral, bacterial, fungal and parasitic
CC
     infections. Note: The sequence data for this patent did not form part of
CC
     the printed specification, but was obtained in electronic format directly
CC
      from WIPO at ftp.wipo.int/pub/published_pct_sequences
CC
XX
     Sequence 118 AA;
 SQ
                                   Score 503; DB 5; Length 118;
  Query Match
                           71.3%;
                           98.1%; Pred. No. 3.2e-51;
   Best Local Similarity
                                                                               0;
                                                                  0;
                                                                      Gaps
                                                    1; Indels
                                  1; Mismatches
  Matches 102; Conservative
```

```
1 MDGOKKNWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 60
Db
           98 FRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
Qу
              61 FRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 104
Db
RESULT 4
AAW53947
    AAW53947 standard; protein; 199 AA.
XX
AC
    AAW53947;
XX
DΤ
     24-JUL-1998 (first entry)
XX
DΕ
    Human NSPLP protein A.
XX
     NSPLP; neuroendocrine-specific protein-like protein; human; gene therapy;
KW
     neurodegenerative disease; amyotrophic lateral sclerosis; cancer.
KW
XX
OS
     Homo sapiens.
XX
    WO9806841-A2.
PN
XX
PD
    19-FEB-1998.
XX
ΡF
     24-JUL-1997;
                   97wo-US013469.
XX
PR
     12-AUG-1996;
                   96US-00700607.
XX
     (INCY-) INCYTE PHARM INC.
PΑ
XX
     Bandman O, Au-Young J, Goli SK, Hillman J;
PΙ
XX
     WPI; 1998-159533/14.
DR
     N-PSDB; AAV23695.
DR
XX
     Human neuro-endocrine-specific protein-like proteins - useful for
PT
     diagnosis, monitoring and treatment of cancer and neuro-degenerative
PT
PT
     disease.
XX
     Claim 1; Page 38; 73pp; English.
PS
XX
     This sequence is a human neuroendocrine-specific protein-like protein
CC
     (NSPLP) of the invention. Recombinant cells transformed with the DNA are
CC
     used to express the NSPLP proteins, which are used to treat cancer and
CC
     neurodegenerative diseases such as amyotrophic lateral sclerosis. Also
CC
     antisense nucleic acids and antagonists of NSPLP can be used to inhibit
CC
     activity of the NSPLP proteins. Antibodies specific for NSPLP are used
CC
     for diagnosis and monitoring treatment of diseases associated with NSPLP
CC
     expression, in usual immunoassays, and to isolate NSPLP from natural
CC
     sources. The NSPLP proteins, or their fragments can also be used in drug
CC
     screening to identify NSPLP antagonists. The nucleic acid can be used
CC
     diagnostically and for monitoring treatment (in hybridisation or
CC
     amplification assays); to isolate closely related sequences; in gene
CC
     therapy for both sense and antisense applications (including use of
CC
```

ribozymes) and for mapping the natural genomic sequence

CC

```
XX
SQ
    Sequence 199 AA;
                                Score 503; DB 2; Length 199;
                         71.3%;
  Query Match
                         98.1%; Pred. No. 6.4e-51;
  Best Local Similarity
                                                                           0;
                                                 1; Indels
                                1; Mismatches
 Matches 102; Conservative
          38 MDGQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 97
Qy
             1 MDGOKKNWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 60
Db
          98 FRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
Qy
             61 FRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 104
Db
RESULT 5
AAW78313
    AAW78313 standard; protein; 199 AA.
XX
AC
    AAW78313;
XX
DΤ
     13-APR-1999
                 (first entry)
XX
     Fragment of human secreted protein encoded by gene 69.
DE
XX
     Human; secreted protein; fusion protein; gene therapy; protein therapy;
KW
     diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;
KW
     developmental abnormality; foetal deficiency; blood; allergy; renal;
KW
     immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;
KW
     inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;
KW
     cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;
KW
     osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;
ΚW
     endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.
KW
XX
OS
     Homo sapiens.
XX
     WO9856804-A1.
PN
XX
     17-DEC-1998.
PD
XX
     11-JUN-1998;
                   98WO-US012125.
ΡF
XX
                   97US-0049547P.
PR
     13-JUN-1997;
PR
     13-JUN-1997;
                   97US-0049548P.
PR
     13-JUN-1997;
                   97US-0049549P.
                   97US-0049550P.
PR
     13-JUN-1997;
                   97US-0049566P.
PR
     13-JUN-1997;
PR
                   97US-0049606P.
     13-JUN-1997;
                   97US-0049607P.
PR
     13-JUN-1997;
                   97US-0049608P.
PR
     13-JUN-1997;
PR
     13-JUN-1997;
                   97US-0049609P.
PR
                   97US-0049610P.
     13-JUN-1997;
                   97US-0049611P.
     13-JUN-1997;
PR
PR
     13-JUN-1997;
                   97US-0050901P.
PR
     13-JUN-1997;
                   97US-0052989P.
     08-JUL-1997;
                   97US-0051919P.
PR
```

```
97US-0055984P.
    18-AUG-1997;
PR
                   97US-0058665P.
PR
    12-SEP-1997;
                   97US-0058668P.
    12-SEP-1997;
PR
                   97US-0058669P.
PR
    12-SEP-1997;
    12-SEP-1997;
                   97US-0058750P.
PR
    12-SEP-1997;
                   97US-0058971P.
PR
                   97US-0058972P.
PR
    12-SEP-1997;
                   97US-0058975P.
PR
    12-SEP-1997;
                   97US-0060834P.
    02-OCT-1997;
PR
                   97US-0060841P.
PR
    02-OCT-1997;
                   97US-0060844P.
PR
    02-OCT-1997;
    02-OCT-1997;
                   97US-0060865P.
PR
                   97US-0061059P.
PR
    02-OCT-1997;
                   97US-0061060P.
PR
    02-OCT-1997;
XX
     (HUMA-) HUMAN GENOME SCI INC.
PA
XX
    Moore PA, Shi Y, Rosen CA, Ruben SM, Lafleur DW, Olsen HS;
PΙ
     Ebner R, Brewer LA, Young P, Greene JM, Ferrie AM, Yu G, Ni J;
PΙ
PΙ
     Feng P;
XX
DR
    WPI; 1999-080881/07.
    N-PSDB; AAX04379.
DR
XX
    New isolated human genes and the secreted polypeptides they encode -
PT
     useful for diagnosis and treatment of e.g. cancers, neurological
PT
     disorders, immune diseases, inflammation or blood disorders.
PT
XX
PS
     Disclosure; Page 62; 380pp; English.
XX
     This sequence represents a fragment of a secreted human protein encoded
CC
     by the nucleic acid molecule detailed in the descriptor line. The gene
CC
     can be used to generate fusion proteins by linking to the gene to a human
CC
     immunoglobulin Fc portion (e.g. AAX04302) for increasing the stability of
CC
     the fused protein as compared to the human protein only. The invention
CC
     relates to 86 novel genes and their fragments (nucleic acid sequences:
CC
     AAX04311-X04410; amino acid sequences AAW78126-W78225) which are useful
CC
     for preventing, treating or ameliorating medical conditions e.g. by
CC
     protein or gene therapy. Also, pathological conditions can be diagnosed
CC
     by determining the amount of the new polypeptides in a sample or by
CC
     determining the presence of mutations in the new polynucleotides.
CC
     Specific uses are described for each of the 86 polynucleotides, based on
CC
     which tissues they are most highly expressed in (see AAX04311 for
CC
CC
     described uses)
XX
SQ
     Sequence 199 AA;
                         71.3%; Score 503; DB 2; Length 199;
  Query Match
                         98.1%; Pred. No. 6.4e-51;
  Best Local Similarity
                                                                   Gaps
                                                                           0;
                                                1; Indels
                                                               0;
                                1; Mismatches
  Matches 102; Conservative
           38 MDGQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 97
QУ
              1 MDGQKKNWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 60
Db
           98 FRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
Qv
```

```
RESULT 6
AAY35903
    AAY35903 standard; protein; 199 AA.
XX
AC
    AAY35903;
XX
DT
     13-SEP-1999 (first entry)
XX
     Extended human secreted protein sequence, SEQ ID NO. 152.
DE
XX
KW
     Secreted protein; human; cytokine; cellular proliferation; cell movement;
     cellular differentiation; immune system regulator; anti-inflammatory;
KW
     haematopoiesis regulator; tissue growth regulator; tumour inhibitor;
KW
     reproductive hormone regulator; chemotaxis; chemokinesis; gene therapy;
KW
ΚW
     genetic disease.
XX
OS
    Homo sapiens.
XX
    W09931236-A2.
ΡN
XX
     24-JUN-1999.
PD
XX
PF
     17-DEC-1998;
                    98WO-IB002122.
XX
PR
     17-DEC-1997;
                    97US-0069957P.
                    98US-0074121P.
PR
     09-FEB-1998;
                    98US-0081563P.
PR
     13-APR-1998;
PR
     10-AUG-1998;
                    98US-0096116P.
XX
PΑ
     (GEST ) GENSET.
XX
     Bouqueleret L, Duclert A, Dumas Milne Edwards J;
PΙ
XX
     WPI; 1999-385906/32.
DR
     N-PSDB; AAX97587.
DR
XX
PT
     New isolated human secreted proteins.
XX
     Claim 9; Page 185-186; 516pp; English.
PS
XX
CC
     This sequence is encoded by an extended human secreted protein coding
CC
     sequence of the invention. The secreted proteins can be used in treating
     or controlling a variety of human conditions. The secreted proteins may
CC
CC
     act as cytokines or may affect cellular proliferation or differentiation
CC
     or may act as immune system regulators, haematopoiesis regulators, tissue
CC
     growth regulators, regulators of reproductive hormones or cell movement
CC
     or have chemotactic/chemokinetic, receptor/ligand, anti-inflammatory or
CC
     tumour inhibition activity. The DNAs can be used in forensic procedures
CC
     to identify individuals or in diagnostic procedures to identify
CC
     individuals having genetic diseases resulting from abnormal expression of
CC
     the genes corresponding to the extended cDNAs. They are also useful for
CC
     constructing a high resolution map of the human chromosomes. They can
CC
     also be used for gene therapy to control or treat genetic diseases
XX
```

```
SQ
    Sequence 199 AA;
                        71.3%; Score 503; DB 2; Length 199;
 Query Match
                        98.1%; Pred. No. 6.4e-51;
 Best Local Similarity
                              1; Mismatches
                                                            0; Gaps
                                                                        0;
                                               1; Indels
 Matches 102; Conservative
          38 MDGQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 97
Qу
             1 MDGQKKNWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 60
Db
          98 FRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
QУ
             61 FRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 104
Db
RESULT 7
AAB12805
    AAB12805 standard; protein; 199 AA.
XX
AC
    AAB12805;
XX
DT
    24-NOV-2000 (first entry)
XX
DE
    Human NSPH protein sequence SEQ ID NO:4.
XX
KW
    Human; neuroendocrine-specific protein; NSPH; NSPA; NSPB; NSPC.
XX
OS
    Homo sapiens.
XX
PN
    CN1253180-A.
XX
    17-MAY-2000.
PD
XX
    30-OCT-1998;
                 98CN-00121473.
PF
XX
    30-OCT-1998; 98CN-00121473.
PR
XX
     (UYFU-) UNIV FUDAN.
PΑ
XX
PΙ
    Yu L, Zhao Y, Zhang H;
XX
    WPI; 2000-466537/41.
DR
DR
    N-PSDB; AAA72981.
XX
PT
    Specific protein of human neuroendocrine, coding sequence and its
PΤ
    preparating process and application.
XX
PS
    Claim 4; Page 14-15; 21pp; Chinese.
XX
     The present invention relates to a new member of the human neuroendocrine
CC
     specific protein family, designated NSPH. The present sequence represents
CC
CC
     the human NSPH protein
XX
     Sequence 199 AA;
SO
  Query Match
                        71.3%; Score 503; DB 3; Length 199;
```

Best Local Similarity 98.1%; Pred. No. 6.4e-51;

```
Matches 102; Conservative
                               1; Mismatches
                                                 1; Indels
                                                                  Gaps
                                                                          0;
Qу
           38 MDGQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 97
              Db
           1 MDGQKKNWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 60
          98 FRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
Qу
              Db
          61 FRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVOKYSNSALG 104
RESULT 8
AAB82348
ID
    AAB82348 standard; protein; 199 AA.
XX
    AAB82348;
AC
XX
DT
    23-JUL-2001 (first entry)
XX
DE
    Human NOGO-C protein.
XX
KW
    NOGO-C; human; chromosome 2p21; neuropathy; spinal injury; brain injury;
    stroke; neuronal degeneration; Alzheimer's disease; Parkinson's disease;
KW
KW
    neuromuscular disorder; psychiatric disorder; developmental disorder;
KW
    neuroprotective; nootropic; neuroleptic; antiparkinsonian;
KW
    cerebroprotective; neuroleptic; diagnosis; therapy.
XX
OS
    Homo sapiens.
XX
PN
    W0200136631-A1.
XX
PD
    25-MAY-2001.
XX
PF
    14-NOV-2000; 2000WO-GB004345.
XX
    15-NOV-1999;
PR
                   99GB-00026995.
PR
    24-JAN-2000; 2000GB-00001550.
XX
PA
    (SMIK ) SMITHKLINE BEECHAM PLC.
XX
PI
    Michalovich D, Prinjha R;
XX
DR
    WPI; 2001-343822/36.
DR
    N-PSDB; AAF90323.
XX
PT
    New polypeptide designated NOGO-C is a splice variant of the human NOGO
    gene and may be useful in the treatment of neural disorders including
PT
PT
    Alzheimer's and Parkinson's diseases.
XX
PS
    Claim 3; Page 25; 25pp; English.
XX
CC
    The present sequence is that of human NOGO-C, encoded by a novel splice
CC
    variant of the human NOGO gene on chromosome 2p21. 2 Other splice
CC
    variants, NOGO-A and NOGO-B, have previously been identified. The
    invention provides NOGO-C polypeptides and polynucleotides, and methods
CC
CC
    for producing such polypeptides by recombinant techniques. Also disclosed
CC
    are methods for utilising NOGO-C polypeptides and polynucleotides in the
```

```
CC
     treatment of diseases including neuropathies, spinal injury, brain
CC
     injury, stroke, neuronal degeneration, for example Alzheimer's disease
CC
     and Parkinson's disease, neuromuscular disorders, psychiatric disorders
CC
     and developmental disorders. Also provided are methods for identifying
CC
     agonists and agonists for use in treating conditions associated with NOGO
CC
     -C imbalance, and diagnostic assays for detecting diseases associated
CC
     with inappropriate NOGO-C activity or levels
XX
SQ
     Sequence 199 AA;
  Query Match
                         71.3%; Score 503; DB 4; Length 199;
  Best Local Similarity
                         98.1%; Pred. No. 6.4e-51;
  Matches 102; Conservative
                               1; Mismatches
                                               1; Indels
                                                                          0;
Qу
          38 MDGQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 97
             Db
           1 MDGQKKNWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 60
QУ
          98 FRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
             Db
          61 FRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 104
RESULT 9
ABG30939
    ABG30939 standard; protein; 199 AA.
XX
AC
    ABG30939;
XX
DT
    21-OCT-2002
                (first entry)
XX
DE
    Human NogoC protein.
XX
KW
    Human; Nogo; BACE; acute neuronal injury; spinal injury; head injury;
KW
    stroke; peripheral nerve damage; neoplastic disorder; glioblastoma;
KW
    neuroblastoma; hyperproliferative disorder; dysproliferative disorder;
KW
    cirrhosis; psoriasis; keloid formation; fibrocystic condition; cancer;
KW
    tissue hypertrophy; central nervous system; axon regeneration; NogoC;
KW
    Nogo-associated disease; metastasis.
XX
OS
    Homo sapiens.
XX
PN
    W0200257483-A2.
XX
PD
    25-JUL-2002.
XX
ΡF
    18-JAN-2002; 2002WO-GB000228.
XX
PR
    18-JAN-2001; 2001GB-00001312.
XX
PΑ
     (GLAX ) GLAXO GROUP LTD.
PA
     (SMIK ) SMITHKLINE BEECHAM PLC.
XX
PΙ
    Blackstock WP, Hale RS, Prinjha R, Rowley A;
XX
DR
    WPI; 2002-599722/64.
DR
    N-PSDB; ABK90135.
```

```
XX
     Identifying modulators of Nogo or BACE activity for treating acute
PT
PΤ
     neuronal injuries, neoplastic or dysproliferative disorders, comprises
PT
     providing and monitoring interaction between Nogo and BACE polypeptides.
XX
PS
     Disclosure; Page 64; 68pp; English.
XX
CC
     The present invention relates to a new method of identifying modulators
     of Nogo function or BACE activity. The method involves providing Nogo and
CC
CC
     BACE polypeptides capable of binding with each other, monitoring the
CC
     interaction between these polypeptides, and determining if the test agent
CC
     is a modulator of Nogo or BACE activity. The method is useful in treating
     acute neuronal injuries, such as spinal or head injury, stroke,
CC
CC
     peripheral nerve damage, and in neoplastic (e.g. glioblastomas,
     neuroblastomas), hyperproliferative or dysproliferative disorders (e.g.
CC
CC
     cirrhosis, psoriasis, keloid formation, fibrocystic conditions, tissue
     hypertrophy) of the central nervous system. The BACE polypeptide is
CC
CC
     useful in screening methods to identify agents that may act as modulators
CC
     of BACE activity and in particular agents that may be useful in treating
     Nogo-associated diseases. The modulators of Nogo or BACE polypeptides,
CC
CC
     and the polynucleotide encoding the BACE polypeptide are useful in
CC
     manufacturing a medicament for the treatment or prevention of disorders
CC
     responsive to the modulation of Nogo activity, in alleviating the
CC
     symptoms or improving the condition of a patient suffering from this
CC
     disorder, in axon regeneration, or in preventing metastasis or spreading
CC
     of a cancer. The polynucleotide may also be an essential component in
CC
     assays, a probe, in recombinant protein synthesis, and in gene therapy
CC
     techniques. The present amino acid sequence represents the human NogoC
CC
     protein of the invention
XX
SO
     Sequence 199 AA;
  Query Match
                         71.3%;
                                 Score 503; DB 5; Length 199;
  Best Local Similarity
                         98.1%;
                                 Pred. No. 6.4e-51;
  Matches 102; Conservative
                                1; Mismatches
                                                 1; Indels
                                                                   Gaps
                                                                           0;
          38 MDGQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 97
Qy
             Db
           1 MDGQKKNWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 60
Qу
          98 FRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
              Db
          61 FRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 104
RESULT 10
ABB81080
    ABB81080 standard; protein; 199 AA.
XX
AC
    ABB81080;
XX
DT
    05-NOV-2002 (first entry)
XX
DE
    Human neurotransmitter receptor protein Nogo-C.
XX
KW
    Nerve regeneration; neuroprotection; neuronal degeneration; CNS; PNS;
    central nervous system; peripheral nervous system; tranquillizer; Nogo;
```

KW vulnerary; cerebroprotective; anti-tumour; antidiabetic; anticonvulsant; KW nootropic; antiparkinsonian; ophthalmological; analgesic; hepatotropic; osteopathic; vasotropic; nephrotropic; cytostatic; antigen; gene therapy; KW KW neurotransmitter receptor; human; receptor. XX OS Homo sapiens. XX PNUS2002072493-A1. XX PD 13-JUN-2002. XX PF28-JUN-2001; 2001US-00893348. XX PR 19-MAY-1998; 98IL-00124500. PR 21-JUL-1998; 98WO-US014715. PR 22-DEC-1998; 98US-00218277. PR 19-MAY-1999; 99US-00314161. XX PA (YEDA) YEDA RES & DEV CO LTD. XX PΙ Eisenbach-Schwartz M, Hauben E, Cohen IR, Beserman P, Mosonego A; PΙ Moalem G; XX DR WPI; 2002-607255/65. DR N-PSDB; ABN86601. XX PTPromoting nerve regeneration and preventing neuronal degeneration in the PTcentral/peripheral nervous system from injury/disease, comprises PTadministering nervous system-specific activated T cells/antigen, or PTanalogs/peptides. XX PS Example; Page 57-58; 93pp; English. XX

CC

The invention relates to promoting nerve regeneration or conferring neuroprotection and preventing or inhibiting neuronal degeneration in the central/peripheral nervous system (NS). The method involves administering NS-specific activated T cells, NS-specific antigen, its analogue or its peptide, a nucleotide sequence the NS-specific antigen or its analogue or combinations. The method is useful for promoting nerve regeneration and preventing neuronal degeneration in central/peripheral nervous system from injury/disease, where the injury is spinal cord injury, blunt trauma, penetrating trauma, hemorrhagic stroke, ischaemic stroke or damages caused by surgery such as tumour excision. The disease is not an autoimmune disease or neoplasm. The disease results in a degenerative process occurring in either gray or white matter or both. The disease is diabetic neuropathy, senile dementia, Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, non-arteritic optic neuropathy, and vitamin deficiency, intervertebral disc herniation, prion diseases such as Creutzfeldt-Jakob disease, carpal tunnel syndrome, peripheral neuropathies associated with various diseases, including but not limited to uremia, porphyria, hypoglycemia, Sjorgren Larsson syndrome, acute sensory neuropathy, chronic ataxic neuropathy, biliary cirrhosis, primary amyloidosis, obstructive lung diseases, acromegaly, malabsorption syndromes, polycythemia vera, immunoglobulin (Ig)A- and IgG gammapathies, complications of various drugs (e.g., metronidazole) and toxins (e.g., alcohol or organophosphates), Charcot-Marie-Tooth disease, ataxia

```
CC
     telangectasia, Friedreich's ataxia, amyloid polyneuropathies,
CC
     adrenomyeloneuropathy, Giant axonal neuropathy, Refsum's disease, Fabry's
CC
     disease, or lipoproteinemia. The present sequence represents the human
CC
     neurotransmitter receptor protein Nogo-C, an example of NS-specific
CC
     antigen
XX
SQ
     Sequence 199 AA;
  Query Match
                         71.3%; Score 503; DB 5; Length 199;
  Best Local Similarity
                         98.1%; Pred. No. 6.4e-51;
  Matches 102; Conservative
                               1; Mismatches
                                               1; Indels
                                                              0; Gaps
                                                                          0;
Qу
           38 MDGQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 97
              1 MDGQKKNWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 60
Db
Qу
          98 FRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
              Db
           61 FRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 104
RESULT 11
     AAY71559 standard; protein; 199 AA.
XX
AC
    AAY71559;
XX
DT
     02-NOV-2000 (first entry)
XX
DE
     Rat Nogo C/Nogo A proteins derived fragment to construct mutant Nogo-C.
XX
KW
     Rat; neurite growth inhibitor; Nogo A; Nogo C; neural cell; myelin; CNS;
ΚW
     central nervous system; neoplastic disease; antiproliferative; glioma;
KW
     antisense gene therapy; neuroblastoma; menagioma; retinoblastoma;
KW
     degenerative nerve disease; Alzheimer's disease; Parkinson's disease;
     hyperproliferative disorder; benign dysproliferative disorder; diagnosis;
KW
KW
     psoriasis; tissue hypertrophy; neuronal regeneration; treatment;
KW
     structural plasticity; screening; mutant; mutein.
XX
OS
     Rattus sp.
XX
FΗ
    Key
                    Location/Qualifiers
FT
    Region
                    1. .11
FT
                    /note= "Corresponds to residues 40-50 of rat Nogo C
FT
                    protein shown in AAY71312"
FT
    Region
                   12. .199
FT
                    /note= "Corresponds to residues 975-1162 of rat Nogo A
FT
                    protein shown in AAY71310"
XX
PN
    W0200031235-A2.
XX
PD
    02-JUN-2000.
XX
ΡF
    05-NOV-1999;
                  99WO-US026160.
XX
PR
    06-NOV-1998;
                  98US-0107446P.
XX
```

```
PA
     (SCHW/) SCHWAB M E.
PA.
     (CHEN/) CHEN M S.
XX
ΡI
     Schwab ME,
                Chen MS;
XX
DR
     WPI; 2000-400052/34.
XX
PT
     Nogo proteins and nucleic acids useful for treating neoplastic disorders
PT
     of the central nervous system and inducing regeneration of neurons.
XX
PS
     Example; Page; 122pp; English.
XX
CC
     The patent relates to neurite growth inhibitor Nogo which is free of all
     central nervous system (CNS) myelin material with which it is natively
CC
     associated. Nogo proteins and fragments displaying neurite growth
CC
CC
     inhibitory activity are used in the treatment of neoplastic disease of
     the CNS e.g. glioma, glioblastoma, medulloblastoma, craniopharyngioma,
CC
     ependyoma, pinealoma, haemangioblastoma, acoustic neuroma,
CC
CC
     oligodendroglioma, menagioma, neuroblastoma or retinoblastoma and
CC
     degenerative nerve diseases e.g. Alzheimer's and Parkinson's diseases.
CC
     Therapeutics which promote Nogo activity can be used to treat or prevent
     hyperproliferative or benign dysproliferative disorders e.g. psoriasis
CC
CC
     and tissue hypertrophy. Ribozymes or antisense Nogo nucleic acids can be
     used to inhibit production of Nogo protein to induce regeneration of
CC
CC
     neurons or to promote structural plasticity of the CNS in disorders where
CC
     neurite growth, regeneration or maintenance are deficient or desired. The
CC
     animal models can be used in diagnostic and screening methods for
CC
     predisposition to disorders and to screen for or test molecules which can
CC
     treat or prevent disorders or diseases of the CNS. The present sequence
CC
     is derived by fusing two fragments from rat Nogo C and Nogo A proteins.
CC
     The fragment is used in the construction of mutant Nogo-C which is
     composed of His-tag/T7-tag/Nogo-C N-terminus (11 aa) + Nogo-A sequence aa
CC
CC
     975-1162. Nogo A deletion mutants were used for mapping the inhibitory
CC
     sites of Nogo protein. Major inhibitory region was identified in the Nogo
     A sequence from amino acids 172-974, particularly amino acids 542-722. In
CC
    addition, N-terminal region 1-171 was found to be inhibitory to NIH 3T3
CC
CC
     fibroblast spreading. Note: The present sequence is not given in the
     specification but is derived from rat Nogo C sequence shown in AAY71312
CC
     and Nogo A sequence shown in AAY71310. SEQ ID numbers 35-42 are referred
CC
CC
     in claim 32 and SEQ ID NO: 29 in disclosure of the specification.
CC
    However, the specification does not include sequences for these SEQ ID
CC
    numbers
XX
SO
    Sequence 199 AA;
 Query Match
                         70.9%;
                                Score 499.5; DB 3; Length 199;
 Best Local Similarity
                         98.1%;
                                Pred. No. 1.7e-50;
 Matches 103; Conservative
                              0; Mismatches
                                                 1; Indels
Qv.
          38 MDGQKKHWKDK-VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTI 96
             Db
           1 MDGQKKHWKDKSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTI 60
          97 SFRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
Qу
             Db
          61 SFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 105
```

```
RESULT 12
 AAY71311
     AAY71311 standard; protein; 1178 AA.
XX
AC
     AAY71311;
XX
 DT
      02-NOV-2000 (first entry)
XX
     Human neurite growth inhibitor Nogo.
DΕ
XX
KW
     Human; neurite growth inhibitor; Nogo; neural cell; myelin; CNS;
KW
     central nervous system; neoplastic disease; antiproliferative; glioma;
     antisense gene therapy; neuroblastoma; menagioma; retinoblastoma;
KW
     degenerative nerve disease; Alzheimer's disease; Parkinson's disease;
KW
     hyperproliferative disorder; benign dysproliferative disorder; diagnosis;
KW
     psoriasis; tissue hypertrophy; neuronal regeneration; treatment;
KW
     structural plasticity; screening.
KW
XX
OS
     Homo sapiens.
XX
FΗ
     Key
                      Location/Qualifiers
FT
     Misc-difference 187
FT
                      /label= Unknown
FT
     Misc-difference 188
FT
                      /label= Unknown
FT
     Misc-difference 189
FT
                      /label= Unknown
     Misc-difference 190
FT
FT
                      /label= Unknown
FT
     Misc-difference 221
FT
                      /label= Unknown
     Misc-difference 328
FT
FT
                      /label= Unknown
FT
     Misc-difference 477
FT
                      /label= Unknown
FT
                      977. .1012
     Region
FT
                      /note= "Region specifically described in claim 16"
FT
     Region
                      994. .1174
FT
                      /note= "Region specifically described in claim 16"
FT
     Region
                      1079. .1114
FT
                      /note= "Region specifically described in claim 16"
XX
PN
     WO200031235-A2.
XX
PD
     02-JUN-2000.
XX
PF
     05-NOV-1999;
                    99WO-US026160.
XX
PR
     06-NOV-1998;
                    98US-0107446P.
XX
PΑ
     (SCHW/) SCHWAB M E.
PA
     (CHEN/) CHEN M S.
XX
PΙ
     Schwab ME, Chen MS;
XX
     WPI; 2000-400052/34.
DR
```

```
XX
PT
     Nogo proteins and nucleic acids useful for treating neoplastic disorders
PT
     of the central nervous system and inducing regeneration of neurons.
XX
PS
     Claim 11; Fig 13; 122pp; English.
XX
CC
     The present sequence is a human Nogo protein which is a potent neural
CC
     cell growth inhibitor and is free of all central nervous system (CNS)
CC
     myelin material with which it is natively associated. The human Nogo
CC
     sequence was derived by aligning human expressed sequence tags (ESTs)
CC
     e.g. AA158636, AA333267, AA081783, AA167765, AA322918, AA092565, AA081525
     and AA081840 with the rat Nogo sequence. Nogo proteins and fragments
CC
CC
     displaying neurite growth inhibitory activity are used in the treatment
     of neoplastic disease of the CNS e.g. glioma, glioblastoma,
CC
CC
     medulloblastoma, craniopharyngioma, ependyoma, pinealoma,
CC
     haemangioblastoma, acoustic neuroma, oligodendroglioma, menagioma,
CC
     neuroblastoma or retinoblastoma and degenerative nerve diseases e.g.
CC
     Alzheimer's and Parkinson's diseases. Therapeutics which promote Nogo
     activity can be used to treat or prevent hyperproliferative or benign
CC
CC
     dysproliferative disorders e.g. psoriasis and tissue hypertrophy.
CC
     Ribozymes or antisense Nogo nucleic acids can be used to inhibit
CC
     production of Nogo protein to induce regeneration of neurons or to
CC
     promote structural plasticity of the CNS in disorders where neurite
CC
     growth, regeneration or maintenance are deficient or desired. The animal
CC
     models can be used in diagnostic and screening methods for predisposition
CC
     to disorders and to screen for or test molecules which can treat or
CC
     prevent disorders or diseases of the CNS. Note: SEQ ID numbers 35-42 are
CC
     referred in claim 32 and SEQ ID NO: 29 in disclosure of the
CC
     specification. However the specification does not include sequences for
CC
     these SEQ ID numbers
XX
SQ
     Sequence 1178 AA;
  Query Match
                         63.5%; Score 448; DB 3; Length 1178;
  Best Local Similarity
                         74.6%; Pred. No. 2.2e-43;
  Matches
           97; Conservative
                               3; Mismatches
                                                 8; Indels
                                                              22; Gaps
Qу
          12 RENFAVYSVSVGMHNLLLLEGRSWQEMDGQKKHWKDKVVDLLYWRDIKKTGVVFGASLFL 71
                1::| :|
                                              976 RSPSAIFSADLG-----KTSVVDLLYWRDIKKTGVVFGASLFL 1013
Db
Qу
          72 LLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIAKSDEGHPFRAYLESEVAISEEL 131
             Db
        1014 LLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSDEGHPFRAYLESEVAISEEL 1073
         132 VQKYSNSALG 141
Qу
             Db
        1074 VQKYSNSALG 1083
RESULT 13
AAY71563
ID
    AAY71563 standard; protein; 403 AA.
XX
AC
    AAY71563;
XX
DT
    02-NOV-2000 (first entry)
```

 ${\tt XX}$ ${\tt DE}$ ${\tt Rat}$ Nogo A protein fragment used in the construction of mutant EST. ${\tt XX}$

Rat; neurite growth inhibitor; Nogo A; neural cell; myelin; CNS; central nervous system; neoplastic disease; antiproliferative; glioma; antisense gene therapy; neuroblastoma; menagioma; retinoblastoma; degenerative nerve disease; Alzheimer's disease; Parkinson's disease; hyperproliferative disorder; benign dysproliferative disorder; diagnosis; psoriasis; tissue hypertrophy; neuronal regeneration; treatment; structural plasticity; screening; mutant; mutein.

OS Rattus sp.

KW

KW

KW

KW

KW

KW

KW

XX

XX

XX

ΧX

XX PR

XX

XX

XX

XX PT

PT XX PS

XX CC

PN W0200031235-A2.

PD 02-JUN-2000.

PF 05-NOV-1999; 99WO-US026160.

06-NOV-1998; 98US-0107446P.

PA (SCHW/) SCHWAB M E. PA (CHEN/) CHEN M S.

PI Schwab ME, Chen MS;

DR WPI; 2000-400052/34.

Nogo proteins and nucleic acids useful for treating neoplastic disorders of the central nervous system and inducing regeneration of neurons.

Example; Page; 122pp; English.

The patent relates to neurite growth inhibitor Nogo which is free of all central nervous system (CNS) myelin material with which it is natively associated. Nogo proteins and fragments displaying neurite growth inhibitory activity are used in the treatment of neoplastic disease of the CNS e.g. glioma, glioblastoma, medulloblastoma, craniopharyngioma, ependyoma, pinealoma, haemangioblastoma, acoustic neuroma, oligodendroglioma, menagioma, neuroblastoma or retinoblastoma and degenerative nerve diseases e.g. Alzheimer's and Parkinson's diseases. Therapeutics which promote Nogo activity can be used to treat or prevent hyperproliferative or benign dysproliferative disorders e.g. psoriasis and tissue hypertrophy. Ribozymes or antisense Nogo nucleic acids can be used to inhibit production of Nogo protein to induce regeneration of neurons or to promote structural plasticity of the CNS in disorders where neurite growth, regeneration or maintenance are deficient or desired. The animal models can be used in diagnostic and screening methods for predisposition to disorders and to screen for or test molecules which can treat or prevent disorders or diseases of the CNS. The present sequence is a fragment of rat Nogo A protein shown in AAY71310, which is used in the construction of mutant EST. The mutant is composed of His-tag/T7tag/Nogo-A sequence aa 760-1162. Nogo A deletion mutants were used for mapping the inhibitory sites of Nogo protein. Major inhibitory region was identified in the Nogo A sequence from amino acids 172-974, particularly amino acids 542-722. In addition, N-terminal region 1-171 was found to be inhibitory to NIH 3T3 fibroblast spreading. Note: The present sequence is

```
not given in the specification but is derived from rat Nogo A sequence
CC
     shown in AAY71310. SEQ ID numbers 35-42 are referred in claim 32 and SEQ
CC
     ID NO: 29 in disclosure of the specification. However, the specification
CC
CC
     does not include sequences for these SEQ ID numbers
XX
SQ
     Sequence 403 AA;
  Query Match
                         63.4%; Score 447; DB 3; Length 403;
  Best Local Similarity
                         96.9%; Pred. No. 6.9e-44;
  Matches
           93; Conservative
                               0; Mismatches
                                                 3; Indels
                                                              0; Gaps
                                                                          0;
          46 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 105
Qу
             Db
          214 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 273
Qу
         106 QAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
              Db
         274 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 309
RESULT 14
AAY95012
    AAY95012 standard; protein; 893 AA.
XX
AC
    AAY95012;
XX
DT
    19-JUN-2000
                (first entry)
XX
DE
    Human secreted protein vb22_1, SEQ ID NO:64.
XX
KW
    Human; secreted protein; cancer; tumour; cardiovascular disorder;
KW
    blood disorder; haemophilia; autoimmune disease; diabetes; inflammation;
KW
    infection; fungal; bacterial; viral; HIV; allergy; arthritis;
KW
    neurodegenerative disease; asthma; contraceptive.
XX
OS
    Homo sapiens.
XX
PN
    WO200011015-A1.
XX
PD
    02-MAR-2000.
XX
PF
    24-AUG-1999;
                   99WO-US019351.
XX
PR
    24-AUG-1998;
                   98US-0097638P.
PR
    24-AUG-1998;
                   98US-0097659P.
PR
    09-SEP-1998;
                   98US-0099618P.
PR
    28-SEP-1998;
                   98US-0102092P.
PR
    25-NOV-1998;
                   98US-0109978P.
PR
    23-DEC-1998;
                   98US-0113645P.
PR
    23-DEC-1998;
                   98US-0113646P.
                   99US-00379246.
PR
    23-AUG-1999;
XX
PA
    (ALPH-) ALPHAGENE INC.
XX
PΙ
    Valenzuela D, Yuan O, Hoffman H, Hall J, Rapiejko P;
XX
DR
    WPI; 2000-224657/19.
```

```
XX
PТ
     New secreted or transmembrane proteins and polynucleotides encoding them,
PT
     useful for treating neurodegenerative disorders, autoimmune diseases and
PT
     cancer.
XX
PS
     Claim 73; Page 322-325; 357pp; English.
XX
CC
     The invention relates to 40 human secreted proteins (AAY94981-Y95020),
CC
     and cDNA sequences encoding them (AAA23423-A23462). The secreted proteins
     of the invention include those that are thought to be only partially
CC
CC
     secreted, i.e., transmembrane proteins. The proteins of the invention may
CC
     exhibit one or more activities selected from the following: cytokine
CC
     activity; cell proliferation; differentiation; immune modulation;
CC
     haematopoiesis regulation; tissue growth activity; activin/inhibin
CC
     activity; chemotactic/chemokinetic activity; haemostatic and thrombolytic
     activity; anti-inflammatory activity; and tumour inhibition activity. The
CC
     proteins may be administered to patients as vaccines, and the nucleotides
CC
CC
     may be used as part of a gene therapy regime. Diseases or conditions that
CC
     may be treated using the proteins or nucleotides of the invention include
CC
     autoimmune diseases; genetic disorders; haemophilia; cardiovascular
CC
     diseases; cancer; bacterial, fungal and viral infections, especially HIV;
CC
     multiple sclerosis; rheumatoid arthritis; pulmonary inflammation;
CC
     Guillain-Barre syndrome; insulin dependent diabetes mellitus; and
CC
     allergic reactions such as asthma and anaemia. They may also be used for
CC
     treating wounds, burns, ulcers, osteoporosis, osteoarthritis, periodontal
CC
     diseases, Alzheimer's disease, Parkinson's disease, Huntington's disease
CC
     and amyotrophic lateral sclerosis (ALS). Proteins with activin/inhibin
     activity may additionally be useful as contraceptives. Nucleic acid
CC
CC
     sequences of the invention may be used in chromosome mapping, and as a
     source of diagnostic primers and probes. The present sequence represents
CC
     one of the 40 proteins of the invention
CC
XX
SQ
     Sequence 893 AA;
  Query Match
                         63.4%;
                                 Score 447; DB 3; Length 893;
  Best Local Similarity
                         96.9%;
                                 Pred. No. 2e-43;
           93; Conservative
                                0; Mismatches
                                                 3; Indels
                                                               0;
                                                                   Gaps
                                                                           0;
          46 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 105
Qу
                Db
         703 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 762
         106 QAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
Qу
             Db
         763 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 798
RESULT 15
ABU11573
ID
    ABU11573 standard; protein; 983 AA.
XX
AC
    ABU11573;
XX
DT
    12-FEB-2003 (first entry)
XX
DΕ
    Human MDDT polypeptide SEQ ID 520.
XX
```

MDDT; human; disease detection and treatment molecule polypeptide; KW KW anti-inflammatory; immunosuppressive; osteopathic; cytostatic; anti-HIV; KW haemostatic; nephrotropic; antianaemic; antipsoriatic; hepatotropic; KW gene therapy; protein replacement therapy; cell proliferative disorder; KW cancer; adenocarcinoma; leukaemia; lymphoma; melanoma; myeloma; sarcoma; KW anaemia; Crohn's disease; acquired immunodeficiency syndrome; AIDS; KW Goodpasture's syndrome; inflammation; osteoporosis; thrombocytopaenia; KW psoriasis; hepatitis. XX OS Homo sapiens. XX WO200279449-A2. PNXX PD 10-OCT-2002. XX PF27-MAR-2002; 2002WO-US009944. XX PR 28-MAR-2001; 2001US-0279619P. PR 29-MAR-2001; 2001US-0280067P. PR 29-MAR-2001; 2001US-0280068P. PR 16-MAY-2001; 2001US-0291280P. PR 17-MAY-2001; 2001US-0291829P. PR 17-MAY-2001; 2001US-0291849P. 19-JUN-2001; 2001US-0299428P. PR 20-JUN-2001; 2001US-0299776P. PR 20-JUN-2001; 2001US-0300001P. PR XX PA (INCY-) INCYTE GENOMICS INC. XX Daffo A, Jones AL, Tran AB, Dahl CR, Gietzen D, PΙ Dufour GE, Hillman JL, Yu JY, Tuason O, Yap PE, Amshey SR; PΙ Daugherty SC, Dam TC, Liu TF, Nguyen DA, Kleefeld Y, Gerstin EH; PΙ Peralta CH, David MH, Lewis SA, Chen AJ, Panzer SR, Harris B; PΙ PΙ Flores V, Marwaha R, Lo A, Lan RY, Urashka ME; XX WPI; 2003-058431/05. DR DR N-PSDB; ABX34563. XX PTNew purified disease detection and treatment molecule proteins and РΤ polynucleotides, useful for diagnosing, treating or preventing cancers PT(e.g. leukemia or sarcoma), anemia, Crohn's disease, AIDS, osteoporosis PTor hepatitis. XX PS Claim 27; SEQ ID NO 520; 339pp + Sequence Listing; English. XX This invention describes a novel disease detection and treatment molecule CC CC polypeptide (MDDT) which has anti-inflammatory, immunosuppressive, CC osteopathic, cytostatic, anti-HIV, haemostatic, nephrotropic, CC antianaemic, antipsoriatic and hepatotropic activity. The polynucleotides and the polypeptides of the invention can be used for gene therapy, CC protein replacement therapy and are useful for treating a variety of CC CC diseases or conditions. These polypeptides or polynucleotides are particularly useful for diagnosing, treating or preventing cell CC CC proliferative disorders (e.g. cancers including adenocarcinoma, CC leukaemia, lymphoma, melanoma, myeloma or sarcoma), anaemia, Crohn's CC disease, acquired immunodeficiency syndrome (AIDS), Goodpasture's CC syndromes, inflammation, osteoporosis, thrombocytopaenia, psoriasis or

```
by ABU11450-ABU11845, described in the disclosure of the invention. NOTE:
CC
CC
    The sequence data for this patent did not form part of the printed
CC
    specification, but was obtained in electronic format from WIPO at
CC
    ftp.wipo.int/pub/published pct sequences
XX
SO
    Sequence 983 AA;
 Query Match
                      63.4%; Score 447; DB 6; Length 983;
 Best Local Similarity
                      96.9%; Pred. No. 2.3e-43;
 Matches 93; Conservative 0; Mismatches 3; Indels
                                                        0; Gaps
                                                                  0;
         46 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 105
Qу
            Db
        793 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 852
Qу
        106 QAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
            Db
        853 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 888
```

hepatitis. ABU11450-ABU11845 represent the MDDT polynucleotides encoded

Search completed: September 29, 2004, 18:14:02 Job time: 13.3745 secs

CC

GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on:

September 29, 2004, 18:09:33 ; Search time 3.50035 Seconds

(without alignments)

2079.581 Million cell updates/sec

Title:

US-09-830-972-32

Perfect score:

705

Sequence:

1 QASGEAGVSCLRENFAVYSV.....ESEVAISEELVQKYSNSALG 141

Scoring table:

BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched:

389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters:

389414

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Issued Patents AA:*

1: /cgn2 6/ptodata/2/iaa/5A COMB.pep:*

/cgn2 6/ptodata/2/iaa/5B COMB.pep:*

3: /cgn2_6/ptodata/2/iaa/6A_COMB.pep:*

4: /cgn2_6/ptodata/2/iaa/6B COMB.pep:*

5: /cgn2_6/ptodata/2/iaa/PCTUS COMB.pep:*

6: /cgn2_6/ptodata/2/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	503	71.3	199	2	US-08-700-607-1	Sequence 1, Appli
2	349	49.5	208	2	US-08-700-607-7	Sequence 7, Appli
3	348	49.4	267	2	US-08-700-607-8	Sequence 8, Appli
4	337	47.8	356	2	US-08-700-607-6	Sequence 6, Appli
5	337	47.8	776	2	US-08-700-607-5	Sequence 5, Appli
6	305	43.3	241	2	US-08-700-607-3	Sequence 3, Appli
7	227	32.2	168	4	US-09-149-476-563	Sequence 563, App
8	99	14.0	80	3	US-08-905-223-411	Sequence 411, App
9	75	10.6	593	4	US-09-328-352-4866	Sequence 4866, Ap
10	72.5	10.3	598	2	US-08-853-659A-53	Sequence 53, Appl
11	71.5	10.1	154	1	US-08-366-783-5	Sequence 5, Appli

12	70	9.9	518	4	US-09-134-001C-4744	Sequence	4744, Ap
13	70	9.9	563	4	US-09-422-936-79	Sequence	79, Appl
14	70	9.9	619	3	US-08-262-220-6	Sequence	6, Appli
15	70	9.9	619	3	US-08-471-733-6	Sequence	6, Appli
16	70	9.9	619	3	US-08-468-878-6		6, Appli
17	70	9.9	619	3	US-08-750-494-6	Sequence	6, Appli
18	70	9.9	619	4	US-08-470-638-6	Sequence	6, Appli
19	70	9.9	844	4	US-09-422-936-47		47, Appl
20	70	9.9	844	4	US-09-422-936-51	· · · · · · · · · · · · · · · · · · ·	51, Appl
21	70	9.9	886	4	US-09-422-936-77		77, Appl
22	70	9.9	892	4	US-09-422-936-75	Sequence	
23	70	9.9	899	4	US-09-422-936-71	Sequence	
24	70	9.9	960	4	US-09-422-936-45	Sequence	
25	70	9.9	961	4	US-09-422-936-49	Sequence	
26	70	9.9	961	4	US-09-914-259-14	Sequence	
27	69	9.8	621	3	US-08-262-220-8	Sequence	
28	69	9.8	621	3	US-08-471-733-8	Sequence	
29	69	9.8	621	3	US-08-468-878-8	Sequence	
30	69	9.8	621	3	US-08-750-494-8	Sequence	
31	69	9.8	621	4	US-08-470-638-8	Sequence	
32	68	9.6	344	4	US-09-107-532A-6886	Sequence	
33	68	9.6	1447	3	US-09-041-886-25	Sequence	
34	68	9.6	1447	5	PCT-US94-05277-2	Sequence	
35	67.5	9.6	659	4	US-09-328-352-6021	Sequence	
36	67	9.5	231	4	US-09-198-452A-419	Sequence	
37	67	9.5	493	4	US-09-540-236-2120	Sequence	
38	67	9.5	507	4	US-09-328-352-7742	Sequence	
39	66.5	9.4	249	4	US-09-107-532A-6706	Sequence	
40	66	9.4	445	4	US-09-328-352-4714	Sequence	_
41	65.5	9.3	187	2	US-08-846-021A-5	Sequence	
42	65.5	9.3	234	1	US-08-366-783-4	Sequence	
43	65.5	9.3	254	2	US-08-767-026-7	Sequence	
44	65.5	9.3	254	4	US-09-319-275A-7	Sequence	
45	65	9.2	424	4	US-09-543-681A-7510	Sequence	

ALIGNMENTS

```
RESULT 1
US-08-700-607-1
; Sequence 1, Application US/08700607
; Patent No. 5858708
; GENERAL INFORMATION:
    APPLICANT: Bandman, Olga
    APPLICANT: Au-Young, Janice
APPLICANT: Goli, Surya K.
APPLICANT: Hillman, Jennifer L.
    TITLE OF INVENTION: TWO NOVEL HUMAN NSP-LIKE PROTEINS
    NUMBER OF SEQUENCES: 9
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Incyte Pharmaceuticals, Inc.
       STREET: 3174 Porter Drive
       CITY: Palo Alto
      STATE: CA
      COUNTRY: U.S.
      ZIP: 94304
```

```
COMPUTER READABLE FORM:
      MEDIUM TYPE: Diskette
      COMPUTER: IBM Compatible
      OPERATING SYSTEM: DOS
      SOFTWARE: FastSEQ Version 1.5
    CURRENT APPLICATION DATA:
     APPLICATION NUMBER: US/08/700,607
     FILING DATE: Filed Herewith
   ATTORNEY/AGENT INFORMATION:
     NAME: Billings, Lucy J.
      REGISTRATION NUMBER: 36,749
      REFERENCE/DOCKET NUMBER: PF-0114 US
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 415-855-0555
      TELEFAX: 415-845-4166
  INFORMATION FOR SEQ ID NO: 1:
   SEQUENCE CHARACTERISTICS:
     LENGTH: 199 amino acids
      TYPE: amino acid
      STRANDEDNESS: single
     TOPOLOGY: linear
   MOLECULE TYPE: peptide
    IMMEDIATE SOURCE:
     LIBRARY:
     CLONE: Consensus
US-08-700-607-1
                       71.3%; Score 503; DB 2; Length 199;
 Query Match
  Best Local Similarity 98.1%; Pred. No. 2.9e-52;
 Matches 102; Conservative 1; Mismatches 1; Indels
                                                        0; Gaps
                                                                     0;
          38 MDGQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 97
QУ
            Db
          1 MDGQKKNWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 60
          98 FRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
Qу
            61 FRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 104
RESULT 2
US-08-700-607-7
; Sequence 7, Application US/08700607
; Patent No. 5858708
  GENERAL INFORMATION:
    APPLICANT: Bandman, Olga
    APPLICANT: Au-Young, Janice
    APPLICANT: Goli, Surya K.
    APPLICANT: Hillman, Jennifer L.
    TITLE OF INVENTION: TWO NOVEL HUMAN NSP-LIKE PROTEINS
    NUMBER OF SEQUENCES: 9
    CORRESPONDENCE ADDRESS:
     ADDRESSEE: Incyte Pharmaceuticals, Inc.
     STREET: 3174 Porter Drive
     CITY: Palo Alto
     STATE: CA
     COUNTRY: U.S.
```

```
ZIP: 94304
;
     COMPUTER READABLE FORM:
      MEDIUM TYPE: Diskette
      COMPUTER: IBM Compatible
      OPERATING SYSTEM: DOS
      SOFTWARE: FastSEO Version 1.5
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/700,607
      FILING DATE: Filed Herewith
    ATTORNEY/AGENT INFORMATION:
      NAME: Billings, Lucy J.
      REGISTRATION NUMBER: 36,749
      REFERENCE/DOCKET NUMBER: PF-0114 US
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 415-855-0555
      TELEFAX: 415-845-4166
   INFORMATION FOR SEQ ID NO: 7:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 208 amino acids
      TYPE: amino acid
      STRANDEDNESS: single
      TOPOLOGY: linear
    MOLECULE TYPE: peptide
    IMMEDIATE SOURCE:
      LIBRARY: GenBank
      CLONE: 307311
US-08-700-607-7
 Query Match
                        49.5%; Score 349; DB 2; Length 208;
 Best Local Similarity 63.4%; Pred. No. 8.6e-34;
 Matches 64; Conservative 19; Mismatches 18; Indels
                                                            0; Gaps
                                                                       0;
Qу
          37 EMDGQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTI 96
                   Db
           9 KMDCVWSNWKSQAIDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATI 68
Qу
          97 SFRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVOKYSN 137
             Db
          69 SFRIYKSVLQAVQKTDEGHPFKAYLELEITLSQEQIQKYTD 109
RESULT 3
US-08-700-607-8
; Sequence 8, Application US/08700607
; Patent No. 5858708
  GENERAL INFORMATION:
    APPLICANT: Bandman, Olga
    APPLICANT: Au-Young, Janice
    APPLICANT: Goli, Surya K.
    APPLICANT: Hillman, Jennifer L.
    TITLE OF INVENTION: TWO NOVEL HUMAN NSP-LIKE PROTEINS
    NUMBER OF SEQUENCES: 9
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Incyte Pharmaceuticals, Inc.
      STREET: 3174 Porter Drive
     CITY: Palo Alto
     STATE: CA
```

```
COUNTRY: U.S.
      ZIP: 94304
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Diskette
     COMPUTER: IBM Compatible
      OPERATING SYSTEM: DOS
      SOFTWARE: FastSEQ Version 1.5
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/700,607
      FILING DATE: Filed Herewith
    ATTORNEY/AGENT INFORMATION:
      NAME: Billings, Lucy J.
      REGISTRATION NUMBER: 36,749
      REFERENCE/DOCKET NUMBER: PF-0114 US
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 415-855-0555
      TELEFAX: 415-845-4166
  INFORMATION FOR SEQ ID NO: 8:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 267 amino acids
      TYPE: amino acid
      STRANDEDNESS: single
      TOPOLOGY: linear
    MOLECULE TYPE: peptide
    IMMEDIATE SOURCE:
      LIBRARY: GenBank
      CLONE: 281046
US-08-700-607-8
 Query Match
                        49.4%; Score 348; DB 2; Length 267;
 Best Local Similarity 64.0%; Pred. No. 1.6e-33;
 Matches
         64; Conservative 18; Mismatches 18; Indels
                                                            0; Gaps
          38 MDGQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 97
Qу
                  Db
           1 MDCVWSNWKSQAIDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATIS 60
          98 FRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVOKYSN 137
Qу
             Db
          61 FRIYKSVLQAVQKTDEGHPFKAYLELEITLSQEQIQKYTD 100
RESULT 4
US-08-700-607-6
; Sequence 6, Application US/08700607
; Patent No. 5858708
  GENERAL INFORMATION:
    APPLICANT: Bandman, Olga
    APPLICANT: Au-Young, Janice
    APPLICANT: Goli, Surya K.
    APPLICANT: Hillman, Jennifer L.
    TITLE OF INVENTION: TWO NOVEL HUMAN NSP-LIKE PROTEINS
    NUMBER OF SEQUENCES: 9
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Incyte Pharmaceuticals, Inc.
      STREET: 3174 Porter Drive
     CITY: Palo Alto
```

```
STATE: CA
       COUNTRY: U.S.
      ZIP: 94304
     COMPUTER READABLE FORM:
      MEDIUM TYPE: Diskette
      COMPUTER: IBM Compatible
      OPERATING SYSTEM: DOS
      SOFTWARE: FastSEO Version 1.5
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/700,607
      FILING DATE: Filed Herewith
    ATTORNEY/AGENT INFORMATION:
      NAME: Billings, Lucy J.
      REGISTRATION NUMBER: 36,749
      REFERENCE/DOCKET NUMBER: PF-0114 US
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 415-855-0555
      TELEFAX: 415-845-4166
   INFORMATION FOR SEQ ID NO: 6:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 356 amino acids
      TYPE: amino acid
      STRANDEDNESS: single
      TOPOLOGY: linear
    MOLECULE TYPE: peptide
    IMMEDIATE SOURCE:
      LIBRARY: GenBank
      CLONE: 307309
US-08-700-607-6
 Query Match
                        47.8%; Score 337; DB 2; Length 356;
 Best Local Similarity 67.4%; Pred. No. 5e-32;
 Matches
           62; Conservative 16; Mismatches 14; Indels
                                                            0; Gaps
                                                                        0;
          46 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 105
Qу
             Db
         166 KQKAIDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATISFRIYKSVL 225
         106 QAIAKSDEGHPFRAYLESEVAISEELVQKYSN 137
Qу
             Db
         226 QAVQKTDEGHPFKAYLELEITLSQEQIQKYTD 257
RESULT 5
US-08-700-607-5
; Sequence 5, Application US/08700607
; Patent No. 5858708
  GENERAL INFORMATION:
    APPLICANT: Bandman, Olga
    APPLICANT: Au-Young, Janice
    APPLICANT: Goli, Surya K.
    APPLICANT: Hillman, Jennifer L.
    TITLE OF INVENTION: TWO NOVEL HUMAN NSP-LIKE PROTEINS
    NUMBER OF SEQUENCES: 9
    CORRESPONDENCE ADDRESS:
;
      ADDRESSEE: Incyte Pharmaceuticals, Inc.
      STREET: 3174 Porter Drive
```

```
CITY: Palo Alto
       STATE: CA
       COUNTRY: U.S.
       ZIP: 94304
     COMPUTER READABLE FORM:
       MEDIUM TYPE: Diskette
       COMPUTER: IBM Compatible
       OPERATING SYSTEM: DOS
       SOFTWARE: FastSEQ Version 1.5
     CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/700,607
       FILING DATE: Filed Herewith
     ATTORNEY/AGENT INFORMATION:
      NAME: Billings, Lucy J.
       REGISTRATION NUMBER: 36,749
       REFERENCE/DOCKET NUMBER: PF-0114 US
     TELECOMMUNICATION INFORMATION:
       TELEPHONE: 415-855-0555
      TELEFAX: 415-845-4166
   INFORMATION FOR SEQ ID NO: 5:
     SEQUENCE CHARACTERISTICS:
      LENGTH: 776 amino acids
      TYPE: amino acid
      STRANDEDNESS: single
      TOPOLOGY: linear
    MOLECULE TYPE: peptide
    IMMEDIATE SOURCE:
      LIBRARY: GenBank
      CLONE: 307307
US-08-700-607-5
  Query Match
                        47.8%; Score 337; DB 2; Length 776;
  Best Local Similarity 67.4%; Pred. No. 1.5e-31;
          62; Conservative 16; Mismatches 14; Indels
  Matches
                                                            0; Gaps
          46 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 105
Qy
             Db
         586 KQKAIDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATISFRIYKSVL 645
Qу
         106 QAIAKSDEGHPFRAYLESEVAISEELVQKYSN 137
             Db
         646 QAVQKTDEGHPFKAYLELEITLSQEQIQKYTD 677
RESULT 6
US-08-700-607-3
; Sequence 3, Application US/08700607
; Patent No. 5858708
  GENERAL INFORMATION:
    APPLICANT: Bandman, Olga
    APPLICANT: Au-Young, Janice
    APPLICANT: Goli, Surya K.
    APPLICANT: Hillman, Jennifer L.
    TITLE OF INVENTION: TWO NOVEL HUMAN NSP-LIKE PROTEINS
    NUMBER OF SEQUENCES:
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Incyte Pharmaceuticals, Inc.
```

```
STREET: 3174 Porter Drive
       CITY: Palo Alto
      STATE: CA
     COUNTRY: U.S.
      ZIP: 94304
     COMPUTER READABLE FORM:
     MEDIUM TYPE: Diskette
      COMPUTER: IBM Compatible
      OPERATING SYSTEM: DOS
      SOFTWARE: FastSEQ Version 1.5
   CURRENT APPLICATION DATA:
     APPLICATION NUMBER: US/08/700,607
      FILING DATE: Filed Herewith
   ATTORNEY/AGENT INFORMATION:
     NAME: Billings, Lucy J.
      REGISTRATION NUMBER: 36,749
     REFERENCE/DOCKET NUMBER: PF-0114 US
     TELECOMMUNICATION INFORMATION:
      TELEPHONE: 415-855-0555
      TELEFAX: 415-845-4166
   INFORMATION FOR SEQ ID NO: 3:
   SEQUENCE CHARACTERISTICS:
      LENGTH: 241 amino acids
      TYPE: amino acid
      STRANDEDNESS: single
;
      TOPOLOGY: linear
;
    MOLECULE TYPE: peptide
     IMMEDIATE SOURCE:
      LIBRARY: THP1NOB01
      CLONE: 31870
US-08-700-607-3
  Query Match 43.3%; Score 305; DB 2; Length 241; Best Local Similarity 60.9%; Pred. No. 2e-28;
 Matches 56; Conservative 17; Mismatches 19; Indels 0; Gaps
Qу
          49 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 108
             Db
          48 VHDLIXWRDVKKTGFVFGTTLIMLLSLAAFSVISVVSYLILALLSVTISFRIYKSVIQAV 107
         109 AKSDEGHPFRAYLESEVAISEELVQKYSNSAL 140
Qy
              11:1111:111: :: :1 1
Db
         108 QKSEEGHPFKAYLDVDITLSSEAFHNYMNAAM 139
RESULT 7
US-09-149-476-563
; Sequence 563, Application US/09149476
; Patent No. 6420526
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
  TITLE OF INVENTION: 186 Human Secreted proteins
; FILE REFERENCE: PZ002P1
  CURRENT APPLICATION NUMBER: US/09/149,476
; CURRENT FILING DATE: 1998-09-08
; EARLIER APPLICATION NUMBER: PCT/US98/04493
; EARLIER FILING DATE: 1998-03-06
```

```
; EARLIER APPLICATION NUMBER: 60/040,162
```

- ; EARLIER FILING DATE: 1997-03-07
- ; EARLIER APPLICATION NUMBER: 60/040,333
- ; EARLIER FILING DATE: 1997-03-07
- EARLIER APPLICATION NUMBER: 60/038,621
- ; EARLIER FILING DATE: 1997-03-07
- ; EARLIER APPLICATION NUMBER: 60/040,626
- ; EARLIER FILING DATE: 1997-03-07
- ; EARLIER APPLICATION NUMBER: 60/040,334
- ; EARLIER FILING DATE: 1997-03-07
- ; EARLIER APPLICATION NUMBER: 60/040,336
- ; EARLIER FILING DATE: 1997-03-07
- ; EARLIER APPLICATION NUMBER: 60/040,163
- ; EARLIER FILING DATE: 1997-03-07
- ; EARLIER APPLICATION NUMBER: 60/047,600
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,615
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,597
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,502
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,633
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,583
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,617
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,618
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,503
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,592
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,581
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,584
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,500
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,587
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,492
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,598
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,613
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,582
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,596
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,612
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,632
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,601

```
; EARLIER FILING DATE: 1997-05-23
```

- ; EARLIER APPLICATION NUMBER: 60/043,580
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,568
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,314
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,569
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,311
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,671
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,674
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,669
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,312
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,313
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,672
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,315
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/048,974
- ; EARLIER FILING DATE: 1997-06-06
- ; EARLIER APPLICATION NUMBER: 60/056,886
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,877
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,889
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,893
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,630
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,878
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,662
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,872
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,882
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,637
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,903
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,888
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,879
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,880
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,894
- ; EARLIER FILING DATE: 1997-08-22

```
; EARLIER APPLICATION NUMBER: 60/056,911
```

- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,636
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,874
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,910
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,864
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,631
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,845
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,892
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/057,761
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/047,595
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,599
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,588
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,585
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,586
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,590
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,594
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,589
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,593
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/047,614
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/043,578
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/043,576
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/047,501
- ; EARLIER FILING DATE: 1997-05-23
- ; EARLIER APPLICATION NUMBER: 60/043,670
- ; EARLIER FILING DATE: 1997-04-11
- ; EARLIER APPLICATION NUMBER: 60/056,632
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,664
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,876
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,881
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,909
- ; EARLIER FILING DATE: 1997-08-22
- ; EARLIER APPLICATION NUMBER: 60/056,875

```
EARLIER FILING DATE: 1997-08-22
  EARLIER APPLICATION NUMBER: 60/056,862
  EARLIER FILING DATE: 1997-08-22
  EARLIER APPLICATION NUMBER: 60/056,887
  EARLIER FILING DATE: 1997-08-22
  EARLIER APPLICATION NUMBER: 60/056,908
  EARLIER FILING DATE: 1997-08-22
  EARLIER APPLICATION NUMBER: 60/048,964
   EARLIER FILING DATE: 1997-06-06
  EARLIER APPLICATION NUMBER: 60/057,650
   EARLIER FILING DATE: 1997-09-05
   EARLIER APPLICATION NUMBER: 60/056,884
  EARLIER FILING DATE: 1997-08-22
   EARLIER APPLICATION NUMBER: 60/057,669
   EARLIER FILING DATE: 1997-09-05
   EARLIER APPLICATION NUMBER: 60/049,610
   EARLIER FILING DATE: 1997-06-13
   EARLIER APPLICATION NUMBER: 60/061,060
  EARLIER FILING DATE: 1997-10-02
  Query Match
                         32.2%; Score 227; DB 4; Length 168;
  Best Local Similarity 60.0%; Pred. No. 2.7e-19;
          42; Conservative 14; Mismatches 14; Indels
                                                              0; Gaps
                                                                          0;
Qу
          71 LLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIAKSDEGHPFRAYLESEVAISEE 130
             Db
           1 MLLSLAAFSVISVVSYLILALLSVTISFRIYKSVIQAVQKSEEGHPFKAYLDVDITLSSE 60
Qу
         131 LVQKYSNSAL 140
                 1 1:1:
Db
          61 AFHNYMNAAM 70
RESULT 8
US-08-905-223-411
; Sequence 411, Application US/08905223
; Patent No. 6222029
  GENERAL INFORMATION:
    APPLICANT: Edwards, Jean-Baptiste D.
    APPLICANT: Duelert, Aymeric
    APPLICANT: Lacroix, Bruno
    TITLE OF INVENTION: 5' ESTS FOR SECRETED PROTEINS
    NUMBER OF SEQUENCES: 503
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Knobbe, Martens, Olson & Bear
      STREET: 501 West Broadway
      CITY: San Diego
      STATE: California
      COUNTRY: USA
      ZIP: 92101-3505
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy Disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: Win95
      SOFTWARE: Word
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/905,223
```

```
FILING DATE:
      CLASSIFICATION: 536
     ATTORNEY/AGENT INFORMATION:
      NAME: Israelsen, Ned A.
      REGISTRATION NUMBER: 29,655
     REFERENCE/DOCKET NUMBER:
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (619) 235-8550
      TELEFAX: (619) 235-0176
   INFORMATION FOR SEQ ID NO: 411:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 80 amino acids
      TYPE: AMINO ACID
      TOPOLOGY: LINEAR
    MOLECULE TYPE: PROTEIN
    ORIGINAL SOURCE:
      ORGANISM: Homo Sapiens
      TISSUE TYPE: Brain
    FEATURE:
     NAME/KEY: sig peptide
      LOCATION: -78..-1
      IDENTIFICATION METHOD: Von Heijne matrix
      OTHER INFORMATION: score 6.3
      OTHER INFORMATION: seq TLIMLLSWQLSVS/SV
US-08-905-223-411
 Query Match
                        14.0%; Score 99; DB 3; Length 80;
  Best Local Similarity 58.8%; Pred. No. 0.0002;
 Matches 20; Conservative 7; Mismatches 5; Indels 2; Gaps
                                                                         1;
Qу
          49 VVDLLYWRDIKKTGVVFGASLFLLLS--LTVFSI 80
             Db
          47 VHDLIFWRDVKKTGFVFGTTLIMLLSWQLSVSSV 80
RESULT 9
US-09-328-352-4866
; Sequence 4866, Application US/09328352
; Patent No. 6562958
; GENERAL INFORMATION:
; APPLICANT: Gary L. Breton et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO
ACINETOBACTER
  TITLE OF INVENTION: BAUMANNII FOR DIAGNOSTICS AND THERAPEUTICS
  FILE REFERENCE: GTC99-03PA
  CURRENT APPLICATION NUMBER: US/09/328,352
  CURRENT FILING DATE: 1999-06-04
 NUMBER OF SEQ ID NOS: 8252
; SEQ ID NO 4866
   LENGTH: 593
   TYPE: PRT
   ORGANISM: Acinetobacter baumannii
US-09-328-352-4866
 Query Match
                        10.6%; Score 75; DB 4; Length 593;
 Best Local Similarity 27.5%; Pred. No. 2.5;
 Matches 25; Conservative 19; Mismatches 27; Indels 20; Gaps
                                                                         5;
```

```
55 WRDIKKT--GVVFGASLFLLLSLTVFSIV-----SVTAYIALALLSVTISFRIYKGVIQA 107
Qу
             Db
         258 WRGVKETWPAVLVGGGAFAIAQYLTSNFIGPELPDITAAIA-SLVSLTLLFRVWK----- 311
        108 IAKSDEGHPFRAYLESEVAISEE--LVQKYS 136
Qу
                  | | | | | : :::: | | | : | |
Db
        312 ----PKHIFRFEPEAGQTLAQQPTTVQRYS 337
RESULT 10
US-08-853-659A-53
; Sequence 53, Application US/08853659A
; Patent No. 5925522
  GENERAL INFORMATION:
    APPLICANT: Wong, K.K.; Saffer, J.D.
    TITLE OF INVENTION: A Salmonella Sequence, Methods Of Detection
    TITLE OF INVENTION: Of A
    TITLE OF INVENTION: Salmonella Sequence, And Methods Of Detection Of
Salmonella
    NUMBER OF SEQUENCES: 67
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Paul W. Zimmerman
      ADDRESSEE: Intellectual Property Services
      ADDRESSEE: Battelle Memorial Institute
     ADDRESSEE: PNNL P.O. Box 999
     STREET: Washington Way
     CITY: Richland
     STATE: Washington
     COUNTRY: U.S.A.
     ZIP: 99352
    COMPUTER READABLE FORM:
     MEDIUM TYPE: Diskette 3.50", 1.44 Mb storage
      COMPUTER: IBM PC/XT/AT
     OPERATING SYSTEM: MS-DOS
     SOFTWARE: Word Processor (WordPerfect 5.1)
;
   CURRENT APPLICATION DATA:
     APPLICATION NUMBER: US/08/853,659A
      FILING DATE: Unknown
      CLASSIFICATION: 435
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: none
      FILING DATE: n/a
  INFORMATION FOR SEO ID NO: 53:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 598 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
US-08-853-659A-53
 Query Match
                       10.3%; Score 72.5; DB 2; Length 598;
 Best Local Similarity 22.5%; Pred. No. 5;
 Matches 25; Conservative 22; Mismatches 53; Indels 11; Gaps 2;
         41 QKKHWKDKVVDLLYWRDIKKTGVVFGASLF-LLLSLTVFSIVSVTAYIALAL----- 91
Qу
             149 KKKNGRSMSSAFVLWNEFQKIKPVLLNSIFQRIADIPIFIIFLIVIYVNLGLVVIVPITM 208
Db
```

```
Qу
          92 --LSVTISFRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSNSAL 140
               :|: || : :: : | || | || || :| :: :| |
 Db
          209 FIVSIIISLVNHHYTNELMNKQKEGQKNRNIFISEVFLSIKMIHTLNNQGL 259
 RESULT 11
US-08-366-783-5
 ; Sequence 5, Application US/08366783
 ; Patent No. 5650554
   GENERAL INFORMATION:
     APPLICANT: Moloney, Maurice M
     TITLE OF INVENTION: Oil-Body Proteins As Carriers Of
     TITLE OF INVENTION: High-Value Peptides In Plants
     NUMBER OF SEQUENCES: 22
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: DEHLINGER & ASSOCIATES
      STREET: 350 CAMBRIDGE AVENUE, SUITE 250
     CITY: PALO ALTO
     STATE: California
     COUNTRY: United States ZIP: 94025-1536
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.30
   CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/366,783
      FILING DATE:
      CLASSIFICATION: 800
   ATTORNEY/AGENT INFORMATION:
     NAME: FABIAN, GARY
     REGISTRATION NUMBER: 33,875
    TELECOMMUNICATION INFORMATION:
     TELEPHONE: 415-324-0880
      TELEFAX: 415-324-0960
   INFORMATION FOR SEQ ID NO: 5:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 154 amino acids
      TYPE: amino acid
      STRANDEDNESS: single
      TOPOLOGY: linear
    MOLECULE TYPE: peptide
US-08-366-783-5
 Query Match
                       10.1%; Score 71.5; DB 1; Length 154;
 Best Local Similarity 26.2%; Pred. No. 1;
 Matches 37; Conservative 16; Mismatches 49; Indels 39; Gaps 5;
          33 RSWQEMDGQKKHWKDKVVDLLYWRDIKK--TGVVFGASLFLLLSLT----- 76
Qy
                6 RDQYQMSGRGSDYSKS-----RQIAKAATAVTAGGSLLVLLSLTLVGTVIALTVATPL 58
Db
         77 --VFSIVSVTAYIALALL------SVTISFRIYKG-VIQAIAKSDEGHPFRAY 120
Qу
              :||:||:|||
                                        ::1: ||| :|: ||:
         59 LVIFSPILVPALITVALLITGFLSSGGFGIAAITVFSWIYKYLLIEHPQGSDKLDSARMK 118
Db
```

```
121 LESEVAISEELVQKYSNSALG 141
Qу
             | |: :: | |
                            Db
         119 LGSKAQDLKDRAQYYGQQHTG 139
RESULT 12
US-09-134-001C-4744
; Sequence 4744, Application US/09134001C
; Patent No. 6380370
; GENERAL INFORMATION:
; APPLICANT: Lynn Doucette-Stamm et al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO
STAPHYLOCOCCUS
; TITLE OF INVENTION: EPIDERMIDIS FOR DIAGNOSTICS AND THERAPEUTICS
  FILE REFERENCE: GTC-007
  CURRENT APPLICATION NUMBER: US/09/134,001C
  CURRENT FILING DATE: 1998-08-13
; PRIOR APPLICATION NUMBER: US 60/064,964
; PRIOR FILING DATE: 1997-11-08
; PRIOR APPLICATION NUMBER: US 60/055,779
; PRIOR FILING DATE: 1997-08-14
; NUMBER OF SEQ ID NOS: 5674
; SEQ ID NO 4744
   LENGTH: 518
   TYPE: PRT
   ORGANISM: Staphylococcus epidermidis
US-09-134-001C-4744
 Query Match
                        9.9%; Score 70; DB 4; Length 518;
  Best Local Similarity 21.0%; Pred. No. 8.1;
 Matches 21; Conservative 28; Mismatches 35; Indels 16; Gaps
          16 AVYSVSVGMH---NLLLLEGRSWQEMDGQKKHWKDKVVDLLYWRDIKK----TGVVFGAS 68
Qу
             |: :::: | :|| |:| | : |: |: |!|:|:::
         400 AIVAITIAWHPNDTILNLVGNAWA---GFGAAFSPLVLYSLYWKDLTRAGAISGMVAGAV 456
Db
          69 LFLLLSLTVFSIVSVTAYIAL-----ALLSVTISFRIYK 102
Qу
             457 VVIVWISWIKPLATINAFFGMYEIIPGFIVSVLITYIVSK 496
Db
RESULT 13
US-09-422-936-79
; Sequence 79, Application US/09422936
; Patent No. 6465213
; GENERAL INFORMATION:
; APPLICANT: Ekstrand, Jonas
; TITLE OF INVENTION: NEW NUCLEOTIDE SEQUENCES
; FILE REFERENCE: 06275-165002
; CURRENT APPLICATION NUMBER: US/09/422,936
; CURRENT FILING DATE: 1999-10-22
  PRIOR APPLICATION NUMBER: US 09/242,608
; PRIOR FILING DATE: 1999-02-19
; PRIOR APPLICATION NUMBER: PCT/SE98/01947
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: SWEDEN 9703914-2
```

```
; PRIOR FILING DATE: 1997-10-27
; PRIOR APPLICATION NUMBER: SWEDEN 9800864-2
; PRIOR FILING DATE: 1998-03-16
  PRIOR APPLICATION NUMBER: SWEDEN 9802575-2
  PRIOR FILING DATE: 1998-07-17
; NUMBER OF SEQ ID NOS: 85
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEO ID NO 79
   LENGTH: 563
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-422-936-79
  Query Match
                         9.9%; Score 70; DB 4; Length 563;
 Best Local Similarity 28.3%; Pred. No. 9.1;
 Matches 26; Conservative 13; Mismatches 35; Indels 18; Gaps 3;
          30 LEGRSWQEMDGQKKHWKDKVVDLLYWRDIKKTGVVFGAS-----LFLLLSLTVFS 79
Qу
             1:| |:::: : | | | | | | | | |
Db
         144 LQGGSYKKIG----YYDSTKDDLSW---SKTDKWIGGSPPADOTLVIKTFRFLSOKLFI 195
Qv
         80 IVSVTAYIALALLSVTISFRIYKGVIQAIAKS 111
              Db
         196 SVSVLSSLGIVLAVVCLSFNIYNSHVRYIQNS 227
RESULT 14
US-08-262-220-6
; Sequence 6, Application US/08262220
; Patent No. 6054296
 GENERAL INFORMATION:
    APPLICANT: BERGSTROM SVEN APPLICANT: BARBOUR ALAN G.
    TITLE OF INVENTION: NEW 66 KDA ANTIGEN FROM BORRELIA
    NUMBER OF SEQUENCES: 14
   CORRESPONDENCE ADDRESS:
      ADDRESSEE: BROWDY AND NEIMARK
     STREET: 419 SEVENTH STREET, N.W.
      CITY: WASHINGTON
      COUNTRY: USA
      ZIP: 20004
   COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.25
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/262,220
      FILING DATE: 20-JUN-1994
      CLASSIFICATION: 514
    ATTORNEY/AGENT INFORMATION:
      NAME: COOPER, IVER P.
      REGISTRATION NUMBER: 28,005
      REFERENCE/DOCKET NUMBER: BERGSTROM=3
   TELECOMMUNICATION INFORMATION:
      TELEPHONE: 202-628-5197
      TELEFAX: 202-737-3528
```

```
TELEX: 248633
  INFORMATION FOR SEO ID NO: 6:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 619 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-262-220-6
 Query Match
                          9.9%; Score 70; DB 3; Length 619;
 Best Local Similarity 39.0%; Pred. No. 10;
 Matches
          16; Conservative 6; Mismatches
                                              15; Indels
                                                               4; Gaps
                                                                          1;
Qу
          32 GRSWQEMDGQKKHWKDKVVD----LLYWRDIKKTGVVFGAS 68
             |:
                                           ||:|| | |
Dh
         384 GLAWNKDDGEKESWKVKGSDSYSTRLFGEQDKKSGVALGIS 424
RESULT 15
US-08-471-733-6
; Sequence 6, Application US/08471733
; Patent No. 6068842
  GENERAL INFORMATION:
    APPLICANT: BERGSTROM SVEN
    APPLICANT: BARBOUR ALAN G.
    TITLE OF INVENTION: NEW 66 KDA ANTIGEN FROM BORRELIA
;
    NUMBER OF SEQUENCES: 14
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: BROWDY AND NEIMARK
      STREET: 419 SEVENTH STREET, N.W.
      CITY: WASHINGTON
      COUNTRY: USA
      ZIP: 20004
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.25
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/471,733
      FILING DATE: 06-JUN-1995
      CLASSIFICATION: 435
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: 08/262,220
      FILING DATE: 20-JUN-1994
    ATTORNEY/AGENT INFORMATION:
      NAME: COOPER, IVER P.
      REGISTRATION NUMBER: 28,005
      REFERENCE/DOCKET NUMBER: BERGSTROM=3
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 202-628-5197
      TELEFAX: 202-737-3528
      TELEX: 248633
  INFORMATION FOR SEQ ID NO:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 619 amino acids
      TYPE: amino acid
```

Search completed: September 29, 2004, 18:21:06 Job time: 4.50035 secs

GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 29, 2004, 18:05:43; Search time 3.45105 Seconds

(without alignments)

3930.111 Million cell updates/sec

Title: US-09-830-972-32

Perfect score: 705

Sequence: 1 QASGEAGVSCLRENFAVYSV.....ESEVAISEELVQKYSNSALG 141

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283366 seqs, 96191526 residues

Total number of hits satisfying chosen parameters: 283366

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: PIR_78:*

1: pir1:*

2: pir2:*

3: pir3:*

4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

		ક				
Result		Query				
No.	Score	Match	Length	DB	ID	Description
1	349	49.5	208	2	160904	neuroendocrine-spe
2	348	49.4	267	2	A60021	tropomyosin-relate
3	337	47.8	776	2	A46583	neuroendocrine-spe
4	162	23.0	2484	2	T26216	hypothetical prote
5	159	22.6	2607	2	T26215	hypothetical prote
6	158	22.4	222	2	T26213	hypothetical prote
7	83.5	11.8	295	2	S59439	probable membrane
8	81.5	11.6	464	2	C88188	protein C18H9.5 [i
9	79	11.2	618	2	T24228	hypothetical prote
10	78.5	11.1	458	2	A72258	hypothetical prote
11	77.5	11.0	261	2	F64924	probable thiosulfa
12	77.5	11.0	583	2	T49359	hypothetical prote
13	76.5	10.9	481	2	C95920	hypothetical membr

14	75.5	10.7	545	2	F64665	
15	74.5	10.6	545	2	E71851	
16	74	10.5	268	2	F64024	
17	73	10.4	393	2	s67763	
18	73	10.4	888	2	T01081	
19	72.5	10.3	278	2	AD0147	
20	72.5	. 10.3	302	2	AE2863	
21	72.5	10.3	302	2	D97640	
22	72.5	10.3	417	2	В96977	
23	72.5	10.3	598	2	T14886	
24	72	10.2	271	2	T13013	
25	72	10.2	299	2	B69155	
26	72	10.2	1783	2	T42386	
27	72	10.2	3511	2	A59295	
28	71.5	10.1	255	2	E84899	
29	71.5	10.1	537	2	G82873	
30	71	10.1	346	1	WMVZ1W	
31	71	10.1	346	1	WMVZ2W	
32	71	10.1	346	2	T37430	
33	71	10.1	476	2	B97096	
34	71	10.1	1065	2	T25068	
35	70.5	10.0	153	2	AB3226	
36	70.5	10.0	261	2	A90926	
37	70.5	10.0	261	2	E85774	
38	70.5	10.0	291	2	B69098	
39	70	9.9	271	2	AC1320	
40	70	9.9	619	2	\$55502	
41	70	9.9	737	2	AE1678	
42	69.5	9.9	188	2	T04714	
43	69.5	9.9	403	2	T04821	
44	69.5	9.9	415	2	D95248	
45	69.5	9.9	504	2	E83898	

glucose-6-phosphat glucose-6-phosphat hypothetical prote probable membrane hypothetical prote probable ABC trans conserved hypothet hypothetical prote probable Mn transp leukotoxin express hypothetical prote hypothetical prote unconventional myo unconventional myo hypothetical prote conserved hypothet 3beta-hydroxy-Delt 3beta-hydroxy-Delt hydroyxsteroid deh 2-oxoglutarate/mal hypothetical prote conserved hypothet hypothetical prote hypothetical prote phosphate transpor hypothetical prote membrane-associate heavy metal-transp hypothetical prote hypothetical prote conserved hypothet spore germination

ALIGNMENTS

RESULT 1 160904

neuroendocrine-specific protein C - human

C; Species: Homo sapiens (man)

C;Date: 24-May-1996 #sequence revision 24-May-1996 #text change 05-Nov-1999

C; Accession: I60904

R; Roebroek, A.J.; van de Velde, H.J.; Van Bokhoven, A.; Broers, J.L.; Ramaekers, F.C.; Van de Ven, W.J.

J. Biol. Chem. 268, 13439-13447, 1993

A; Title: Cloning and expression of alternative transcripts of a novel neuroendocrine-specific gene and identification of its 135-kDa translational product.

A; Reference number: A46583; MUID: 93293865; PMID: 7685762

A; Accession: I60904

A; Status: preliminary; translated from GB/EMBL/DDBJ

A; Molecule type: mRNA A; Residues: 1-208 < RES>

A;Cross-references: GB:L10335; NID:g307310; PIDN:AAA59952.1; PID:g307311

C; Genetics:

A; Gene: GDB: RTN1; NSP

```
Query Match
                        49.5%;
                               Score 349; DB 2; Length 208;
                              Pred. No. 5.3e-28;
 Best Local Similarity 63.4%;
 Matches
          64; Conservative 19; Mismatches 18; Indels
                                                           0; Gaps
                                                                      0;
Qy
          37 EMDGOKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTI 96
                   9 KMDCVWSNWKSQAIDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATI 68
Db
Qу
          97 SFRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSN 137
             Db
          69 SFRIYKSVLQAVQKTDEGHPFKAYLELEITLSQEQIQKYTD 109
RESULT 2
A60021
tropomyosin-related protein, neuronal - rat
C; Species: Rattus norvegicus (Norway rat)
C;Date: 03-Mar-1993 #sequence revision 03-Mar-1993 #text change 05-Nov-1999
C; Accession: A60021
R; Wieczorek, D.F.; Hughes, S.R.
Brain Res. Mol. Brain Res. 10, 33-41, 1991
A; Title: Developmentally regulated cDNA expressed exclusively in neural tissue.
A; Reference number: A60021; MUID: 91278684; PMID: 1647480
A; Accession: A60021
A; Molecule type: mRNA
A; Residues: 1-267 <WIE>
A;Cross-references: EMBL:X52817; NID:q456549; PIDN:CAA37001.1; PID:q456550
C; Comment: This neuronal-specific mRNA was identified by hybridization to an
alpha-tropomyosin probe but does not show homology in amino acid sequence.
 Query Match
                        49.4%;
                               Score 348; DB 2; Length 267;
 Best Local Similarity
                       64.0%; Pred. No. 8.9e-28;
         64; Conservative 18; Mismatches
                                            18; Indels
                                                           0; Gaps
                                                                      0;
 Matches
          38 MDGQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 97
Qу
                  1 MDCVWSNWKSQAIDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATIS 60
Db
          98 FRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSN 137
QУ
             Db
          61 FRIYKSVLQAVQKTDEGHPFKAYLELEITLSQEQIQKYTD 100
RESULT 3
A46583
neuroendocrine-specific protein, splice form A - human
N; Contains: neuroendocrine-specific protein, splice form B
C; Species: Homo sapiens (man)
C; Date: 24-May-1996 #sequence revision 24-May-1996 #text change 05-Nov-1999
C; Accession: A46583; I60903
R; Roebroek, A.J.; van de Velde, H.J.; Van Bokhoven, A.; Broers, J.L.; Ramaekers,
F.C.; Van de Ven, W.J.
J. Biol. Chem. 268, 13439-13447, 1993
```

A; Cross-references: GDB:203968; OMIM:600865

A; Map position: 14q21-14q22

```
A; Title: Cloning and expression of alternative transcripts of a novel
neuroendocrine-specific gene and identification of its 135-kDa translational
product.
A; Reference number: A46583; MUID: 93293865; PMID: 7685762
A; Accession: A46583
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-776 < ROE1>
A; Cross-references: GB:L10333; NID:q307306; PIDN: AAA59950.1; PID:q307307
A; Accession: I60903
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 421-776 < ROE2>
A; Cross-references: GB:L10334; NID:g307308; PIDN: AAA59951.1; PID:g307309
C; Genetics:
A; Gene: GDB: RTN1; NSP
A; Cross-references: GDB:203968; OMIM:600865
A; Map position: 14q21-14q22
                         47.8%; Score 337; DB 2; Length 776;
 Query Match
 Best Local Similarity
                         67.4%; Pred. No. 3.7e-26;
           62; Conservative
                             16; Mismatches
                                               14; Indels
                                                                0; Gaps
                                                                            0;
           46 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 105
Qу
              Db
          586 KQKAIDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATISFRIYKSVL 645
          106 QAIAKSDEGHPFRAYLESEVAISEELVQKYSN 137
QУ
              ||: |:|||||:||| ||: :|:| :|||::
          646 QAVQKTDEGHPFKAYLELEITLSQEQIQKYTD 677
Db
RESULT 4
T26216
hypothetical protein W06A7.3c - Caenorhabditis elegans
C; Species: Caenorhabditis elegans
C;Date: 15-Oct-1999 #sequence revision 15-Oct-1999 #text change 15-Oct-1999
C; Accession: T26216
R; Ainscough, R.
submitted to the EMBL Data Library, August 1996
A; Reference number: Z20173
A; Accession: T26216
A; Status: preliminary; translated from GB/EMBL/DDBJ
A: Molecule type: DNA
A; Residues: 1-2484 <WIL>
A; Cross-references: EMBL: Z78066; PIDN: CAB51467.1; GSPDB: GN00023; CESP: W06A7.3c
A; Experimental source: clone W06A7
C: Genetics:
A; Gene: CESP: W06A7.3c
A; Map position: 5
A;Introns: 1827/1; 1866/3; 1963/3; 1990/3; 2262/1; 2289/1; 2339/2; 2463/2
                         23.0%; Score 162; DB 2; Length 2484;
  Query Match
                         31.5%; Pred. No. 7.9e-08;
  Best Local Similarity
  Matches
           34; Conservative 22; Mismatches 48; Indels
                                                                4; Gaps
```

25 HNLLLLEGRSWQEMDGQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVT 84

Qу

```
- [
                                    Db
        2269 HSILKHHGDAWIDF----KTVPPCVLDVIYWRDAKKSAIVLSLALLVLFVLAKYPLLTVV 2324
          85 AYIALALLSVTISFRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELV 132
Qy
                         Db
        2325 TYSLLLALGAAAGFRVFKKVEAQIKKTDSEHPFSEILAQDLTLPQEKV 2372
RESULT 5
T26215
hypothetical protein W06A7.3a - Caenorhabditis elegans
C; Species: Caenorhabditis elegans
C; Date: 15-Oct-1999 #sequence revision 15-Oct-1999 #text change 15-Oct-1999
C; Accession: T26215
R; Ainscough, R.
submitted to the EMBL Data Library, August 1996
A; Reference number: Z20173
A; Accession: T26215
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-2607 <WIL>
A;Cross-references: EMBL:Z78066; PIDN:CAB01522.2; GSPDB:GN00023; CESP:W06A7.3a
A; Experimental source: clone W06A7
C; Genetics:
A; Gene: CESP: W06A7.3a
A; Map position: 5
A; Introns: 1827/1; 1866/3; 1963/3; 1990/3; 2262/1; 2289/1; 2412/1; 2462/2;
2586/2
 Query Match
                        22.6%; Score 159; DB 2; Length 2607;
 Best Local Similarity 34.5%; Pred. No. 1.7e-07;
           30; Conservative 19; Mismatches
                                                             0; Gaps
                                                                         0;
 Matches
                                              38; Indels
          46 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 105
Qу
             2409 KKEVLDVIYWRDAKKSAIVLSLALLVLFVLAKYPLLTVVTYSLLLALGAAAGFRVFKKVE 2468
Db
         106 QAIAKSDEGHPFRAYLESEVAISEELV 132
Qу
               1 1:1 111
                          | :: : : | |
Db
        2469 AQIKKTDSEHPFSEILAQDLTLPQEKV 2495
RESULT 6
T26213
hypothetical protein W06A7.3b - Caenorhabditis elegans
C; Species: Caenorhabditis elegans
C;Date: 15-Oct-1999 #sequence revision 15-Oct-1999 #text change 15-Oct-1999
C; Accession: T26213
R; Ainscough, R.
submitted to the EMBL Data Library, August 1996
A: Reference number: Z20173
A; Accession: T26213
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-222 <WIL>
A;Cross-references: EMBL:Z78066; PIDN:CAB01523.1; GSPDB:GN00023; CESP:W06A7.3b
A; Experimental source: clone W06A7
```

```
C; Genetics:
A; Gene: CESP: W06A7.3b
A; Map position: 5
A; Introns: 27/1; 77/2; 201/2
                        22.4%; Score 158; DB 2; Length 222;
  Query Match
 Best Local Similarity 34.1%; Pred. No. 1.4e-08;
                                                           0; Gaps
          29; Conservative 19; Mismatches 37; Indels
          48 KVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 107
Qу
             26 KILDVIYWRDAKKSAIVLSLALLVLFVLAKYPLLTVVTYSLLLALGAAAGFRVFKKVEAQ 85
Db
         108 IAKSDEGHPFRAYLESEVAISEELV 132
Qу
             | |:| ||| | ::::| |
Db
          86 IKKTDSEHPFSEILAQDLTLPQEKV 110
RESULT 7
S59439
probable membrane protein YDR233c - yeast (Saccharomyces cerevisiae)
N; Alternate names: hypothetical protein YD9934.17c
C; Species: Saccharomyces cerevisiae
C;Date: 30-Nov-1995 #sequence revision 16-Feb-1996 #text change 19-Apr-2002
C; Accession: S59439
R; Murphy, L.; Harris, D.
submitted to the EMBL Data Library, March 1995
A; Reference number: S59423
A; Accession: S59439
A; Molecule type: DNA
A; Residues: 1-295 <MUR>
A;Cross-references: EMBL:Z48612; NID:g728671; PID:g728688; GSPDB:GN00004;
MIPS:YDR233c
A; Experimental source: strain AB972
C; Genetics:
A; Gene: MIPS: YDR233c
A; Cross-references: SGD: S0002641
A; Map position: 4R
C; Keywords: transmembrane protein
F;40-56/Domain: transmembrane #status predicted <TM1>
F;146-162/Domain: transmembrane #status predicted <TM2>
                        11.8%; Score 83.5; DB 2; Length 295;
  Query Match
  Best Local Similarity 26.3%; Pred. No. 0.73;
          25; Conservative 17; Mismatches
                                               32; Indels
  Matches
          41 QKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRI 100
Qу
                      12 QQQQQKSCNCDLLLWRNPVQTGKYFGGSLLALLILKKVNLITFFLKVAYTILFTT---- 66
Db
         101 YKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKY 135
QУ
                                   : : : |: ||
               | |: ::|
          67 --GSIEFVSK-----LFLGQGLITKY 85
Db
```

RESULT 8 C88188

```
protein C18H9.5 [imported] - Caenorhabditis elegans
C; Species: Caenorhabditis elegans
C;Date: 10-May-2001 #sequence_revision 10-May-2001 #text_change 10-May-2001
C; Accession: C88188
R; anonymous, The C. elegans Sequencing Consortium.
Science 282, 2012-2018, 1998
A; Title: Genome sequence of the nematode C. elegans: a platform for
investigating biology.
A; Reference number: A75000; MUID: 99069613; PMID: 9851916
A; Note: see websites genome.wustl.edu/gsc/C elegans/ and
www_sanger.ac.uk/Projects/C_elegans/ for a list of authors
A; Note: published errata appeared in Science 283, 35, 1999; Science 283, 2103,
1999; and Science 285, 1493, 1999
A; Accession: C88188
A; Status: preliminary
A; Molecule type: DNA
A; Residues: 1-464 <STO>
A;Cross-references: GB:chr II; PID:g722384; GSPDB:GN00020; CESP:C18H9.5
C; Genetics:
A; Gene: C18H9.5
A; Map position: 2
                          11.6%; Score 81.5; DB 2; Length 464;
  Query Match
  Best Local Similarity 25.9%; Pred. No. 1.9;
          38; Conservative 28; Mismatches
                                                  50; Indels
                                                                31; Gaps
            8 VSCLRENFAVYSVSVGMHNLLLLEGRSWQEMDGQKKHWKDKVVDLLYWRDIKKTGVVFG- 66
Qу
                              41 ITCTNANMILMNFTVICMNDVIIEQKSF----SNQTHWLEKSSDISLTFSAAAVGAIFGT 96
Dh
           67 ASLFLLLS-----LTVFSIVSV--TAYIALA----LLSVTISFRIYKGV------I 105
Qу
                            |||: ::| | : ||
                                                 |: | |: |:::||
           97 VPAVTLISKYGIRKVLTVYGLLSAGGTLLMPLAVNYGLIPVLIA-RLFQGVGASILYSSI 155
dQ
          106 QAIAKS----DEGHPFRAYLESEVAIS 128
Qу
                       : | | | : | |
          156 GTISESWSPINEIGTFVAFLSSAFQIS 182
Db
RESULT 9
T24228
hypothetical protein R166.2 - Caenorhabditis elegans
C; Species: Caenorhabditis elegans
C; Date: 15-Oct-1999 #sequence revision 15-Oct-1999 #text change 15-Oct-1999
C; Accession: T24228
R; Matthews, P.
submitted to the EMBL Data Library, August 1995
A; Reference number: Z19859
A; Accession: T24228
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 1-618 <WIL>
A;Cross-references: EMBL:Z50795; PIDN:CAA90663.1; GSPDB:GN00020; CESP:R166.2
A; Experimental source: clone R166
C; Genetics:
A; Gene: CESP:R166.2
A; Map position: 2
```

```
A; Introns: 41/3; 86/3; 118/3; 164/3; 207/3; 554/3
                        11.2%; Score 79; DB 2; Length 618;
 Query Match
 Best Local Similarity 29.1%; Pred. No. 4.7;
 Matches 32; Conservative 22; Mismatches 32; Indels 24; Gaps 6;
          51 DLLYWRDIKK-TGVVFGASLF-LLLSLTVF-----SIVSVTAYIALAL----- 91
Qv
             1::1:1 1: :11:
                                                ::| || | | | | :
         353 DIQFWNNRKDLVGLSVRSVLFNIFQSLIVFLYICDNETNTMVKVTVGIGLLIECWKIPKV 412
Db
QУ
         92 LSVTISFR-IYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSNSAL 140
             ::|:| :: : ||| : ||:| :|:|| | | ::: ||
Db
         413 MNVSIDWQNKWFGVIPRLVISDKG----SYVESETKIYDQMAFKYLGWAL 458
RESULT 10
A72258
hypothetical protein - Thermotoga maritima (strain MSB8)
C; Species: Thermotoga maritima
C;Date: 11-Jun-1999 #sequence revision 11-Jun-1999 #text change 21-Jul-2000
C; Accession: A72258
R; Nelson, K.E.; Clayton, R.A.; Gill, S.R.; Gwinn, M.L.; Dodson, R.J.; Haft,
D.H.; Hickey, E.K.; Peterson, J.D.; Nelson, W.C.; Ketchum, K.A.; McDonald, L.;
Utterback, T.R.; Malek, J.A.; Linher, K.D.; Garrett, M.M.; Stewart, A.M.;
Cotton, M.D.; Pratt, M.S.; Phillips, C.A.; Richardson, D.; Heidelberg, J.;
Sutton, G.G.; Fleischmann, R.D.; White, O.; Salzberg, S.L.; Smith, H.O.; Venter,
J.C.; Fraser, C.M.
Nature 399, 323-329, 1999
A; Title: Evidence for lateral gene transfer between Archaea and Bacteria from
genome sequence of Thermotoga maritima.
A; Reference number: A72200; MUID:99287316; PMID:10360571
A; Accession: A72258
A; Status: preliminary
A; Molecule type: DNA
A; Residues: 1-458 <ARN>
A;Cross-references: GB:AE001793; GB:AE000512; NID:g4981963; PIDN:AAD36479.1;
PID:q4981972; TIGR:TM1408
A; Experimental source: strain MSB8
C; Genetics:
A; Gene: TM1408
                        11.1%; Score 78.5; DB 2; Length 458;
  Query Match
  Best Local Similarity 26.6%; Pred. No. 3.8;
  Matches 42; Conservative 17; Mismatches 34; Indels 65; Gaps
          14 NFAVY----SVSVGMHNLLLLEGRSWQEMDGQKKH-----WKD 47
Qу
                      |::| ||| :||
         196 NFLILSYLRSSIRIGFDFLLL-----TRKHPQLLFIGYFYYLSIWIDNFIAWKV 244
Db
          48 KVVDLL-----YWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFR 99
Qу
                         245 KGIEIAPGFFMSPEY--DIPK----FMASLFFIPSLVVFN-----LSMETVFQR 287
Db
         100 IYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSN 137
QУ
              |||::|:| ||: || ||: :||
```

288 NYKGLMQSIV-SDK--PMRVISENLKKLSLSLRHAFSN 322

Db

```
RESULT 11
F64924
probable thiosulfate-dithiol sulfurtransferase (EC 2.8.1.5) - Escherichia coli
(strain K-12)
C; Species: Escherichia coli
C;Date: 12-Sep-1997 #sequence_revision 17-Sep-1997 #text change 03-Jun-2002
C; Accession: F64924
R; Blattner, F.R.; Plunkett III, G.; Bloch, C.A.; Perna, N.T.; Burland, V.;
Riley, M.; Collado-Vides, J.; Glasner, J.D.; Rode, C.K.; Mayhew, G.F.; Gregor,
J.; Davis, N.W.; Kirkpatrick, H.A.; Goeden, M.A.; Rose, D.J.; Mau, B.; Shao, Y.
Science 277, 1453-1462, 1997
A; Title: The complete genome sequence of Escherichia coli K-12.
A; Reference number: A64720; MUID: 97426617; PMID: 9278503
A; Accession: F64924
A; Status: nucleic acid sequence not shown; translation not shown
A; Molecule type: DNA
A; Residues: 1-261 <BLAT>
A;Cross-references: GB:AE000262; GB:U00096; NID:g1787955; PIDN:AAC74740.1;
PID:g1787959; UWGP:b1670
A; Experimental source: strain K-12, substrain MG1655
C; Superfamily: hyaC protein
C; Keywords: sulfurtransferase; transmembrane protein
F;30-46/Domain: transmembrane #status predicted <TM01>
F;83-99/Domain: transmembrane #status predicted <TM02>
F;112-128/Domain: transmembrane #status predicted <TM03>
F;187-203/Domain: transmembrane #status predicted <TM04>
F;224-240/Domain: transmembrane #status predicted <TM05>
                         11.0%; Score 77.5; DB 2; Length 261;
 Query Match
 Best Local Similarity 27.6%; Pred. No. 2.6;
                                                               17; Gaps
           29; Conservative 16; Mismatches 43; Indels
 Matches
           22 VGMHNLLLLEGRSWQEMD-GQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLL----SLT 76
QУ
              :|:| || |
                              | |:| :
                                       Db
           44 LGLHALLRARGVKKSATDHGEKIYLYSKAVRLWHWSN-----ALLFVLLLASGLIN 94
           77 VFSIVSVTAYIALALLSVTISFRI---YKGVIQAIAKSDEGHPFR 118
Qу
               1::| || :| : |: | : | :|
           95 HFAMVGATAVKSLVAVHEVCGFLLLACWLGFVLINAVGDNGHHYR 139
Db
RESULT 12
T49359
hypothetical protein B1D1.130 [imported] - Neurospora crassa
C; Species: Neurospora crassa
C;Date: 02-Jun-2000 #sequence_revision 02-Jun-2000 #text_change 02-Jun-2000
C; Accession: T49359
R; Schulte, U.; Aign, V.; Hoheisel, J.; Brandt, P.; Fartmann, B.; Holland, R.;
Nyakatura, G.; Mewes, H.W.; Mannhaupt, G.
submitted to the Protein Sequence Database, May 2000
A; Reference number: Z25022
A; Accession: T49359
A; Status: preliminary
A; Molecule type: DNA
A; Residues: 1-583 <SCH>
A;Cross-references: EMBL:AL355927; GSPDB:GN00116; NCSP:B1D1.130
```

```
A; Experimental source: BAC clone B1D1; strain OR74A
C; Genetics:
A; Gene: NCSP:B1D1.130
A; Map position: 6
A; Introns: 44/1
                          11.0%; Score 77.5; DB 2; Length 583;
  Query Match
  Best Local Similarity
                          27.5%; Pred. No. 6.2;
                                                  28;
                                                       Indels
                                                                33; Gaps
            28; Conservative
                              13; Mismatches
Qу
           52 LLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIAKS 111
                   ::: :| | | | | | | | | |
                                              67 LCYW-PLERRLLVLHALLLLLLSLEHYS----AYTRVLLLHITSSLNL----- 109
Db
          112 DEGHPFRAYLESEVAIS-----EELVQKYSNSALG 141
QУ
                  | | :: || ::
                                           111:11
          110 ----PLRVLVDDEVRVAKAIAWMAKDINPEELIQKRIEECAG 147
Db
RESULT 13
C95920
hypothetical membrane protein [imported] - Sinorhizobium meliloti (strain 1021)
magaplasmid pSymB
C; Species: Sinorhizobium meliloti
C;Date: 24-Aug-2001 #sequence revision 24-Aug-2001 #text_change 30-Sep-2001
C; Accession: C95920
R; Finan, T.M.; Weidner, S.; Wong, K.; Buhrmester, J.; Chain, P.; Vorholter,
F.J.; Hernandez-Lucas, I.; Becker, A.; Cowie, A.; Gouzy, J.; Golding, B.;
Puhler, A.
Proc. Natl. Acad. Sci. U.S.A. 98, 9889-9894, 2001
A; Title: The complete sequence of the 1,683-kb pSymB megaplasmid from the N2-
fixing endosymbiont Sinorhizobium meliloti.
A; Reference number: A95842; MUID:21396508; PMID:11481431
A; Accession: C95920
A; Status: preliminary
A; Molecule type: DNA
A; Residues: 1-481 <KUR>
A; Cross-references: GB: AL591985; PIDN: CAC49027.1; PID: g15140512; GSPDB: GN00167
A; Experimental source: strain 1021, megaplasmid pSymB
R; Galibert, F.; Finan, T.M.; Long, S.R.; Puhler, A.; Abola, P.; Ampe, F.;
Barloy-Hubler, F.; Barnett, M.J.; Becker, A.; Boistard, P.; Bothe, G.; Boutry,
M.; Bowser, L.; Buhrmester, J.; Cadieu, E.; Capela, D.; Chain, P.; Cowie, A.;
Davis, R.W.; Dreano, S.; Federspiel, N.A.; Fisher, R.F.; Gloux, S.; Godrie, T.;
Goffeau, A.; Golding, B.; Gouzy, J.; Gurjal, M.; Hernandez-Lucas, I.; Hong, A.;
Huizar, L.; Hyman, R.W.; Jones, T.
Science 293, 668-672, 2001
A; Authors: Kahn, D.; Kahn, M.L.; Kalman, S.; Keating, D.H.; Kiss, E.; Komp, C.;
Lelaure, V.; Masuy, D.; Palm, C.; Peck, M.C.; Pohl, T.M.; Portetelle, D.;
Purnelle, B.; Ramsperger, U.; Surzycki, R.; Thebault, P.; Vandenbol, M.;
Vorholter, F.J.; Weidner, S.; Wells, D.H.; Wong, K.; Yeh, K.C.; Batut, J.
A; Title: The composite genome of the legume symbiont Sinorhizobium meliloti.
A; Reference number: A96039; MUID: 21368234; PMID: 11474104
A; Contents: annotation
C; Genetics:
A; Gene: SMb21048
A; Genome: plasmid
```

```
Query Match
                         10.9%; Score 76.5; DB 2; Length 481;
 Best Local Similarity 37.7%; Pred. No. 6.4;
                             8; Mismatches 27; Indels
                                                               3; Gaps
                                                                           2:
           23; Conservative
 Matches
          53 LYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIAKSD 112
QУ
                       238 VYWRKTKSR--VAQALAFLLLVLLLSTSSV-AYVGLAVLSIPVALSISWSFLSGRMDKD 294
Db
         113 E 113
Qу
Db
         295 E 295
RESULT 14
F64665
glucose-6-phosphate isomerase (EC 5.3.1.9) - Helicobacter pylori (strain 26695)
C; Species: Helicobacter pylori
C; Date: 09-Aug-1997 #sequence revision 09-Aug-1997 #text_change 16-Jul-1999
C; Accession: F64665
R; Tomb, J.F.; White, O.; Kerlavage, A.R.; Clayton, R.A.; Sutton, G.G.;
Fleischmann, R.D.; Ketchum, K.A.; Klenk, H.P.; Gill, S.; Dougherty, B.A.;
Nelson, K.; Quackenbush, J.; Zhou, L.; Kirkness, E.F.; Peterson, S.; Loftus, B.;
Richardson, D.; Dodson, R.; Khalak, H.G.; Glodek, A.; McKenney, K.; Fitzegerald,
L.M.; Lee, N.; Adams, M.D.; Hickey, E.K.; Berg, D.E.; Gocayne, J.D.; Utterback,
T.R.; Peterson, J.D.; Kelley, J.M.; Cotton, M.D.; Weidman, J.M.; Fujii, C.;
Bowman, C.; Watthey, L.
Nature 388, 539-547, 1997
A; Authors: Wallin, E.; Hayes, W.S.; Borodovsky, M.; Karpk, P.D.; Smith, H.O.;
Fraser, C.M.; Venter, J.C.
A; Title: The complete genome sequence of the gastric pathogen Helicobacter
pylori.
A; Reference number: A64520; MUID: 97394467; PMID: 9252185
A; Accession: F64665
A; Status: preliminary; nucleic acid sequence not shown; translation not shown
A; Molecule type: DNA
A; Residues: 1-545 < TOM>
A;Cross-references: GB:AE000622; GB:AE000511; NID:g2314317; PIDN:AAD08211.1;
PID:g2314323; TIGR:HP1166
C; Superfamily: glucose-6-phosphate isomerase
C; Keywords: intramolecular oxidoreductase; isomerase
                         10.7%; Score 75.5; DB 2; Length 545;
  Query Match
  Best Local Similarity 25.3%; Pred. No. 9.2;
           37; Conservative 20; Mismatches
                                                44;
                                                    Indels
                                                              45; Gaps
                                                                           6;
  Matches
           23 GMHNLL-----LLEGRSWQEMDGQ---KKHWKDKVVDLLYWRDIKKTGVVFGASL 69
Qу
                             ::|:|::| |: | ||: || : |
          411 GHHEILFSNVLAQAQAFMKGKSYEEALGELLFKGLDKDEAKDLAHHR-----VFFGNRP 464
Db
           70 FLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIAKSD----- 112
Qу
                     : | | | | |
          465 SNILLLEKISPSNIGALVALYEHKVFV----QGVIWDINSFDQWGVELGKELAVPILQE 519
Db
          113 -EGHPFRAYLESEVAISEELVQKYSN 137
Qу
                    |\cdot|: |\cdot|
                             :: |:: | |
               520 LEGHKSNAYFDSS---TKHLIELYKN 542
Db
```

```
RESULT 15
E71851
qlucose-6-phosphate isomerase - Helicobacter pylori (strain J99)
C; Species: Helicobacter pylori
A; Variety: strain J99
C; Date: 12-Feb-1999 #sequence revision 12-Feb-1999 #text change 16-Jul-1999
C; Accession: E71851
R; Alm, R.A.; Ling, L.S.L.; Moir, D.T.; King, B.L.; Brown, E.D.; Doig, P.C.;
Smith, D.R.; Noonan, B.; Guild, B.C.; deJonge, B.L.; Carmel, G.; Tummino, P.J.;
Caruso, A.; Uria-Nickelsen, M.; Mills, D.M.; Ives, C.; Gibson, R.; Merberg, D.;
Mills, S.D.; Jiang, Q.; Taylor, D.E.; Vovis, G.F.; Trust, T.J.
Nature 397, 176-180, 1999
A; Title: Genomic sequence comparison of two unrelated isolates of the human
gastric pathogen Helicobacter pylori.
A; Reference number: A71800; MUID: 99120557; PMID: 9923682
A; Accession: E71851
A; Status: preliminary
A; Molecule type: DNA
A; Residues: 1-545 <ARN>
A;Cross-references: GB:AE001536; GB:AE001439; NID:g4155675; PIDN:AAD06664.1;
PID:g4155679
A; Experimental source: strain J99
C: Genetics:
A; Gene: pgi
C; Superfamily: glucose-6-phosphate isomerase
                         10.6%; Score 74.5; DB 2; Length 545;
  Best Local Similarity 25.3%; Pred. No. 12;
                                                                            6;
 Matches
           37; Conservative 19; Mismatches
                                                 45; Indels
           23 GMHNLL-----LLEGRSWQEMDGQ---KKHWKDKVVDLLYWRDIKKTGVVFGASL 69
Qy
                             ::|:|::| |: | ||: |
                                                             1 11
              1 | : |
Db
          411 GHHEILFSNVLAQAQAFMKGKSYEEALGELLSKGLDKDEAKDLAHHR------VFFGNRP 464
           70 FLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIAKSD----- 112
Qу
                : | | | :: | : | | | | | | |
          465 SNILLLEKISPSNIGALVALYEHKVFV-----QGVIWDINSFDQWGVELGKELAVPILQE 519
Db
          113 -EGHPFRAYLESEVAISEELVQKYSN 137
Qу
                   || :|
                           : |:: | |
               520 LEGHKSNAYFDSS---TRHLIELYKN 542
Db
```

Search completed: September 29, 2004, 18:16:07

Job time : 5.45105 secs

GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 29, 2004, 18:16:15; Search time 15.1353 Seconds

(without alignments)

2997.869 Million cell updates/sec

Title: US-09-830-972-32

Perfect score: 705

Sequence: 1 QASGEAGVSCLRENFAVYSV.....ESEVAISEELVQKYSNSALG 141

Scoring table: BLOSUM62

Gapop 10.0, Gapext 0.5

Searched: 1351062 seqs, 321799191 residues

Total number of hits satisfying chosen parameters: 1351062

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0% Maximum Match 100%

Listing first 45 summaries

Database: Published Applications AA:*

1: /cgn2 6/ptodata/2/pubpaa/US07_PUBCOMB.pep:*

2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep:*

3: /cgn2_6/ptodata/2/pubpaa/US06 NEW PUB.pep:*

4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep:*

5: /cgn2 6/ptodata/2/pubpaa/US07_NEW_PUB.pep:*

6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep:*

7: /cgn2_6/ptodata/2/pubpaa/US08 NEW PUB.pep:*

8: /cgn2 6/ptodata/2/pubpaa/US08 PUBCOMB.pep:*

9: /cgn2_6/ptodata/2/pubpaa/US09A_PUBCOMB.pep:*

10: /cgn2_6/ptodata/2/pubpaa/US09B PUBCOMB.pep:*

11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep:*

12: /cgn2_6/ptodata/2/pubpaa/US09 NEW PUB.pep:*

13: /cgn2 6/ptodata/2/pubpaa/US10A PUBCOMB.pep:*

14: /cgn2 6/ptodata/2/pubpaa/US10B PUBCOMB.pep:*

15: /cgn2 6/ptodata/2/pubpaa/US10C PUBCOMB.pep:*

16: /cgn2 6/ptodata/2/pubpaa/US10 NEW PUB.pep:*

17: /cgn2 6/ptodata/2/pubpaa/US60 NEW PUB.pep:*

18: /cgn2 6/ptodata/2/pubpaa/US60 PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Q.

Result Query

1 510 72.3 199 9 US-09-893-348-21 Sequence 21, Appl 2 503 71.3 118 15 US-10-264-237-1568 Sequence 1568, Appl 3 503 71.3 199 9 US-09-893-348-25 Sequence 25, Appl 5 503 71.3 199 12 US-10-660-946-1 Sequence 1. Appli 5 503 71.3 199 12 US-09-978-360A-467 Sequence 1. Appli 6 5 503 71.3 199 12 US-10-466-258-11 Sequence 11, Appli 7 496 70.4 199 12 'US-10-408-967-9 Sequence 11, Appli 8 447 63.4 1163 9 US-09-893-348-18 Sequence 18, Appli 9 447 63.4 1192 9 US-09-789-386-2 Sequence 28, Appli 10 447 63.4 1192 9 US-09-789-386-2 Sequence 29, Appli 11 447 63.4 1192 9 US-09-972-599A-6 Sequence 23, Appli 12 447 63.4 1192 9 US-09-972-599A-6 Sequence 23, Appli 13 447 63.4 1192 12 US-10-267-502-429 Sequence 23, Appli 14 447 63.4 1192 12 US-10-267-502-429 Sequence 249, Appli 15 447 63.4 1192 16 US-10-327-213-9 Sequence 27, Appli 16 447 63.4 1192 16 US-10-466-258-9 Sequence 29, Appli 17 443 62.8 373 9 US-09-893-348-20 Sequence 20, Appli 18 443 62.8 373 9 US-09-785-205-6 Sequence 20, Appli 19 443 62.8 373 9 US-09-785-205-6 Sequence 20, Appli 22 443 62.8 373 12 US-10-408-967-8 Sequence 27, Appli 23 443 62.8 373 14 US-10-060-036-72 Sequence 27, Appli 24 443 62.8 373 14 US-10-060-036-72 Sequence 27, Appli 25 440 62.4 1192 12 US-10-466-258-4 Sequence 28, Appli 29 348 49.4 267 14 US-10-265-194-164 Sequence 4, Appli 29 348 49.4 267 12 US-10-660-946-7 Sequence 7, Appli 33 337 47.8 776 12 US-10-660-946-7 Sequence 7, Appli 34 337 47.8 776 12 US-10-660-946-6 Sequence 6, Appli 33 337 47.8 776 12 US-10-660-946-6 Sequence 6, Appli 34 337 47.8 776 12 US-10-660-946-6 Sequence 6, Appli 34 337 47.8 776 12 US-10-660-946-6 Sequence 6, Appli 34 337 47.8 776 12 US-10-660-946-6 Sequence 6, Appli 34 337 47.8 776 12 US-10-660-946-6 Sequence 6, Appli 34 337 47.8 776 12 US-10-660-946-6 Sequence 6, Appli 34 337 47.8 776 12 US-10-660-946-6 Sequence 6, Appli 34 337 47.8 776 12 US-10-660-946-6 Sequence 6, Appli 34 337 47.8 776 12 US-10-660-946-6 Sequence 93, Appl 34 338 236 9 US-09-765-205-26 Sequence 20, Appl 34 38 236 9 US-09-765-205-26 Sequence 2330, App 343.8	No.	Score	Match	Length	DB	ID	Description
2 503 71.3 118 15 US-10-264-237-1568 Sequence 1568, Ap 3 503 71.3 199 9 US-09-893-348-25 Sequence 25, Appl 4 503 71.3 199 12 US-10-660-946-1 Sequence 1, Appli 5 503 71.3 199 12 US-10-466-258-11 Sequence 11, Appl 6 503 71.3 199 16 US-10-466-258-11 Sequence 467, App 7 496 70.4 199 12 US-10-408-967-9 Sequence 9, Appli 8 447 63.4 1163 9 US-09-893-348-18 Sequence 18, Appl 9 447 63.4 1192 9 US-09-789-386-2 Sequence 2, Appli 10 447 63.4 1192 9 US-09-789-386-2 Sequence 6, Appli 11 447 63.4 1192 9 US-09-972-599A-6 Sequence 6, Appli 12 447 63.4 1192 12 US-10-406-258-4 Sequence 23, Appl 13 447 63.4 1192 12 US-10-600-036-71 Sequence 6, Appli 14 447 63.4 1192 14 US-10-060-036-71 Sequence 9, Appli 15 447 63.4 1192 16 US-10-327-213-9 Sequence 9, Appli 16 447 63.4 1192 16 US-10-327-213-9 Sequence 9, Appli 17 443 62.8 373 9 US-09-893-348-20 Sequence 20, Appl 18 443 62.8 373 9 US-09-893-348-20 Sequence 20, Appl 19 443 62.8 373 9 US-09-893-348-20 Sequence 20, Appl 19 443 62.8 373 9 US-09-893-348-24 Sequence 24, Appl 22 443 62.8 373 12 US-10-408-967-8 Sequence 6, Appli 22 443 62.8 373 12 US-10-408-967-8 Sequence 7, Appli 22 443 62.8 373 14 US-10-060-036-72 Sequence 7, Appli 23 443 62.8 373 14 US-10-060-036-72 Sequence 7, Appli 24 443 62.8 373 14 US-10-060-036-72 Sequence 7, Appli 25 440 62.4 1192 12 US-10-408-967-8 Sequence 7, Appli 26 436.5 61.9 1163 12 US-10-267-502-431 Sequence 7, Appli 28 348 49.4 267 14 US-10-205-194-164 Sequence 164, App 33 337 47.8 356 12 US-10-660-946-8 Sequence 7, Appli 31 337 47.8 766 12 US-10-267-502-430 Sequence 432, App 343 337 47.8 776 12 US-10-267-502-430 Sequence 20, Appl 33 337 47.8 776 12 US-10-267-502-430 Sequence 20, Appl 34 38 236 9 US-09-725-205-26 Sequence 20, Appl 35 309 43.8 236 9 US-09-725-02-432 Sequence 20, Appl 36 309 43.8 236 9 US-09-725-02-432 Sequence 20, Appl 36 309 43.8 236 12 US-10-267-502-432 Sequence 20, Appl 37 309 43.8 236 12 US-10-267-502-432 Sequence 22, Appl 37 309 43.8 236 12 US-10-267-502-432 Sequence 22, Appl 38 309 43.8 236 12 US-10-267-502-430 Sequence 22, Appl 38 309	1	510	72.3	199	9	US-09-893-348-21	Sequence 21, Appl
3 503 71.3 199 9 US-09-893-348-25 Sequence 25, Appl 4 503 71.3 199 12 US-10-660-946-1 Sequence 1, Appli 5 503 71.3 199 12 US-09-978-360A-467 Sequence 467, Apple 6 503 71.3 199 16 US-10-466-258-11 Sequence 9, Appli 8 447 63.4 1192 9 US-09-893-348-18 Sequence 9, Appli 9 447 63.4 1192 9 US-09-893-348-18 Sequence 2, Appli 10 447 63.4 1192 9 US-09-893-348-2 Sequence 2, Appli 11 447 63.4 1192 9 US-09-893-348-23 Sequence 6, Appli 12 447 63.4 1192 9 US-09-893-348-23 Sequence 6, Appli 12 447 63.4 1192 9 US-09-893-348-23 Sequence 6, Appli 13 447 63.4 1192 12 US-10-267-502-429 Sequence 6, Appli 14 447 63.4 1192 14 US-10-060-036-71 Sequence 6, Appli 15 447 63.4 1192 16 US-10-327-213-9 Sequence 9, Appli 16 447 63.4 1192 16 US-10-466-258-9 Sequence 9, Appli 17 443 62.8 360 9 US-09-893-348-20 Sequence 9, Appli 18 443 62.8 373 9 US-09-893-348-20 Sequence 20, Appl 18 443 62.8 373 9 US-09-893-348-24 Sequence 6, Appli 20 443 62.8 373 12 US-10-060-036-72 Sequence 6, Appli 22 443 62.8 373 12 US-10-060-036-72 Sequence 6, Appli 22 443 62.8 373 12 US-10-408-967-8 Sequence 6, Appli 24 43 62.8 373 12 US-10-408-967-8 Sequence 7, Appli 25 440 62.4 1192 12 US-10-600-036-72 Sequence 7, Appli 26 436.5 61.9 1163 12 US-10-267-502-431 Sequence 7, Appli 28 348 49.4 267 12 US-10-660-946-7 Sequence 8, Appli 29 348 49.4 267 12 US-10-660-946-7 Sequence 7, Appli 29 348 49.4 267 12 US-10-660-946-6 Sequence 8, Appli 33 337 47.8 776 12 US-10-660-946-6 Sequence 8, Appli 32 337 47.8 776 12 US-10-660-946-5 Sequence 5, Appli 33 337 47.8 776 12 US-10-660-946-5 Sequence 5, Appli 33 337 47.8 776 12 US-10-660-946-5 Sequence 5, Appli 34 337 47.8 776 12 US-10-267-502-432 Sequence 5, Appli 34 337 47.8 776 12 US-10-267-502-432 Sequence 5, Appli 34 337 47.8 776 12 US-10-267-502-432 Sequence 5, Appli 34 337 47.8 776 12 US-10-267-502-432 Sequence 5, Appli 34 337 47.8 776 12 US-10-267-502-432 Sequence 5, Appli 34 337 47.8 776 12 US-10-267-502-432 Sequence 5, Appli 34 337 47.8 776 12 US-10-267-502-432 Sequence 6, Appli 34 38 236 9 US-09-729-674-20 Sequence 20, Appl 35 3				118	15	US-10-264-237-1568	Sequence 1568, Ap
4 503 71.3 199 12 US-10-660-946-1 Sequence 1, Appli 5 503 71.3 199 12 US-09-978-360A-467 Sequence 467, App 6 503 71.3 199 16 US-10-466-258-11 Sequence 11, Appl 7 496 70.4 199 12 US-10-408-967-9 Sequence 9, Appli 8 447 63.4 1163 9 US-09-893-348-18 Sequence 18, Appl 10 447 63.4 1192 9 US-09-789-386-2 Sequence 2, Appli 11 447 63.4 1192 9 US-09-789-386-2 Sequence 2, Appli 11 447 63.4 1192 9 US-09-789-384-23 Sequence 6, Appli 11 447 63.4 1192 9 US-09-893-348-23 Sequence 6, Appli 12 447 63.4 1192 12 US-10-267-502-429 Sequence 6, Appli 13 447 63.4 1192 12 US-10-267-502-429 Sequence 6, Appli 14 447 63.4 1192 14 US-10-060-036-71 Sequence 6, Appli 15 447 63.4 1192 16 US-10-327-213-9 Sequence 9, Appli 16 447 63.4 1192 16 US-10-466-258-9 Sequence 9, Appli 17 443 62.8 360 9 US-09-789-386-6 Sequence 9, Appli 18 443 62.8 373 9 US-09-789-386-6 Sequence 6, Appli 20 443 62.8 373 9 US-09-789-386-6 Sequence 6, Appli 22 443 62.8 373 12 US-10-408-967-8 Sequence 6, Appli 22 443 62.8 373 12 US-10-408-967-8 Sequence 7, Appli 23 443 62.8 373 14 US-10-060-036-72 Sequence 7, Appli 24 443 62.8 373 14 US-10-060-036-72 Sequence 7, Appli 25 440 62.4 1192 12 US-10-408-967-7 Sequence 7, Appli 26 436.5 61.9 1163 12 US-10-408-967-7 Sequence 7, Appli 29 348 49.4 267 12 US-10-660-946-7 Sequence 7, Appli 33 337 47.8 776 12 US-10-660-946-7 Sequence 7, Appli 32 337 47.8 776 12 US-10-660-946-5 Sequence 8, Appli 33 337 47.8 776 12 US-10-660-946-5 Sequence 7, Appli 33 337 47.8 776 12 US-10-660-946-5 Sequence 7, Appli 34 337 47.8 776 12 US-10-660-946-5 Sequence 7, Appli 34 337 47.8 776 12 US-10-267-502-430 Sequence 430, App 343.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 9 US-09-765-205-26 Sequence 20, Appl 38 309 43.8 236 12 US-10-267-502-432 Sequence 20, Appl 38 309 43.8 236 12 US-10-267-502-432 Sequence 21, Appl 38 309 43.8 236 12 US-10-267-502-432 Sequence 22, Appl 38 309 43.8 236 12 US-10-267-502-432 Sequence 23, Appl 38 309 43.8 236 12 US-10-267-502-432 Sequence 24, Appl 38 309 43.8				199	9	US-09-893-348-25	Sequence 25, Appl
6 503 71.3 199 16 US-10-466-258-11 Sequence 11, Appl 7 496 70.4 199 12 US-10-408-967-9 Sequence 9, Appli 8 447 63.4 1163 9 US-09-893-348-18 Sequence 18, Appl 9 447 63.4 1192 9 US-09-789-386-2 Sequence 2, Appli 10 447 63.4 1192 9 US-09-789-386-2 Sequence 6, Appli 11 447 63.4 1192 9 US-09-789-348-23 Sequence 6, Appli 12 447 63.4 1192 9 US-09-789-348-23 Sequence 6, Appli 13 447 63.4 1192 12 US-10-267-502-429 Sequence 6, Appli 13 447 63.4 1192 12 US-10-267-502-429 Sequence 71, Appl 15 447 63.4 1192 16 US-10-327-213-9 Sequence 71, Appl 16 447 63.4 1192 16 US-10-327-213-9 Sequence 9, Appli 17 443 62.8 360 9 US-09-893-348-20 Sequence 9, Appli 18 443 62.8 373 9 US-09-893-348-20 Sequence 9, Appli 19 443 62.8 373 9 US-09-789-386-6 Sequence 6, Appli 20 443 62.8 373 9 US-09-789-348-20 Sequence 6, Appli 22 443 62.8 373 12 US-10-406-258-9 Sequence 6, Appli 22 443 62.8 373 12 US-10-408-967-8 Sequence 6, Appli 24 443 62.8 373 12 US-10-408-967-8 Sequence 6, Appli 24 443 62.8 373 14 US-10-060-036-72 Sequence 72, Appl 25 440 62.4 1192 12 US-10-466-258-4 Sequence 74, Appl 26 436.5 61.9 1163 12 US-10-408-967-7 Sequence 75, Appli 27 349 49.5 208 12 US-10-660-946-7 Sequence 75, Appli 28 348 49.4 267 12 US-10-660-946-7 Sequence 75, Appli 31 337 47.8 776 12 US-10-660-946-6 Sequence 75, Appli 31 337 47.8 776 12 US-10-660-946-5 Sequence 75, Appli 32 337 47.8 776 12 US-10-660-946-6 Sequence 75, Appli 33 337 47.8 776 12 US-10-660-946-5 Sequence 75, Appli 34 337 47.8 776 12 US-10-660-946-6 Sequence 75, Appli 34 337 47.8 776 12 US-10-660-946-6 Sequence 75, Appli 34 337 47.8 776 12 US-10-267-502-430 Sequence 75, Appli 34 337 47.8 776 12 US-10-267-502-430 Sequence 75, Appli 34 337 47.8 776 12 US-10-267-502-430 Sequence 75, Appli 36 309 43.8 236 12 US-10-267-502-432 Sequence 20, Appli 36 309 43.8 236 12 US-10-408-967-2 Sequence 20, Appli 38 309 43.8 236 12 US-10-408-967-2 Sequence 20, Appli 38 309 43.8 236 12 US-10-408-967-2 Sequence 20, Appli 38 309 43.8 236 12 US-10-408-967-2 Sequence 20, Appli 38 309 43.8 236 12 US-10-408-967-2		503	71.3	199	12	US-10-660-946-1	
7 496 70.4 199 12 · US-10-408-967-9 Sequence 9, Appli 8 447 63.4 1163 9 US-09-893-348-18 Sequence 18, Appl 10 447 63.4 1192 9 US-09-758-140-6 Sequence 2, Appli 11 447 63.4 1192 9 US-09-758-140-6 Sequence 6, Appli 11 447 63.4 1192 9 US-09-9758-140-6 Sequence 23, Appl 12 447 63.4 1192 9 US-09-973-599A-6 Sequence 23, Appl 12 447 63.4 1192 12 US-10-267-502-429 Sequence 429, Appl 13 447 63.4 1192 12 US-10-267-502-429 Sequence 429, Appl 14 447 63.4 1192 16 US-10-327-213-9 Sequence 71, Appl 15 447 63.4 1192 16 US-10-466-258-9 Sequence 9, Appli 17 443 62.8 360 9 US-09-893-348-20 Sequence 9, Appli 18 443 62.8 373 9 US-09-789-386-6 Sequence 6, Appli 19 443 62.8 373 9 US-09-789-386-6 Sequence 6, Appli 20 443 62.8 373 9 US-09-893-348-24 Sequence 6, Appli 21 443 62.8 373 12 US-10-408-967-8 Sequence 6, Appli 22 443 62.8 373 12 US-10-408-967-8 Sequence 72, Appl 23 443 62.8 373 14 US-10-060-036-72 Sequence 72, Appl 24 443 62.8 373 14 US-10-266-258-4 Sequence 72, Appl 25 440 62.4 1192 12 US-10-466-258-4 Sequence 73, Appl 26 436.5 61.9 1163 12 US-10-408-967-7 Sequence 74, Appl 27 349 49.5 208 12 US-10-660-946-7 Sequence 75, Appli 28 348 49.4 267 12 US-10-660-946-7 Sequence 76, Appli 29 348 49.4 267 12 US-10-660-946-7 Sequence 77, Appli 29 348 49.4 267 12 US-10-660-946-7 Sequence 8, Appli 31 337 47.8 776 12 US-10-660-946-5 Sequence 8, Appli 32 337 47.8 776 12 US-10-660-946-5 Sequence 6, Appli 33 337 47.8 776 12 US-10-660-946-5 Sequence 75, Appli 34 337 47.8 776 12 US-10-660-946-5 Sequence 6, Appli 34 337 47.8 776 12 US-10-660-946-5 Sequence 6, Appli 34 337 47.8 776 12 US-10-267-502-430 Sequence 6, Appli 36 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 37 309 43.8 236 12 US-10-408-967-2 Sequence 26, Appl 38 309 43.8 236 12 US-10-408-967-2 Sequence 26, Appl 38 309 43.8 236 12 US-10-408-967-2 Sequence 26, Appl 39 309 43.8 236 12 US-10-408-967-2 Sequence 26, Appl 39 309 43.8 236 12 US-10-408-967-2 Sequence 26, Appl 39 309 43.8 236 12 US-10-408-967-2 Sequence 26, Appl 39 309 43.	5	503	71.3	199	12	US-09-978-360A-467	-
8 447 63.4 1163 9 US-09-893-348-18 Sequence 18, Appl 9 447 63.4 1192 9 US-09-789-386-2 Sequence 2, Appli 10 447 63.4 1192 9 US-09-789-386-2 Sequence 2, Appli 11 447 63.4 1192 9 US-09-893-348-23 Sequence 23, Appl 12 447 63.4 1192 9 US-09-893-348-23 Sequence 6, Appli 13 447 63.4 1192 12 US-10-267-502-429 Sequence 6, Appli 14 447 63.4 1192 12 US-10-267-502-429 Sequence 71, Appl 15 447 63.4 1192 16 US-10-327-213-9 Sequence 9, Appli 16 447 63.4 1192 16 US-10-327-213-9 Sequence 9, Appli 17 443 62.8 360 9 US-09-893-348-20 Sequence 9, Appli 18 443 62.8 373 9 US-09-893-348-20 Sequence 20, Appl 18 443 62.8 373 9 US-09-789-386-6 Sequence 6, Appli 20 443 62.8 373 9 US-09-789-348-24 Sequence 6, Appli 22 443 62.8 373 12 US-10-406-258-9 Sequence 6, Appli 22 443 62.8 373 12 US-10-406-258-4 Sequence 8, Appli 24 443 62.8 373 12 US-10-406-258-4 Sequence 8, Appli 24 443 62.8 373 14 US-10-060-036-72 Sequence 9, Appli 25 440 62.4 1192 12 US-10-408-967-7 Sequence 72, Appl 26 436.5 61.9 1163 12 US-10-205-194-164 Sequence 164, App 27 349 49.5 208 12 US-10-660-946-7 Sequence 7, Appli 28 348 49.4 267 14 US-10-205-194-127 Sequence 7, Appli 29 348 49.4 267 14 US-10-205-194-127 Sequence 7, Appli 31 337 47.8 776 12 US-10-660-946-6 Sequence 8, Appli 32 337 47.8 776 12 US-10-660-946-6 Sequence 6, Appli 33 337 47.8 776 12 US-10-660-946-6 Sequence 7, Appli 34 337 47.8 776 12 US-10-660-946-6 Sequence 6, Appli 34 337 47.8 776 12 US-10-660-946-6 Sequence 9, Appli 34 337 47.8 776 12 US-10-660-946-6 Sequence 6, Appli 34 337 47.8 776 12 US-10-205-194-127 Sequence 5, Appli 34 337 47.8 776 12 US-10-205-194-127 Sequence 6, Appli 34 337 47.8 776 12 US-10-267-502-430 Sequence 9, Appli 34 337 47.8 776 12 US-10-267-502-430 Sequence 9, Appli 34 337 47.8 776 12 US-10-267-502-430 Sequence 430, App 343.8 236 9 US-09-729-674-20 Sequence 20, Appl 343.8 236 9 US-09-729-674-20 Sequence 20, Appl 343.8 236 12 US-10-408-967-2 Sequence 20, Appl 343.8 236 12 US-10-408-967-2 Sequence 23, App 343.8 236 12 US-10-408-967-2 Sequence 23, App 343.8 236 12 US-10-408-967-2 Sequen	6	503	71.3	199	16	US-10-466-258-11	
9 447 63.4 1192 9 US-09-789-386-2 Sequence 2, Appli 10 447 63.4 1192 9 US-09-758-140-6 Sequence 6, Appli 11 447 63.4 1192 9 US-09-893-348-23 Sequence 23, Appl 12 447 63.4 1192 12 US-10-267-502-429 Sequence 429, Appl 13 447 63.4 1192 12 US-10-267-502-429 Sequence 429, Appl 14 447 63.4 1192 14 US-10-060-036-71 Sequence 71, Appl 15 447 63.4 1192 16 US-10-327-213-9 Sequence 9, Appli 16 447 63.4 1192 16 US-10-466-258-9 Sequence 9, Appli 17 443 62.8 360 9 US-09-893-348-20 Sequence 20, Appl 18 443 62.8 373 9 US-09-893-348-20 Sequence 6, Appli 19 443 62.8 373 9 US-09-893-348-20 Sequence 6, Appli 20 443 62.8 373 9 US-09-893-348-24 Sequence 6, Appli 21 443 62.8 373 12 US-10-408-967-8 Sequence 24, Appl 22 443 62.8 373 12 US-10-408-967-8 Sequence 8, Appli 22 443 62.8 373 14 US-10-060-036-72 Sequence 72, Appl 23 443 62.8 373 14 US-10-060-036-72 Sequence 72, Appl 24 443 62.8 373 16 US-10-466-258-4 Sequence 6, Appli 24 443 62.8 373 16 US-10-466-258-4 Sequence 6, Appli 25 440 62.4 1192 12 US-10-408-967-7 Sequence 164, Appl 25 440 62.4 1192 12 US-10-660-946-7 Sequence 164, Appl 26 436.5 61.9 1163 12 US-10-660-946-7 Sequence 431, App 27 349 49.5 208 12 US-10-660-946-8 Sequence 431, App 348 49.4 267 14 US-10-205-194-127 Sequence 7, Appli 36 337 47.8 356 12 US-10-660-946-6 Sequence 6, Appli 31 337 47.8 356 12 US-10-660-946-6 Sequence 6, Appli 32 337 47.8 776 12 US-10-660-946-6 Sequence 6, Appli 33 337 47.8 776 12 US-10-267-502-430 Sequence 6, Appli 34 337 47.8 776 12 US-10-267-502-430 Sequence 93, Appl 34 337 47.8 776 12 US-10-267-502-430 Sequence 93, Appl 34 337 47.8 776 12 US-10-267-502-430 Sequence 93, Appl 34 337 47.8 776 12 US-10-267-502-430 Sequence 93, Appl 34 337 47.8 776 12 US-10-267-502-430 Sequence 93, Appl 35 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 38 236 12 US-10-276-774-2330 Sequence 2330, App	7						
10 447 63.4 1192 9 US-09-758-140-6 Sequence 6, Appli 11 447 63.4 1192 9 US-09-893-348-23 Sequence 23, Appl 12 447 63.4 1192 9 US-09-972-599A-6 Sequence 6, Appli 13 447 63.4 1192 12 US-10-267-502-429 Sequence 429, App 14 447 63.4 1192 14 US-10-060-036-71 Sequence 71, Appl 15 447 63.4 1192 16 US-10-327-213-9 Sequence 9, Appli 16 447 63.4 1192 16 US-10-327-213-9 Sequence 9, Appli 17 443 62.8 360 9 US-09-893-348-20 Sequence 20, Appl 18 443 62.8 373 9 US-09-789-386-6 Sequence 20, Appli 20 443 62.8 373 9 US-09-789-348-24 Sequence 6, Appli 21 443 62.8 373 9 US-09-893-348-24 Sequence 24, Appli 22 443 62.8 373 12 US-10-408-967-8 Sequence 24, Appli 22 443 62.8 373 12 US-10-408-967-8 Sequence 72, Appli 23 443 62.8 373 14 US-10-060-036-72 Sequence 72, Appli 24 443 62.8 373 16 US-10-468-258-4 Sequence 4, Appli 25 440 62.4 1192 12 US-10-408-967-7 Sequence 7, Appli 26 436.5 61.9 1163 12 US-10-267-502-431 Sequence 7, Appli 29 348 49.4 267 12 US-10-660-946-8 Sequence 7, Appli 33 337 47.8 356 12 US-10-660-946-6 Sequence 8, Appli 31 337 47.8 356 12 US-10-660-946-6 Sequence 6, Appli 32 337 47.8 776 12 US-10-660-946-6 Sequence 6, Appli 33 337 47.8 776 12 US-10-267-502-430 Sequence 73, Appli 34 337 47.8 776 12 US-10-267-502-430 Sequence 73, Appli 34 337 47.8 776 12 US-10-267-502-430 Sequence 6, Appli 34 337 47.8 776 12 US-10-267-502-430 Sequence 93, Appl 34 337 47.8 776 12 US-10-267-502-430 Sequence 93, Appl 34 337 47.8 776 12 US-10-267-502-430 Sequence 93, Appl 34 337 47.8 776 12 US-10-267-502-430 Sequence 93, Appl 34 337 47.8 776 12 US-10-267-502-430 Sequence 93, Appl 34 337 47.8 776 12 US-10-267-502-430 Sequence 93, Appl 34 337 47.8 776 12 US-10-267-502-430 Sequence 93, Appl 35 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 38 236 12 US-10-276-774-2330 Sequence 22, Appl 38 309 43.8 236 12 US-10-276-774-2330 Sequence 2330, App							-
11 447 63.4 1192 9 US-09-893-348-23 Sequence 23, Appl 12 447 63.4 1192 12 US-10-267-502-429 Sequence 6, Appli 13 447 63.4 1192 12 US-10-660-946-5 Sequence 71, Appl 15 447 63.4 1192 16 US-10-327-213-9 Sequence 9, Appli 16 447 63.4 1192 16 US-10-466-258-9 Sequence 9, Appli 17 443 62.8 360 9 US-09-893-348-20 Sequence 20, Appl 18 443 62.8 373 9 US-09-789-386-6 Sequence 6, Appli 19 443 62.8 373 9 US-09-789-386-6 Sequence 6, Appli 20 443 62.8 373 9 US-09-789-384-24 Sequence 24, Appl 21 443 62.8 373 12 US-10-408-967-8 Sequence 8, Appli 22 443 62.8 373 14 US-10-600-036-72 Sequence 72, Appl 23 443 62.8 373 16 US-10-468-258-4 Sequence 72, Appl 24 443 62.8 373 16 US-10-468-258-4 Sequence 72, Appl 24 443 62.8 373 16 US-10-408-967-7 Sequence 73, Appli 24 443 62.8 373 16 US-10-408-967-7 Sequence 74, Appli 25 440 62.4 1192 12 US-10-408-967-7 Sequence 75, Appli 26 436.5 61.9 1163 12 US-10-600-946-7 Sequence 77, Appli 28 348 49.4 267 12 US-10-660-946-7 Sequence 77, Appli 29 348 49.4 267 12 US-10-660-946-6 Sequence 8, Appli 31 337 47.8 356 12 US-10-660-946-6 Sequence 77, Appli 32 337 47.8 776 12 US-10-660-946-6 Sequence 6, Appli 33 337 47.8 776 12 US-10-660-946-6 Sequence 77, Appli 34 337 47.8 776 12 US-10-267-502-430 Sequence 77, Appli 34 337 47.8 776 12 US-10-267-502-430 Sequence 77, Appli 36 309 43.8 236 9 US-09-765-205-26 Sequence 430, App 36 309 43.8 236 9 US-09-765-205-26 Sequence 26, Appli 37 309 43.8 236 9 US-09-765-205-26 Sequence 27, Appli 38 309 43.8 236 12 US-10-408-967-2 Sequence 27, Appli 39 309 43.8 236 12 US-10-408-967-2 Sequence 28, Appli 39 309 43.8 236 12 US-10-408-967-2 Sequence 26, Appli 39 309 43.8 236 12 US-10-408-967-2 Sequence 27, Appli 39 309 43.8 236 12 US-10-408-967-2 Sequence 28, Appli 39 309 43.8 236 12 US-10-276-774-2330 Sequence 27, Appli 39 309 43.8 236 12 US-10-408-967-2 Sequence 28, Appli 39 309 43.8 236 12 US-10-408-967-2 Sequence 27, Appli 39 309 43.8 236 12 US-10-408-967-2 Sequence 28, Appli 39 309 43.8 236 12 US-10-276-774-2330 Sequence 28, Appli 39 309 43.8 236 12 US-10-276-774-2330 Sequen							
12 447 63.4 1192 9 US-09-972-599A-6 13 447 63.4 1192 12 US-10-267-502-429 14 447 63.4 1192 14 US-10-060-036-71 15 447 63.4 1192 16 US-10-327-213-9 16 447 63.4 1192 16 US-10-466-258-9 17 443 62.8 360 9 US-09-893-348-20 18 443 62.8 373 9 US-09-789-386-6 19 443 62.8 373 9 US-09-785-205-6 20 443 62.8 373 12 US-10-408-967-8 21 443 62.8 373 12 US-10-408-967-8 22 443 62.8 373 12 US-10-408-967-8 23 443 62.8 373 14 US-10-060-036-72 24 443 62.8 373 16 US-10-466-258-4 24 443 62.8 373 16 US-10-408-967-8 25 440 62.4 1192 12 US-10-408-967-7 26 436.5 61.9 1163 12 US-10-408-967-7 27 349 49.5 208 12 US-10-60-946-7 28 348 49.4 267 12 US-10-60-946-8 29 348 49.4 267 12 US-10-60-946-8 348 49.4 267 12 US-10-60-946-8 349 337 47.8 776 12 US-10-60-946-6 340 337 347.8 776 12 US-10-267-502-430 347 337 47.8 776 12 US-10-267-502-430 348 337 47.8 776 12 US-10-267-502-430 349 49.8 236 9 US-09-765-205-26 340 43.8 236 12 US-10-408-967-2 340 43.8 236 9 US-09-765-205-26 340 43.8 236 12 US-10-408-967-2 340 43.8 236 12 US-10-408-967-2 340 43.8 236 12 US-10-267-502-432 340 43.8 236 12 US-10-408-967-2 340 43.8 236 12 US-10-267-502-432 340 43.8 236 12 US-10-267-502-432 340 43.8 236 12 US-10-267-502-432 340 43.8 236 12 US-10-408-967-2 340 43.8 236 12 US-10-276-774-2330 340 43.8 236 12 US-10-276-774-2330 340 43.8 236 12 US-10-276-774-2330							
13 447 63.4 1192 12 US-10-267-502-429 Sequence 429, App 14 447 63.4 1192 14 US-10-060-036-71 Sequence 71, Appl 15 447 63.4 1192 16 US-10-327-213-9 Sequence 9, Appli 16 447 63.4 1192 16 US-10-466-258-9 Sequence 9, Appli 17 443 62.8 360 9 US-09-893-348-20 Sequence 20, Appl 18 443 62.8 373 9 US-09-789-386-6 Sequence 6, Appli 20 443 62.8 373 9 US-09-893-348-24 Sequence 24, Appl 21 443 62.8 373 12 US-10-408-967-8 Sequence 24, Appl 22 443 62.8 373 12 US-10-408-967-8 Sequence 72, Appl 23 443 62.8 373 14 US-10-060-036-72 Sequence 72, Appl 23 443 62.8 373 16 US-10-466-258-4 Sequence 72, Appl 24 443 62.8 373 16 US-10-466-258-4 Sequence 72, Appl 25 440 62.4 1192 12 US-10-408-967-7 Sequence 73, Appl 26 436.5 61.9 1163 12 US-10-408-967-7 Sequence 74, Appli 26 436.5 61.9 1163 12 US-10-660-946-7 Sequence 75, Appli 29 348 49.4 267 12 US-10-660-946-7 Sequence 77, Appli 29 348 49.4 267 12 US-10-660-946-8 Sequence 8, Appli 33 337 47.8 776 12 US-10-660-946-6 Sequence 75, Appli 31 337 47.8 776 12 US-10-660-946-5 Sequence 75, Appli 32 337 47.8 776 12 US-10-660-946-5 Sequence 75, Appli 34 337 47.8 776 12 US-10-660-946-5 Sequence 75, Appli 36 309 43.8 236 9 US-09-765-205-26 Sequence 20, Appl 36 309 43.8 236 9 US-09-765-205-26 Sequence 20, Appl 37 309 43.8 236 12 US-10-408-967-2 Sequence 20, Appl 38 309 43.8 236 12 US-10-408-967-2 Sequence 20, Appl 36 309 43.8 236 12 US-10-408-967-2 Sequence 20, Appl 37 309 43.8 236 12 US-10-408-967-2 Sequence 20, Appl 38 309 43.8 236 12 US-10-408-967-2 Sequence 20, Appl 39 309 43.8 236 12 US-10-408-967-2 Sequence 20, Appl 39 309 43.8 236 12 US-10-408-967-2 Sequence 20, Appl 39 309 43.8 236 12 US-10-408-967-2 Sequence 20, Appl 39 309 43.8 236 12 US-10-408-967-2 Sequence 2330, Appl 309 43.8 236 12							
14 447 63.4 1192 14 US-10-060-036-71 Sequence 71, Appl 15 447 63.4 1192 16 US-10-327-213-9 Sequence 9, Appli 16 447 63.4 1192 16 US-10-466-258-9 Sequence 9, Appli 17 443 62.8 360 9 US-09-893-348-20 Sequence 20, Appl 18 443 62.8 373 9 US-09-789-386-6 Sequence 6, Appli 19 443 62.8 373 9 US-09-789-386-6 Sequence 6, Appli 20 443 62.8 373 9 US-09-893-348-24 Sequence 24, Appl 21 443 62.8 373 12 US-10-408-967-8 Sequence 24, Appl 22 443 62.8 373 14 US-10-060-036-72 Sequence 72, Appl 23 443 62.8 373 14 US-10-060-036-72 Sequence 72, Appl 24 443 62.8 379 14 US-10-205-194-164 Sequence 72, Appl 25 440 62.4 1192 12 US-10-408-967-7 Sequence 74, Appli 26 436.5 61.9 1163 12 US-10-267-502-431 Sequence 75, Appli 28 348 49.4 267 12 US-10-660-946-7 Sequence 77, Appli 29 348 49.4 267 12 US-10-660-946-7 Sequence 77, Appli 31 337 47.8 356 12 US-10-660-946-6 Sequence 8, Appli 31 337 47.8 776 12 US-10-660-946-6 Sequence 6, Appli 32 337 47.8 776 12 US-10-660-946-5 Sequence 5, Appli 32 337 47.8 776 12 US-10-267-502-430 Sequence 5, Appli 32 337 47.8 776 12 US-10-267-502-430 Sequence 5, Appli 32 337 47.8 776 12 US-10-267-502-430 Sequence 6, Appli 32 337 47.8 776 12 US-10-267-502-430 Sequence 7, Appli 34 337 47.8 776 12 US-10-267-502-430 Sequence 6, Appli 36 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 37 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 37 309 43.8 236 12 US-10-408-967-2 Sequence 20, Appl 38 309 43.8 236 12 US-10-408-967-2 Sequence 20, Appl 37 309 43.8 236 12 US-10-408-967-2 Sequence 20, Appl 38 309 43.8 236 12 US-10-276-774-2330 Sequence 20, Appl 38 309 43.8 236 12 US-10-276-774-2330 Sequence 20, Appl 38 309 43.8 236 12 US-10-276-774-2330 Sequence 2330, Ap							
15 447 63.4 1192 16 US-10-327-213-9 Sequence 9, Appli 16 447 63.4 1192 16 US-10-466-258-9 Sequence 9, Appli 17 443 62.8 360 9 US-09-893-348-20 Sequence 20, Appl 18 443 62.8 373 9 US-09-789-386-6 Sequence 6, Appli 20 443 62.8 373 9 US-09-789-384-24 Sequence 6, Appli 21 443 62.8 373 9 US-09-893-348-24 Sequence 24, Appl 21 443 62.8 373 12 US-10-408-967-8 Sequence 24, Appl 22 443 62.8 373 14 US-10-060-036-72 Sequence 72, Appl 23 443 62.8 373 14 US-10-060-036-72 Sequence 72, Appl 24 443 62.8 379 14 US-10-205-194-164 Sequence 4, Appli 25 440 62.4 1192 12 US-10-408-967-7 Sequence 7, Appli 26 436.5 61.9 1163 12 US-10-267-502-431 Sequence 7, Appli 28 348 49.4 267 12 US-10-660-946-7 Sequence 7, Appli 39 337 47.8 356 12 US-10-660-946-6 Sequence 8, Appli 31 337 47.8 356 12 US-10-660-946-5 Sequence 6, Appli 32 337 47.8 776 12 US-10-660-946-5 Sequence 7, Appli 32 337 47.8 776 12 US-10-660-946-5 Sequence 7, Appli 34 337 47.8 776 12 US-10-267-502-430 Sequence 6, Appli 36 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 12 US-10-408-967-2 Sequence 20, Appl 37 309 43.8 236 12 US-10-408-967-2 Sequence 20, Appl 38 309 43.8 236 12 US-10-276-774-2330 Sequence 20, Appl 38 309 43.8 236 12 US-10-276-774-2330 Sequence 20, Appl 36 309 43.8 236 9 US-09-765-205-26 Sequence 20, Appl 36 309 43.8 236 12 US-10-276-774-2330 Sequence 20, Appl 37 309 43.8 236 12 US-10-276-774-2330 Sequence 20, Appl 38 309 43.8 236 12 US-10-276-774-2330 Sequence 20, Appl 38 309 43.8 236 12 US-10-276-774-2330 Sequence 20, Appl 38 309 43.8 236 12 US-10-276-774-2330 Sequence 20, Appl 38 309 43.8 236 12 US-10-276-774-2330							=
16 447 63.4 1192 16 US-10-466-258-9 Sequence 9, Appli 17 443 62.8 360 9 US-09-893-348-20 Sequence 20, Appl 18 443 62.8 373 9 US-09-789-386-6 Sequence 6, Appli 19 443 62.8 373 9 US-09-893-348-24 Sequence 6, Appli 20 443 62.8 373 12 US-10-408-967-8 Sequence 24, Appl 21 443 62.8 373 12 US-10-408-967-8 Sequence 8, Appli 22 443 62.8 373 14 US-10-466-258-4 Sequence 72, Appl 23 443 62.8 373 14 US-10-205-194-164 Sequence 164, App 24 443 62.8 379 14 US-10-267-502-431 Sequence 7, Appli 25 440 62.4 1192 12 US-10-660-946-7 Sequence 431, App 27 349 49.5 208 12 US-10-660-946-8 Sequence 8, Appli 28 348 49.4 267 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
17 443 62.8 360 9 US-09-893-348-20 Sequence 20, Appl 18 443 62.8 373 9 US-09-789-386-6 Sequence 6, Appli 19 443 62.8 373 9 US-09-765-205-6 Sequence 6, Appli 20 443 62.8 373 9 US-09-893-348-24 Sequence 24, Appl 21 443 62.8 373 12 US-10-408-967-8 Sequence 8, Appli 22 443 62.8 373 14 US-10-060-036-72 Sequence 72, Appl 23 443 62.8 373 16 US-10-466-258-4 Sequence 72, Appl 24 443 62.8 379 14 US-10-205-194-164 Sequence 164, App 25 440 62.4 1192 12 US-10-408-967-7 Sequence 7, Appli 26 436.5 61.9 1163 12 US-10-660-946-7 Sequence 7, Appli 28 348 49.4 267 12 US-10-660-946-8 Sequence 8, Appli 29 348 49.4 267 14 US-10-205-194-127 Sequence 7, Appli 31 337 47.8 356 12 US-10-660-946-6 Sequence 8, Appli 32 337 47.8 376 12 US-10-660-946-5 Sequence 6, Appli 32 337 47.8 776 12 US-10-660-946-5 Sequence 6, Appli 33 337 47.8 776 12 US-10-660-946-5 Sequence 7, Appli 34 38 37 47.8 776 12 US-10-267-502-430 Sequence 7, Appli 36 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 37 309 43.8 236 12 US-10-408-967-2 Sequence 20, Appl 38 309 43.8 236 12 US-10-408-967-2 Sequence 20, Appl 38 309 43.8 236 12 US-10-267-502-432 Sequence 20, Appl 37 309 43.8 236 12 US-10-408-967-2 Sequence 20, Appl 38 309 43.8 236 12 US-10-267-502-265 Sequence 20, Appl 38 309 43.8 236 12 US-10-267-502-265 Sequence 20, Appl 38 309 43.8 236 12 US-10-267-507-26 Sequence 20, Appl 39 43.8 236 12 US-10-267-507-267 Sequence 20, Appl 39 43.8 236 12 US-10-267-507-26 Sequence 20, Appl 39 43.8 236 12 US-10-267-507-26 Sequence 20, Appl 39 43.8 236 12 US-10-267-507-2430 Sequence 20, Appl 39 43.8 236 12 US-10-267-507-24 Sequence 2330, Ap							
18 443 62.8 373 9 US-09-789-386-6 Sequence 6, Appli 19 443 62.8 373 9 US-09-765-205-6 Sequence 6, Appli 20 443 62.8 373 9 US-09-893-348-24 Sequence 24, Appl 21 443 62.8 373 12 US-10-408-967-8 Sequence 8, Appli 22 443 62.8 373 14 US-10-060-036-72 Sequence 72, Appl 23 443 62.8 373 16 US-10-466-258-4 Sequence 72, Appl 24 443 62.8 379 14 US-10-205-194-164 Sequence 164, App 25 440 62.4 1192 12 US-10-408-967-7 Sequence 7, Appli 26 436.5 61.9 1163 12 US-10-660-946-7 Sequence 431, App 27 349 49.5 208 12 US-10-660-946-8 Sequence 7, Appli 28 348 49.4 267 12 US-10-660-946-8 Sequence 127, App 30 337 47.8 776 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
19 443 62.8 373 9 US-09-765-205-6 Sequence 6, Appli 20 443 62.8 373 9 US-09-893-348-24 Sequence 24, Appl 21 443 62.8 373 12 US-10-408-967-8 Sequence 8, Appli 22 443 62.8 373 14 US-10-060-036-72 Sequence 72, Appl 23 443 62.8 373 16 US-10-466-258-4 Sequence 4, Appli 24 443 62.8 379 14 US-10-205-194-164 Sequence 164, App 25 440 62.4 1192 12 US-10-408-967-7 Sequence 7, Appli 26 436.5 61.9 1163 12 US-10-267-502-431 Sequence 7, Appli 28 348 49.4 267 12 US-10-660-946-7 Sequence 7, Appli 29 348 49.4 267 12 US-10-660-946-8 Sequence 8, Appli 337 47.8 356 12 US-10-660-946-6 Sequence 6, Appli 31 337 47.8 776 12 US-10-660-946-6 Sequence 6, Appli 32 337 47.8 776 12 US-10-660-946-5 Sequence 5, Appli 33 337 47.8 776 12 US-10-267-502-430 Sequence 430, App 33 337 47.8 780 12 US-10-267-502-430 Sequence 432, App 343.8 236 9 US-09-765-205-26 Sequence 20, Appl 36 309 43.8 236 9 US-09-765-205-26 Sequence 20, Appl 36 309 43.8 236 12 US-10-408-967-2 Sequence 2, Appli 309 43.8 236 12 US-10-408-967-2 Sequence 2, Appli 309 43.8 236 12 US-10-408-967-2 Sequence 2, Appli 309 43.8 236 12 US-10-276-774-2330 Sequence 2, Appli 36 309 43.8 236 12 US-10-276-774-2330 Sequence 2330, Appli 38 309 43.8 236 12 US-10-276-774-2330 Sequence 2330, Appli 36 309 43.8 236 12 US-10-276-774-2330 Sequence 2330, Appli 36 309 43.8 236 12 US-10-276-774-2330 Sequence 2330, Appli 36 309 43.8 236 12 US-10-276-774-2330 Sequence 2330, Appli 36 309 43.8 236 12 US-10-276-774-2330 Sequence 2330, Appli 36 309 43.8 236 12 US-10-276-774-2330 Sequence 2330, Appli 37 309 43.8 236 12 US-10-276-774-2330 Sequence 2330, Appli 37 309 43.8 236 12 US-10-276-774-2330 Sequence 2330, Appli 37 309 43.8 236 12 US-10-276-774-2330 Sequence 23330, Appli 38 309 43.8 236 12 US-10-276-774-2330							
20 443 62.8 373 9 US-09-893-348-24 Sequence 24, Appl 21 443 62.8 373 12 US-10-408-967-8 Sequence 8, Appli 22 443 62.8 373 14 US-10-060-036-72 Sequence 72, Appl 23 443 62.8 373 16 US-10-466-258-4 Sequence 72, Appl 24 443 62.8 379 14 US-10-205-194-164 Sequence 164, App 25 440 62.4 1192 12 US-10-408-967-7 Sequence 7, Appli 26 436.5 61.9 1163 12 US-10-267-502-431 Sequence 431, App 27 349 49.5 208 12 US-10-660-946-7 Sequence 7, Appli 28 348 49.4 267 12 US-10-660-946-8 Sequence 8, Appli 29 348 49.4 267 12 US-10-660-946-8 Sequence 7, Appli 31 337 47.8 356 12 US-10-660-946-6 Sequence 127, App 30 337 47.8 776 12 US-10-660-946-5 Sequence 6, Appli 32 337 47.8 776 12 US-10-660-946-5 Sequence 5, Appli 34 337 47.8 780 12 US-10-267-502-430 Sequence 93, Appl 34 337 47.8 780 12 US-10-267-502-432 Sequence 93, Appl 36 309 43.8 236 9 US-09-765-205-26 Sequence 20, Appl 36 309 43.8 236 9 US-09-765-205-26 Sequence 26, Appl 37 309 43.8 236 12 US-10-408-967-2 Sequence 27, Appli 38 309 43.8 236 12 US-10-408-967-2 Sequence 27, Appli 36 309 43.8 236 12 US-10-408-967-2 Sequence 27, Appli 38 309 43.8 236 12 US-10-408-967-2 Sequence 27, Appli 38 309 43.8 236 12 US-10-276-774-2330 Sequence 2330, Appli 38 309 43.8 236 12 US-10-276-774-2330 Sequence 2330, Appli 38 309 43.8 236 12 US-10-276-774-2330 Sequence 2330, Appli 38 309 43.8 236 12 US-10-276-774-2330 Sequence 2330, Appli 38 309 43.8 236 12 US-10-276-774-2330 Sequence 2330, Appli 38 309 43.8 236 12 US-10-276-774-2330 Sequence 2330, Appli 38 309 43.8 236 12 US-10-276-774-2330 Sequence 2330, Appli 38 309 43.8 236 12 US-10-276-774-2330 Sequence 2330, Appli 38 309 43.8 236 12 US-10-276-774-2330 Sequence 2330, Appli 38 309 43.8 236 12 US-10-276-774-2330							
21 443 62.8 373 12 US-10-408-967-8 Sequence 8, Appli 22 443 62.8 373 14 US-10-060-036-72 Sequence 72, Appl 23 443 62.8 373 16 US-10-466-258-4 Sequence 72, Appli 24 443 62.8 379 14 US-10-205-194-164 Sequence 164, App 25 440 62.4 1192 12 US-10-408-967-7 Sequence 7, Appli 26 436.5 61.9 1163 12 US-10-267-502-431 Sequence 431, App 27 349 49.5 208 12 US-10-660-946-7 Sequence 7, Appli 28 348 49.4 267 12 US-10-660-946-8 Sequence 8, Appli 29 348 49.4 267 12 US-10-660-946-8 Sequence 8, Appli 31 337 47.8 356 12 US-10-660-946-6 Sequence 127, App 30 337 47.8 356 12 US-10-660-946-6 Sequence 6, Appli 32 337 47.8 776 12 US-10-660-946-5 Sequence 5, Appli 32 337 47.8 776 12 US-10-267-502-430 Sequence 430, App 33 337 47.8 776 12 US-10-267-502-430 Sequence 93, Appl 34 337 47.8 780 12 US-10-267-502-432 Sequence 93, Appl 35 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 9 US-09-765-205-26 Sequence 26, Appl 37 309 43.8 236 12 US-10-408-967-2 Sequence 27, Appli 38 309 43.8 236 12 US-10-276-774-2330 Sequence 27, Appli 36 309 43.8 236 12 US-10-408-967-2 Sequence 27, Appli 36 309 43.8 236 12 US-10-408-967-2 Sequence 27, Appli 38 309 43.8 236 12 US-10-276-774-2330 Sequence 2330, Appli 38 309 43.8 236 12 US-10-276-774-2330 Sequence 2330, Appli 38 309 43.8 236 12 US-10-276-774-2330 Sequence 2330, Appli 38 309 43.8 236 12 US-10-276-774-2330							
22 443 62.8 373 14 US-10-060-036-72 Sequence 72, Appl 23 443 62.8 373 16 US-10-466-258-4 Sequence 4, Appli 24 443 62.8 379 14 US-10-205-194-164 Sequence 164, App 25 440 62.4 1192 12 US-10-408-967-7 Sequence 7, Appli 26 436.5 61.9 1163 12 US-10-267-502-431 Sequence 431, App 27 349 49.5 208 12 US-10-660-946-7 Sequence 7, Appli 28 348 49.4 267 12 US-10-660-946-8 Sequence 8, Appli 29 348 49.4 267 14 US-10-205-194-127 Sequence 127, App 30 337 47.8 356 12 US-10-660-946-6 Sequence 6, Appli 31 337 47.8 776 12 US-10-660-946-5 Sequence 5, Appli 32 337 47.8 776 12 US-10-267-502-430 Sequence 5, Appli 33 337 47.8 776 12 US-10-267-502-430 Sequence 430, App 33 337 47.8 780 12 US-10-267-502-430 Sequence 93, Appl 34 337 47.8 780 12 US-10-267-502-432 Sequence 93, Appl 36 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 9 US-09-765-205-26 Sequence 26, Appl 37 309 43.8 236 12 US-10-408-967-2 Sequence 27, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 27, Appli 36 309 43.8 236 12 US-10-408-967-2 Sequence 27, Appli 37 309 43.8 236 12 US-10-408-967-2 Sequence 27, Appli 38 309 43.8 236 12 US-10-276-774-2330 Sequence 27, Appli 38 309 43.8 236 12 US-10-276-774-2330 Sequence 27, Appli 39 43.8 236 12 US-10-276-774-2330							
23 443 62.8 373 16 US-10-466-258-4 Sequence 4, Appli 24 443 62.8 379 14 US-10-205-194-164 Sequence 164, App 25 440 62.4 1192 12 US-10-408-967-7 Sequence 7, Appli 26 436.5 61.9 1163 12 US-10-267-502-431 Sequence 431, App 27 349 49.5 208 12 US-10-660-946-7 Sequence 7, Appli 28 348 49.4 267 12 US-10-660-946-8 Sequence 8, Appli 29 348 49.4 267 14 US-10-205-194-127 Sequence 127, App 30 337 47.8 356 12 US-10-660-946-6 Sequence 6, Appli 31 337 47.8 776 12 US-10-660-946-5 Sequence 5, Appli 32 337 47.8 776 12 US-10-267-502-430 Sequence 5, Appli 33 337 47.8 776 12 US-10-267-502-430 Sequence 93, Appl 34 337 47.8 780 12 US-10-267-502-430 Sequence 93, Appl 36 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 9 US-09-765-205-26 Sequence 26, Appl 37 309 43.8 236 12 US-10-408-967-2 Sequence 27, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 2330, Appl 38 309 43.8 266 12 US-10-276-774-2330 Sequence 2330, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 2330, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 2330, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 2330, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 2330, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 2330, Appli 38 309 43.8 266 12 US-10-276-774-2330							-
24 443 62.8 379 14 US-10-205-194-164 Sequence 164, App 25 440 62.4 1192 12 US-10-408-967-7 Sequence 7, Appli 26 436.5 61.9 1163 12 US-10-267-502-431 Sequence 431, App 27 349 49.5 208 12 US-10-660-946-7 Sequence 7, Appli 28 348 49.4 267 12 US-10-660-946-8 Sequence 8, Appli 29 348 49.4 267 14 US-10-205-194-127 Sequence 127, App 30 337 47.8 356 12 US-10-660-946-6 Sequence 6, Appli 31 337 47.8 776 12 US-10-267-502-430 Sequence 5, Appli 32 337 47.8 776 12 US-10-267-502-430 Sequence 430, App 33 337 47.8 777 14 US-10-267-502-432 Sequence 93, Appl 34 337 47.8 780 12 US-10-267-502-432 Sequence 20, Appl 35 309 43.8							-
25 440 62.4 1192 12 US-10-408-967-7 Sequence 7, Appli 26 436.5 61.9 1163 12 US-10-267-502-431 Sequence 431, App 27 349 49.5 208 12 US-10-660-946-7 Sequence 7, Appli 28 348 49.4 267 12 US-10-660-946-8 Sequence 8, Appli 29 348 49.4 267 14 US-10-205-194-127 Sequence 127, App 30 337 47.8 356 12 US-10-660-946-6 Sequence 6, Appli 31 337 47.8 776 12 US-10-660-946-5 Sequence 5, Appli 32 337 47.8 776 12 US-10-267-502-430 Sequence 5, Appli 33 337 47.8 777 14 US-10-205-219-93 Sequence 93, Appl 34 337 47.8 780 12 US-10-267-502-432 Sequence 432, App 35 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 9 US-09-765-205-26 Sequence 26, Appl 37 309 43.8 236 12 US-10-408-967-2 Sequence 27, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 27, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 27, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 27, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 27, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 27, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 27, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 27, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 27, Appli						US-10-205-194-164	Sequence 164, App
26 436.5 61.9 1163 12 US-10-267-502-431 Sequence 431, App 27 349 49.5 208 12 US-10-660-946-7 Sequence 7, Appli 28 348 49.4 267 12 US-10-660-946-8 Sequence 8, Appli 29 348 49.4 267 14 US-10-205-194-127 Sequence 127, App 30 337 47.8 356 12 US-10-660-946-6 Sequence 6, Appli 31 337 47.8 776 12 US-10-660-946-5 Sequence 5, Appli 32 337 47.8 776 12 US-10-267-502-430 Sequence 5, Appli 33 337 47.8 777 14 US-10-205-219-93 Sequence 93, Appl 34 337 47.8 780 12 US-10-267-502-432 Sequence 93, Appl 35 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 37 309 43.8 236 12 US-10-408-967-2 Sequence 2, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 2330, App				1192	12	US-10-408-967-7	Sequence 7, Appli
28 348 49.4 267 12 US-10-660-946-8 Sequence 8, Appli 29 348 49.4 267 14 US-10-205-194-127 Sequence 127, App 30 337 47.8 356 12 US-10-660-946-6 Sequence 6, Appli 31 337 47.8 776 12 US-10-267-502-430 Sequence 5, Appli 32 337 47.8 776 12 US-10-267-502-430 Sequence 430, App 33 337 47.8 777 14 US-10-205-219-93 Sequence 93, Appl 34 337 47.8 780 12 US-10-267-502-432 Sequence 432, App 35 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 9 US-09-765-205-26 Sequence 26, Appl 37 309 43.8 236 12 US-10-408-967-2 Sequence 2, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 2330, Ap		436.5	61.9	1163	12	US-10-267-502-431	
29 348 49.4 267 14 US-10-205-194-127 Sequence 127, App 30 337 47.8 356 12 US-10-660-946-6 Sequence 6, Appli 31 337 47.8 776 12 US-10-660-946-5 Sequence 5, Appli 32 337 47.8 776 12 US-10-267-502-430 Sequence 430, App 33 337 47.8 777 14 US-10-205-219-93 Sequence 93, Appl 34 337 47.8 780 12 US-10-267-502-432 Sequence 432, App 35 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 9 US-09-765-205-26 Sequence 26, Appl 37 309 43.8 236 12 US-10-408-967-2 Sequence 2, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 2330, Ap	27	349	49.5	208	12	US-10-660-946-7	
30 337 47.8 356 12 US-10-660-946-6 Sequence 6, Appli 31 337 47.8 776 12 US-10-660-946-5 Sequence 5, Appli 32 337 47.8 776 12 US-10-267-502-430 Sequence 430, App 33 337 47.8 777 14 US-10-205-219-93 Sequence 93, Appl 34 337 47.8 780 12 US-10-267-502-432 Sequence 432, App 35 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 9 US-09-765-205-26 Sequence 26, Appl 37 309 43.8 236 12 US-10-408-967-2 Sequence 2, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 2330, Ap	28	348	49.4	267	12	US-10-660-946-8	
31 337 47.8 776 12 US-10-660-946-5 Sequence 5, Appli 32 337 47.8 776 12 US-10-267-502-430 Sequence 430, App 33 337 47.8 777 14 US-10-205-219-93 Sequence 93, Appl 34 337 47.8 780 12 US-10-267-502-432 Sequence 432, App 35 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 9 US-09-765-205-26 Sequence 26, Appl 37 309 43.8 236 12 US-10-408-967-2 Sequence 2, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 2330, Ap							-
32 337 47.8 776 12 US-10-267-502-430 Sequence 430, App 33 337 47.8 777 14 US-10-205-219-93 Sequence 93, Appl 34 337 47.8 780 12 US-10-267-502-432 Sequence 432, App 35 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 9 US-09-765-205-26 Sequence 26, Appl 37 309 43.8 236 12 US-10-408-967-2 Sequence 2, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 2330, Ap							
33 337 47.8 777 14 US-10-205-219-93 Sequence 93, Appl 34 337 47.8 780 12 US-10-267-502-432 Sequence 432, App 35 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 9 US-09-765-205-26 Sequence 26, Appl 37 309 43.8 236 12 US-10-408-967-2 Sequence 2, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 2330, Ap							
34 337 47.8 780 12 US-10-267-502-432 Sequence 432, App 35 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 9 US-09-765-205-26 Sequence 26, Appl 37 309 43.8 236 12 US-10-408-967-2 Sequence 2, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 2330, Ap							
35 309 43.8 236 9 US-09-729-674-20 Sequence 20, Appl 36 309 43.8 236 9 US-09-765-205-26 Sequence 26, Appl 37 309 43.8 236 12 US-10-408-967-2 Sequence 2, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 2330, Ap							
36 309 43.8 236 9 US-09-765-205-26 Sequence 26, Appl 37 309 43.8 236 12 US-10-408-967-2 Sequence 2, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 2330, Ap							<u>-</u>
37 309 43.8 236 12 US-10-408-967-2 Sequence 2, Appli 38 309 43.8 266 12 US-10-276-774-2330 Sequence 2330, Ap							
38 309 43.8 266 12 US-10-276-774-2330 Sequence 2330, Ap							<u>-</u>
							-
	39	309	43.8				Sequence 6222, Ap
40 305 43.3 241 12 US-10-660-946-3 Sequence 3, Appli							
41 304 43.1 593 15 US-10-108-260A-2892 Sequence 2892, Ap							
42 269 38.2 161 9 US-09-925-302-808 Sequence 808, App							
43 269 38.2 161 12 US-09-925-302-808 Sequence 808, App							
44 259.5 36.8 204 12 US-10-424-599-194160 Sequence 194160,							Sequence 194160,
45 256 36.3 234 12 US-10-424-599-200840 Sequence 200840,	45				12	US-10-424-599-200840	Sequence 200840,

ALIGNMENTS

RESULT 1

US-09-893-348-21

[;] Sequence 21, Application US/09893348; Patent No. US20020072493A1

[;] GENERAL INFORMATION:

```
APPLICANT: EISENBACH-SCHWARTZ, Michal
  APPLICANT: COHEN, Irun R.
  APPLICANT: BESERMAN, Pierre
  APPLICANT: MOSONEGO, Alon
  APPLICANT: MOALEM, Gila
  TITLE OF INVENTION: ACTIVATED T-CELLS, NERVOUS SYSTEM-SPECIFIC ANTIGENS AND
THEIR USES
  FILE REFERENCE: EIS-SCHWARTZ=2A
  CURRENT APPLICATION NUMBER: US/09/893,348
  CURRENT FILING DATE: 2001-06-28
  PRIOR APPLICATION NUMBER: US 09/314,161
  PRIOR FILING DATE: 1999-05-19
  PRIOR APPLICATION NUMBER: US 09/218,277
  PRIOR FILING DATE: 1998-12-22
  PRIOR APPLICATION NUMBER: PCT/US98/14715
  PRIOR FILING DATE: 1998-07-21
  PRIOR APPLICATION NUMBER: IL 124500
  PRIOR FILING DATE: 1998-05-19
  NUMBER OF SEQ ID NOS: 29
  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 21
   LENGTH: 199
   TYPE: PRT
    ORGANISM: Rattus norvegicus
US-09-893-348-21
                                Score 510; DB 9; Length 199;
                        72.3%;
  Query Match
                        99.0%; Pred. No. 5.9e-51;
  Best Local Similarity
                               0; Mismatches
                                               1; Indels
                                                             0; Gaps
  Matches 103; Conservative
          38 MDGQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 97
Qy
             1 MDGOKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 60
Db
          98 FRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
QУ
             61 FRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 104
Db
RESULT 2
US-10-264-237-1568
; Sequence 1568, Application US/10264237
; Publication No. US20040009491A1
: GENERAL INFORMATION:
  APPLICANT: Birse et al.
   TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
   FILE REFERENCE: PA131P1
   CURRENT APPLICATION NUMBER: US/10/264,237
   CURRENT FILING DATE: 2002-10-04
   PRIOR APPLICATION NUMBER: PCT/US01/16450
   PRIOR FILING DATE: 2001-05-18
  PRIOR APPLICATION NUMBER: US 60/205,515
  PRIOR FILING DATE: 2000-05-19
; NUMBER OF SEQ ID NOS: 2876
; SOFTWARE: PatentIn Ver. 3.1
; SEQ ID NO 1568
   LENGTH: 118
```

```
TYPE: PRT
   ORGANISM: Homo sapiens
   FEATURE:
   NAME/KEY: MISC FEATURE
   LOCATION: (118)
   OTHER INFORMATION: Xaa equals any of the twenty naturally occurring L-amino
acids
US-10-264-237-1568
                        71.3%; Score 503; DB 15; Length 118;
 Query Match
 Best Local Similarity 98.1%; Pred. No. 1.9e-50;
                                                            0;
                                                                Gaps
                             1; Mismatches
                                              1; Indels
 Matches 102; Conservative
          38 MDGQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 97
Qу
             1 MDGQKKNWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 60
Db
          98 FRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
Qу
             61 FRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 104
Db
RESULT 3
US-09-893-348-25
; Sequence 25, Application US/09893348
; Patent No. US20020072493A1
; GENERAL INFORMATION:
; APPLICANT: EISENBACH-SCHWARTZ, Michal
; APPLICANT: COHEN, Irun R.
; APPLICANT: BESERMAN, Pierre
  APPLICANT: MOSONEGO, Alon
  APPLICANT: MOALEM, Gila
  TITLE OF INVENTION: ACTIVATED T-CELLS, NERVOUS SYSTEM-SPECIFIC ANTIGENS AND
THEIR USES
  FILE REFERENCE: EIS-SCHWARTZ=2A
   CURRENT APPLICATION NUMBER: US/09/893,348
   CURRENT FILING DATE: 2001-06-28
  PRIOR APPLICATION NUMBER: US 09/314,161
  PRIOR FILING DATE: 1999-05-19
  PRIOR APPLICATION NUMBER: US 09/218,277
  PRIOR FILING DATE: 1998-12-22
  PRIOR APPLICATION NUMBER: PCT/US98/14715
  PRIOR FILING DATE: 1998-07-21
  PRIOR APPLICATION NUMBER: IL 124500
   PRIOR FILING DATE: 1998-05-19
   NUMBER OF SEQ ID NOS: 29
   SOFTWARE: PatentIn version 3.1
; SEQ ID NO 25
    LENGTH: 199
    TYPE: PRT
    ORGANISM: Homo sapiens
US-09-893-348-25
                        71.3%; Score 503; DB 9; Length 199;
  Query Match
  Best Local Similarity 98.1%; Pred. No. 3.9e-50;
                                                                        0;
  Matches 102; Conservative
                              1; Mismatches
                                              1; Indels
                                                             0; Gaps
```

```
38 MDGQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 97
Qу
             1 MDGQKKNWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 60
Db
          98 FRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
Qу
             61 FRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 104
Db
RESULT 4
US-10-660-946-1
; Sequence 1, Application US/10660946
; Publication No. US20040063131A1
    GENERAL INFORMATION:
        APPLICANT: Bandman, Olga
                   Au-Young, Janice
                   Goli, Surya K.
                   Hillman, Jennifer L.
        TITLE OF INVENTION: TWO NOVEL HUMAN NSP-LIKE PROTEINS
        NUMBER OF SEQUENCES: 9
        CORRESPONDENCE ADDRESS:
             ADDRESSEE: Incyte Pharmaceuticals, Inc.
             STREET: 3174 Porter Drive
             CITY: Palo Alto
             STATE: CA
             COUNTRY: U.S.
             ZIP: 94304
        COMPUTER READABLE FORM:
             MEDIUM TYPE: Diskette
             COMPUTER: IBM Compatible
             OPERATING SYSTEM: DOS
             SOFTWARE: FastSEQ Version 1.5
        CURRENT APPLICATION DATA:
             APPLICATION NUMBER: US/10/660,946
             FILING DATE: 12-Sep-2003
        PRIOR APPLICATION DATA:
             APPLICATION NUMBER: US/09/228,213A
             FILING DATE: <Unknown>
             APPLICATION NUMBER: 08/700,607
             FILING DATE: <Unknown>
        ATTORNEY/AGENT INFORMATION:
             NAME: Billings, Lucy J.
             REGISTRATION NUMBER: 36,749
             REFERENCE/DOCKET NUMBER: PF-0114 US
         TELECOMMUNICATION INFORMATION:
             TELEPHONE: 415-855-0555
             TELEFAX: 415-845-4166
    INFORMATION FOR SEQ ID NO: 1:
         SEQUENCE CHARACTERISTICS:
             LENGTH: 199 amino acids
             TYPE: amino acid
             STRANDEDNESS: single
             TOPOLOGY: linear
         MOLECULE TYPE: peptide
         IMMEDIATE SOURCE:
             LIBRARY: <Unknown>
             CLONE: Consensus
```

```
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-10-660-946-1
                        71.3%; Score 503; DB 12; Length 199;
  Query Match
 Best Local Similarity 98.1%; Pred. No. 3.9e-50;
 Matches 102; Conservative 1; Mismatches
                                              1; Indels
          38 MDGOKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 97
Qy
             1 MDGOKKNWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 60
Db
          98 FRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
Qу
             61 FRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 104
Db
RESULT 5
US-09-978-360A-467
; Sequence 467, Application US/09978360A
; Publication No. US20040110939A1
; GENERAL INFORMATION:
  APPLICANT: Edwards, Jean-Baptiste Dumas Milne
  APPLICANT: Duclert, Aymeric
  APPLICANT: Bougueleret, Lydie
  APPLICANT: Jobert, Severin
  APPLICANT: Clusel, Catherine
  TITLE OF INVENTION: Complementary DNA's Encoding Proteins with Signal
; FILE REFERENCE: 56.US4.CIP
   CURRENT APPLICATION NUMBER: US/09/978,360A
   CURRENT FILING DATE: 2001-10-15
   PRIOR APPLICATION NUMBER: US 60/066,677
  PRIOR FILING DATE: 1997-11-13
  PRIOR APPLICATION NUMBER: US 60/069,957
  PRIOR FILING DATE: 1997-12-17
  PRIOR APPLICATION NUMBER: US 60/074,121
  PRIOR FILING DATE: 1998-02-09
   PRIOR APPLICATION NUMBER: US 60/081,563
  PRIOR FILING DATE: 1998-04-13
  PRIOR APPLICATION NUMBER: US 60/096,116
  PRIOR FILING DATE: 1998-08-10
   PRIOR APPLICATION NUMBER: US 60/099,273
  PRIOR FILING DATE: -09-04
   PRIOR APPLICATION NUMBER: US 09/191,997
   PRIOR FILING DATE: 1998-11-13
   PRIOR APPLICATION NUMBER: US 09/215,435
   PRIOR FILING DATE: 1998-12-17
  PRIOR APPLICATION NUMBER: PCT/IB98/02122
   PRIOR FILING DATE: 1998-12-17
   PRIOR APPLICATION NUMBER: US 09/247,155
   PRIOR FILING DATE: 1999-02-09
   Remaining Prior Application data removed - See File Wrapper or PALM.
  NUMBER OF SEQ ID NOS: 810
  SOFTWARE: Patent.pm
; SEQ ID NO 467
    LENGTH: 199
    TYPE: PRT
```

```
ORGANISM: Homo sapiens
   FEATURE:
   NAME/KEY: SIGNAL
   LOCATION: -42..-1
US-09-978-360A-467
                       71.3%; Score 503; DB 12; Length 199;
 Query Match
                      98.1%; Pred. No. 3.9e-50;
 Best Local Similarity
                            1; Mismatches
                                            1; Indels
                                                         0; Gaps
                                                                    0;
 Matches 102; Conservative
         38 MDGQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 97
Qу
            1 MDGQKKNWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 60
Db
         98 FRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
Qу
            61 FRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 104
Db
RESULT 6
US-10-466-258-11
; Sequence 11, Application US/10466258
; Publication No. US20040132096A1
; GENERAL INFORMATION:
  APPLICANT: GLAXO GROUP LIMITED
  TITLE OF INVENTION: ASSAY
  FILE REFERENCE: P80966 GCW
  CURRENT APPLICATION NUMBER: US/10/466,258
  CURRENT FILING DATE: 2003-07-15
  NUMBER OF SEQ ID NOS: 13
  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 11
   LENGTH: 199
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-466-258-11
                       71.3%; Score 503; DB 16; Length 199;
  Query Match
  Best Local Similarity
                       98.1%; Pred. No. 3.9e-50;
                             1; Mismatches
                                            1;
                                                         0; Gaps
                                                                    0:
  Matches 102; Conservative
                                                Indels
          38 MDGQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 97
Qу
            1 MDGQKKNWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 60
Db
          98 FRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
Qy
             61 FRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 104
Db
RESULT 7
US-10-408-967-9
; Sequence 9, Application US/10408967
; Publication No. US20040063161A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia & Upjohn Company
; APPLICANT: Yan, Rigiang
```

```
APPLICANT: Lu, Yifeng
  TITLE OF INVENTION: Compositions and Methods of Treating Alzheimer's Disease
  FILE REFERENCE: 00925
  CURRENT APPLICATION NUMBER: US/10/408,967
  CURRENT FILING DATE: 2003-04-08
  NUMBER OF SEQ ID NOS: 9
  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
   LENGTH: 199
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-408-967-9
                        70.4%; Score 496; DB 12; Length 199;
 Query Match
                        97.1%; Pred. No. 2.5e-49;
 Best Local Similarity
 Matches 101; Conservative
                              1; Mismatches
                                               2; Indels
                                                             0; Gaps
                                                                        0:
          38 MDGQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 97
Qу
             1 MDGQKKNWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 60
Db
          98 FRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
Qу
             61 FRIYKGVIQAIQKSDEGHPFPAYLESEVAISEELVQKYSNSALG 104
Db
RESULT 8
US-09-893-348-18
; Sequence 18, Application US/09893348
; Patent No. US20020072493A1
; GENERAL INFORMATION:
  APPLICANT: EISENBACH-SCHWARTZ, Michal
  APPLICANT: COHEN, Irun R.
  APPLICANT: BESERMAN, Pierre
  APPLICANT: MOSONEGO, Alon
; APPLICANT: MOALEM, Gila
  TITLE OF INVENTION: ACTIVATED T-CELLS, NERVOUS SYSTEM-SPECIFIC ANTIGENS AND
THEIR USES
; FILE REFERENCE: EIS-SCHWARTZ=2A
 CURRENT APPLICATION NUMBER: US/09/893,348
; CURRENT FILING DATE: 2001-06-28
  PRIOR APPLICATION NUMBER: US 09/314,161
  PRIOR FILING DATE: 1999-05-19
  PRIOR APPLICATION NUMBER: US 09/218,277
  PRIOR FILING DATE: 1998-12-22
  PRIOR APPLICATION NUMBER: PCT/US98/14715
  PRIOR FILING DATE: 1998-07-21
  PRIOR APPLICATION NUMBER: IL 124500
  PRIOR FILING DATE: 1998-05-19
  NUMBER OF SEQ ID NOS: 29
   SOFTWARE: PatentIn version 3.1
; SEQ ID NO 18
   LENGTH: 1163
   TYPE: PRT
   ORGANISM: Rattus norvegicus
US-09-893-348-18
```

```
63.4%; Score 447; DB 9; Length 1163;
 Query Match
 Best Local Similarity 96.9%; Pred. No. 1.3e-42;
         93; Conservative 0; Mismatches
 Matches
                                            3; Indels
                                                         0;
                                                             Gaps
         46 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 105
Qу
               973 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 1032
Qy
        106 QAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
            Db
        1033 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 1068
RESULT 9
US-09-789-386-2
; Sequence 2, Application US/09789386
; Patent No. US20020010324A1
; GENERAL INFORMATION:
 APPLICANT: MICHALOVICH, DAVID
  APPLICANT: PRINJHA, RABINDER KUMAR
  TITLE OF INVENTION: NOVEL COMPOUNDS
  FILE REFERENCE: GP-30165-C1
  CURRENT APPLICATION NUMBER: US/09/789,386
  CURRENT FILING DATE: 2001-02-21
  PRIOR APPLICATION NUMBER: U.K. 9916898.1
  PRIOR FILING DATE: 1999-07-19
  PRIOR APPLICATION NUMBER: U.K. 9816024.5
  PRIOR FILING DATE: 1998-07-22
  PRIOR APPLICATION NUMBER: US 09/359,208
  PRIOR FILING DATE: 1999-07-22
  NUMBER OF SEQ ID NOS: 6
  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 2
   LENGTH: 1192
   TYPE: PRT
   ORGANISM: HOMO SAPIENS
US-09-789-386-2
 Query Match
                       63.4%; Score 447; DB 9; Length 1192;
 Best Local Similarity 96.9%; Pred. No. 1.4e-42;
 Matches 93; Conservative 0; Mismatches 3; Indels
                                                        0; Gaps
                                                                    0;
         46 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 105
Qу
            1002 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 1061
Db
Qу
        106 QAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
            Db
        1062 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 1097
RESULT 10
US-09-758-140-6
; Sequence 6, Application US/09758140
; Patent No. US20020012965A1
: GENERAL INFORMATION:
; APPLICANT: Strittmatter, Stephen M.
```

```
; TITLE OF INVENTION: No. US20020012965Alo Receptor-Mediated Blockade of
Axonal Growth
; FILE REFERENCE: 44574-5073-US
  CURRENT APPLICATION NUMBER: US/09/758,140
  CURRENT FILING DATE: 2001-01-12
  PRIOR APPLICATION NUMBER: US 60/175,707
  PRIOR FILING DATE: 2000-01-12
  PRIOR APPLICATION NUMBER: US 60/207,366
  PRIOR FILING DATE: 2000-05-26
  PRIOR APPLICATION NUMBER: US 60/236,378
  PRIOR FILING DATE: 2000-09-29
  NUMBER OF SEQ ID NOS: 20
  SOFTWARE: PatentIn Ver. 2.1
 SEQ ID NO 6
   LENGTH: 1192
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-758-140-6
                        63.4%; Score 447; DB 9; Length 1192;
 Query Match
 Best Local Similarity 96.9%; Pred. No. 1.4e-42;
         93; Conservative 0; Mismatches
                                                                        0;
                                              3; Indels
                                                             0; Gaps
          46 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 105
Qу
              1002 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 1061
Db
Qу
         106 QAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
             1062 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 1097
Db
RESULT 11
US-09-893-348-23
; Sequence 23, Application US/09893348
; Patent No. US20020072493A1
; GENERAL INFORMATION:
; APPLICANT: EISENBACH-SCHWARTZ, Michal
  APPLICANT: COHEN, Irun R.
; APPLICANT: BESERMAN, Pierre
; APPLICANT: MOSONEGO, Alon
  APPLICANT: MOALEM, Gila
  TITLE OF INVENTION: ACTIVATED T-CELLS, NERVOUS SYSTEM-SPECIFIC ANTIGENS AND
THEIR USES
  FILE REFERENCE: EIS-SCHWARTZ=2A
  CURRENT APPLICATION NUMBER: US/09/893,348
  CURRENT FILING DATE: 2001-06-28
  PRIOR APPLICATION NUMBER: US 09/314,161
  PRIOR FILING DATE: 1999-05-19
  PRIOR APPLICATION NUMBER: US 09/218,277
  PRIOR FILING DATE: 1998-12-22
  PRIOR APPLICATION NUMBER: PCT/US98/14715
  PRIOR FILING DATE: 1998-07-21
; PRIOR APPLICATION NUMBER: IL 124500
; PRIOR FILING DATE: 1998-05-19
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.1
```

```
; SEQ ID NO 23
   LENGTH: 1192
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-893-348-23
                      63.4%; Score 447; DB 9; Length 1192;
 Query Match
 Best Local Similarity 96.9%; Pred. No. 1.4e-42;
 Matches 93; Conservative 0; Mismatches 3; Indels
                                                         0; Gaps
                                                                    0;
         46 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 105
Qу
            1002 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 1061
Db
        106 QAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
Qу
            1062 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 1097
Db
RESULT 12
US-09-972-599A-6
; Sequence 6, Application US/09972599A
; Patent No. US20020077295A1
; GENERAL INFORMATION:
 APPLICANT: STRITTMATTER, STEPHEN M.
 TITLE OF INVENTION: NOGO-RECEPTOR-MEDIATED BLOCKADE OF AXONAL GROWTH
; FILE REFERENCE: C077 CIP US
  CURRENT APPLICATION NUMBER: US/09/972,599A
  CURRENT FILING DATE: 2001-10-06
  PRIOR APPLICATION NUMBER: PCT/US01/01041
  PRIOR FILING DATE: 2001-01-12
  PRIOR APPLICATION NUMBER: 09/758,140
  PRIOR FILING DATE: 2001-01-12
  PRIOR APPLICATION NUMBER: 60/236,378
  PRIOR FILING DATE: 2000-09-29
 PRIOR APPLICATION NUMBER: 60/207,366
 PRIOR FILING DATE: 2000-05-26
  PRIOR APPLICATION NUMBER: 60/175,707
  PRIOR FILING DATE: 2000-01-12
; NUMBER OF SEQ ID NOS: 57
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
   LENGTH: 1192
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-972-599A-6
 Query Match
                       63.4%; Score 447; DB 9; Length 1192;
 Best Local Similarity 96.9%; Pred. No. 1.4e-42;
 Matches 93; Conservative 0; Mismatches
                                            3; Indels
                                                         0; Gaps
         46 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 105
Qу
            1002 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 1061
Db
Qy
         106 QAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
```

```
RESULT 13
US-10-267-502-429
; Sequence 429, Application US/10267502
; Publication No. US20040071700A1
; GENERAL INFORMATION:
; APPLICANT: Kim, Jaeseob
  APPLICANT: Galant, Ron
  TITLE OF INVENTION: Obesity Linked Genes
  FILE REFERENCE: LSD-07416
  CURRENT APPLICATION NUMBER: US/10/267,502
  CURRENT FILING DATE: 2003-01-27
  NUMBER OF SEQ ID NOS: 439
  SOFTWARE: PatentIn version 3.2
 SEQ ID NO 429
   LENGTH: 1192
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-267-502-429
                        63.4%; Score 447; DB 12; Length 1192;
 Query Match
                        96.9%; Pred. No. 1.4e-42;
 Best Local Similarity
                             0; Mismatches 3; Indels
                                                             0; Gaps
 Matches
         93; Conservative
                                                                        0:
Qу
          46 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 105
             1002 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 1061
Db
         106 QAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
Qу
             Db
        1062 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 1097
RESULT 14
US-10-060-036-71
; Sequence 71, Application US/10060036
; Publication No. US20030073144A1
; GENERAL INFORMATION:
; APPLICANT: Benson, Darin R.
; APPLICANT: Kalos, Michael D.
  APPLICANT: Lodes, Michael J.
  APPLICANT: Persing, David H.
  APPLICANT: Hepler, William T.
  APPLICANT: Jiang, Yuqiu
  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY
  TITLE OF INVENTION: AND DIAGNOSIS OF PANCREATIC CANCER
  FILE REFERENCE: 210121.566
  CURRENT APPLICATION NUMBER: US/10/060,036
  CURRENT FILING DATE: 2002-01-30
  NUMBER OF SEQ ID NOS: 4560
  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 71
   LENGTH: 1192
   TYPE: PRT
   ORGANISM: Homo sapiens
```

```
Query Match
                      63.4%; Score 447; DB 14; Length 1192;
 Best Local Similarity 96.9%; Pred. No. 1.4e-42;
                                                        0; Gaps
 Matches
         93; Conservative
                            0; Mismatches 3; Indels
                                                                   0;
         46 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 105
Qу
             Db
       1002 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 1061
        106 QAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
Qу
            Db
       1062 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 1097
RESULT 15
US-10-327-213-9
; Sequence 9, Application US/10327213
; Publication No. US20040121341A1
; GENERAL INFORMATION:
; APPLICANT: FILBIN, MARIE T.
  APPLICANT: DOMENICONI, MARCO
  APPLICANT: CAO, ZIXUAN
  TITLE OF INVENTION: INHIBITORS OF MYELIN-ASSOCIATED GLYCOPROTEIN (MAG)
  TITLE OF INVENTION: ACTIVITY FOR REGULATING NEURAL GROWTH AND REGENERATION
  FILE REFERENCE: CUNY/003
  CURRENT APPLICATION NUMBER: US/10/327,213
  CURRENT FILING DATE: 2002-12-20
  NUMBER OF SEQ ID NOS: 43
  SOFTWARE: PatentIn Ver. 2.1
 SEQ ID NO 9
   LENGTH: 1192
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-327-213-9
                      63.4%; Score 447; DB 16; Length 1192;
 Query Match
 Best Local Similarity 96.9%; Pred. No. 1.4e-42;
                           0; Mismatches
 Matches 93; Conservative
                                           3; Indels
                                                       0; Gaps
                                                                  0;
         46 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 105
Qу
            Db
       1002 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 1061
Qу
        106 QAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
            Db
       1062 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 1097
```

Search completed: September 29, 2004, 18:48:20 Job time: 16.1353 secs

GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on:

September 29, 2004, 18:06:43; Search time 11.0927 Seconds

(without alignments)

4010.587 Million cell updates/sec

Title:

US-09-830-972-32

Perfect score: 705

Sequence:

1 QASGEAGVSCLRENFAVYSV.....ESEVAISEELVQKYSNSALG 141

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched:

1017041 segs, 315518202 residues

Total number of hits satisfying chosen parameters:

1017041

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

SPTREMBL 25:*

- 1: sp_archea:*
- 2: sp_bacteria:*
- 3: sp_fungi:*
- 4: sp human:*
- 5: sp invertebrate:*
- 6: sp mammal:*
- 7: sp mhc:*
- 8: sp_organelle:*
- 9: sp phage:*
- 10: sp plant:*
- 11: sp rodent:*
- 12: sp virus:*
- 13: sp vertebrate:*
- 14: sp_unclassified:*
 15: sp_rvirus:*
- 16: sp_bacteriap:*
- 17: sp_archeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

ક્ર

Result

Query Score Match Length DB ID

1	460	65.2	199	13	Q7T224	Q7t224 gallus gall
2	447	63.4	578	11	Q80W95	Q80w95 mus musculu
3	447	63.4	639	11	Q8K290	Q8k290 mus musculu
4	447	63.4	986	4	Q8IUA4	Q8iua4 homo sapien
5	447	63.4	1046	11	Q8BGK7	Q8bgk7 mus musculu
6	447	63.4	1162	11	Q8BGM9	Q8bgm9 mus musculu
7	443	62.8	356	11	Q8BH78	Q8bh78 mus musculu
8	443	62.8	375	11	Q8BHF5	Q8bhf5 mus musculu
9	443	62.8	392	4	Q96B16	Q96b16 homo sapien
10	436.5	61.9	1163	11	Q8K3G8	Q8k3g8 mus musculu
11	432.5	61.3	357	11	Q8K3G7	Q8k3g7 mus musculu
12	417	59.1	184	6	Q7YRW9	Q7yrw9 bos taurus
13	386	54.8	179	6	Q9GM33	Q9gm33 macaca fasc
14	384	54.5	214	13	Q7T222	Q7t222 carassius a
15	348	49.4	199	4	Q9BQ59	Q9bq59 homo sapien
16	348	49.4	267	11	Q63765	Q63765 rattus sp.
17	337	47.8	780	11	Q8K4S4	Q8k4s4 mus musculu
18	337	47.8	780	11	Q8K0T0	Q8k0t0 mus musculu
19	325	46.1	208	13	Q90637	Q90637 gallus gall
20	320	45.4	760	13	Q90638	Q90638 gallus gall
21	308	43.7	236	11	Q8VBU0	Q8vbu0 rattus norv
22	308	43.7	237	11	Q8C6D5	Q8c6d5 mus musculu
23	308	43.7	643	11	Q8CCU2	Q8ccu2 mus musculu
24	283.5	40.2	221	13	Q7ZUD6	Q7zud6 brachydanio
25	255	36.2	234	5	Q9VMW3	Q9vmw3 drosophila
26	253	35.9	224	5	Q9VMW1	Q9vmwl drosophila
27	252	35.7	222	5	Q9VMW4	Q9vmw4 drosophila
28	252	35.7	595	5	Q9VMV9	Q9vmv9 drosophila
29	250	35.5	202	5	Q9VMW2	Q9vmw2 drosophila
30	162	23.0	2484	5	Q9U347	Q9u347 caenorhabdi
31	159	22.6	2607	5	Q23187	Q23187 caenorhabdi
32	158	22.4	222	5	Q23188	Q23188 caenorhabdi
33	104	14.8	107	13	Q7T223	Q7t223 carassius a
34	102.5	14.5	154	5	Q9VIB7	Q9vib7 drosophila
35	102.5	14.5	158	5	Q24199	Q24199 drosophila
36	85	12.1	457	10	Q8LDS3	Q8lds3 arabidopsis
37	83.5	11.8	295	3	Q04947	Q04947 saccharomyc
38	82.5	11.7	1247	16	Q88QU8	Q88qu8 pseudomonas
39	81.5	11.6	464	5	Q09484	Q09484 caenorhabdi
40	80	11.3	564	10	Q8L7Z9	Q817z9 spinacia ol
41	79	11.2	568	16	Q9CKM1	Q9ckml pasteurella
42	79	11.2	618	5	Q22003	Q22003 caenorhabdi
43	79	11.2	638	16	Q83F64	Q83f64 coxiella bu
44	78.5	11.1	261	16	Q83KX1	Q83kx1 shigella fl
45	78.5	11.1	458	16	Q9X1C8	Q9x1c8 thermotoga
					~	*···

ALIGNMENTS

```
RESULT 1
Q7T224

ID Q7T224

AC Q7T224;

DT 01-OCT-2003 (TrEMBLrel. 25, Created)

DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)

DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
```

```
DE
    RTN4-C.
GN
    RTN4.
OS
    Gallus gallus (Chicken).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC
    Gallus.
OX
    NCBI TaxID=9031;
RN
    [1]
RP
    SEQUENCE FROM N.A.
    MEDLINE=22715887; PubMed=12832288;
RX
RA
    Oertle T., Klinger M., Stuermer C.A., Schwab M.E.;
RT
    "A reticular rhapsody: phylogenic evolution and nomenclature of the
RT
    RTN/Nogo gene family.";
RL
    FASEB J. 17:1238-1247(2003).
DR
    EMBL; AY164737; AAP47312.1; -.
SO
    SEQUENCE 199 AA; 22293 MW; 07CF4E4EF2723251 CRC64;
 Query Match
                         65.2%; Score 460; DB 13; Length 199;
 Best Local Similarity
                        88.5%; Pred. No. 6.3e-39;
 Matches
          92; Conservative
                               5; Mismatches
                                                7; Indels
                                                              0; Gaps
                                                                          0;
          38 MDGQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 97
Qy
                    Db
           1 MDSQPSGWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 60
          98 FRIYKGVIOAIAKSDEGHPFRAYLESEVAISEELVOKYSNSALG 141
Qу
             61 FRIYKGVIQAIQKSDEGHPFRAYLESDVAVSEDLIQKYSSVVLG 104
Db
RESULT 2
Q80W95
ID
    Q80W95
                PRELIMINARY;
                                 PRT;
                                        578 AA.
AC
    Q80W95;
    01-JUN-2003 (TrEMBLrel. 24, Created)
DT
    01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
    Nogo-A (Fragment).
DE
GN
    NOGO-A.
OS
    Mus musculus (Mouse).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
OX
    NCBI TaxID=10090;
RN
    [1]
RP
    SEQUENCE FROM N.A.
    Tozaki H., Hirata T.;
RA
     "The partial sequence of mouse nogo-A cDNA clone#4109.";
RT
     Submitted (OCT-2001) to the EMBL/GenBank/DDBJ databases.
RL
    EMBL; AB073672; BAC75974.1; -.
DR
DR
    GO; GO:0005783; C:endoplasmic reticulum; IEA.
    InterPro; IPR003388; Reticulon.
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
DR
FT
    NON TER
                  1
     SEQUENCE
               578 AA; 63696 MW; 832670C171E4AC61 CRC64;
SO
  Query Match
                        63.4%; Score 447; DB 11; Length 578;
```

```
Best Local Similarity
                       96.9%; Pred. No. 4.4e-37;
                             0; Mismatches 3; Indels
          93; Conservative
Qу
          46 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 105
               388 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 447
Db
Qу
        106 OAIAKSDEGHPFRAYLESEVAISEELVOKYSNSALG 141
            448 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 483
Db
RESULT 3
Q8K290
ID
    Q8K290
               PRELIMINARY;
                               PRT;
                                      639 AA.
AC
    Q8K290;
    01-OCT-2002 (TrEMBLrel. 22, Created)
DT
    01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
    Hypothetical protein.
DΕ
    RTN4.
GN
    Mus musculus (Mouse).
OS
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
OX
    NCBI TaxID=10090;
RN
    [1]
    SEQUENCE FROM N.A.
RP
    Strausberg R.;
RA
    Submitted (JUN-2002) to the EMBL/GenBank/DDBJ databases.
RL
DR
    EMBL; BC032192; AAH32192.1; -.
    MGD; MGI:1915835; Rtn4.
DR
    GO; GO:0005783; C:endoplasmic reticulum; IDA.
DR
    GO; GO:0007399; P:neurogenesis; IDA.
DR
DR
    InterPro; IPR003388; Reticulon.
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
DR
    Hypothetical protein.
KW
    SEQUENCE 639 AA; 70312 MW; 309A19DA37603F11 CRC64;
SQ
                       63.4%; Score 447; DB 11; Length 639;
 Query Match
 Best Local Similarity
                       96.9%; Pred. No. 4.9e-37;
 Matches 93; Conservative
                            0; Mismatches
                                           3; Indels
                                                           0; Gaps
                                                                      0;
          46 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 105
Qу
               449 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 508
Db
         106 QAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
Qу
            Db
         509 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 544
RESULT 4
Q8IUA4
ID
    Q8IUA4
               PRELIMINARY;
                               PRT:
                                      986 AA.
AC
    Q8IUA4;
DТ
    01-MAR-2003 (TrEMBLrel. 23, Created)
```

```
01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT
    01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DT
DE
    RNT4 (RTN4).
GN
    RTN4.
OS
    Homo sapiens (Human).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC
OX
    NCBI TaxID=9606;
RN
    [1]
    SEQUENCE FROM N.A.
RP
RA
    Oertle T., van der Putten H., Schwab M.E.;
RT
    "Genomic Structure and Functional Characterization of the Promoter
    Structures of Human and Mouse Nogo/Rtn-4.";
RT
RL
    Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RN
RP
    SEQUENCE FROM N.A.
RA
    Oertle T., Schwab M.E.;
RL
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RN
RP
    SEQUENCE FROM N.A.
RA
    Van der Putten H.;
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
    SEQUENCE FROM N.A.
RP
    TISSUE=Testis;
RC
    MEDLINE=22376540; PubMed=12488097;
RX
    Oertle T., van der Putten H., Schwab M.E.;
RA
    "Genomic Structure and Functional Characterization of the Promoter
RT
    Structures of Human and Mouse Nogo/Rtn-4.";
RT
RT.
    J. Mol. Biol. 325:299-323(2003).
    EMBL; AY102285; AAM64244.1; -.
DR
    EMBL; AY123245; AAM64249.1;
DR
    EMBL; AY123246; AAM64250.1; -.
DR
    EMBL; AY123247; AAM64251.1; -.
DR
    EMBL; AY123248; AAM64252.1; -.
DR
DR
    EMBL; AY123249; AAM64253.1; -.
    EMBL; AY123250; AAM64254.1; -.
DR
    GO; GO:0005783; C:endoplasmic reticulum; IEA.
DR
    InterPro; IPR003388; Reticulon.
DR
DR
    Pfam; PF02453; Reticulon; 1.
    PROSITE; PS50845; RETICULON; 1.
DR
    SEQUENCE 986 AA; 108449 MW; 0CDE8F647036415A CRC64;
SQ
                         63.4%; Score 447; DB 4; Length 986;
 Query Match
                        96.9%; Pred. No. 7.9e-37;
 Best Local Similarity
          93; Conservative
                                                                           0;
                                0; Mismatches
                                                               0; Gaps
 Matches
                                                3; Indels
          46 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 105
Qу
                Db
         796 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 855
         106 QAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
Qу
              856 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 891
Db
```

```
Q8BGK7
ID
                PRELIMINARY; PRT; 1046 AA.
    O8BGK7
AC
    Q8BGK7;
    01-MAR-2003 (TrEMBLrel. 23, Created)
DT
    01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
DΕ
    RTN4.
GN
    RTN4.
OS
    Mus musculus (Mouse).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
    NCBI TaxID=10090;
OX
RN
    [1]
RP
    SEQUENCE FROM N.A.
RC
    STRAIN=129/SvcJ7, and 129SvcJ7;
RA
    Oertle T., van der Putten H., Schwab M.E.;
    "Genomic Structure and Functional Characterization of the Promoter
RT
RT
    Structures of Human and Mouse Nogo/Rtn-4.";
RL
    Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RN
    [2]
    SEQUENCE FROM N.A.
RP
    STRAIN=129/SvcJ7, and 129SvcJ7;
RC
RA
    Oertle T., Schwab M.E.;
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
    SEOUENCE FROM N.A.
RC
    STRAIN=129/SvcJ7;
RA
    Van der Putten H.;
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
    SEQUENCE FROM N.A.
RP
    STRAIN=129SvcJ7;
RC
RA
    Van der Putten H., Mir A.;
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
DR
    EMBL; AY102280; AAM73502.1; -.
    EMBL; AY102286; AAM73507.1; -.
DR
    MGD; MGI:1915835; Rtn4.
DR
    GO; GO:0005783; C:endoplasmic reticulum; IDA.
DR
    GO; GO:0007399; P:neurogenesis; IDA.
DR
DR
    InterPro; IPR003388; Reticulon.
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
DR
    SEQUENCE 1046 AA; 114221 MW; 8CE2E2238ED51222 CRC64;
SQ
                         63.4%; Score 447; DB 11; Length 1046;
  Query Match
                         96.9%; Pred. No. 8.5e-37;
  Best Local Similarity
                            0; Mismatches
                                               3; Indels
                                                              0; Gaps
  Matches 93; Conservative
          46 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 105
Qу
                Db
         856 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 915
         106 QAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
QУ
             916 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 951
Db
```

```
RESULT 6
Q8BGM9
ID
    Q8BGM9
                PRELIMINARY;
                                 PRT; 1162 AA.
AC
    Q8BGM9;
    01-MAR-2003 (TrEMBLrel. 23, Created)
DT
     01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DТ
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
    RTN4.
DE
    RTN4.
GN
OS
    Mus musculus (Mouse).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX
    NCBI TaxID=10090;
RN
    [1]
RΡ
    SEQUENCE FROM N.A.
RC
    STRAIN=129/SvcJ7, and 129SvcJ7;
    Oertle T., van der Putten H., Schwab M.E.;
RA
RT
    "Genomic Structure and Functional Characterization of the Promoter
    Structures of Human and Mouse Nogo/Rtn-4.";
RT
    Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
    [2]
RP
    SEQUENCE FROM N.A.
RC
    STRAIN=129/SvcJ7, and 129SvcJ7;
RΑ
    Oertle T., Schwab M.E.;
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
RΡ
    SEQUENCE FROM N.A.
RC
    STRAIN=129/SvcJ7:
RA
    Van der Putten H.;
RL
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RN
    [4]
RP
    SEQUENCE FROM N.A.
RC
    STRAIN=129SvcJ7;
RΑ
    Van der Putten H., Mir A.;
RL
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
DR
    EMBL; AY102284; AAM73506.1; -.
DR
    EMBL; AY102286; AAM73511.1; -.
DR
    MGD; MGI:1915835; Rtn4.
DR
    GO; GO:0005783; C:endoplasmic reticulum; IDA.
    GO; GO:0007399; P:neurogenesis; IDA.
DR
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
SQ
    SEQUENCE 1162 AA; 126613 MW; 855697FBEE11781F CRC64;
                         63.4%; Score 447; DB 11; Length 1162;
 Query Match
 Best Local Similarity 96.9%; Pred. No. 9.5e-37;
 Matches
          93; Conservative 0; Mismatches
                                               3; Indels
                                                              0; Gaps
Qу
          46 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 105
                Db
         972 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 1031
QУ
         106 QAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
             Db
        1032 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 1067
```

```
RESULT 7
Q8BH78
                                PRT:
ID
                PRELIMINARY;
                                        356 AA.
    Q8BH78
AC
    Q8BH78;
DT
    01-MAR-2003 (TrEMBLrel. 23, Created)
DT
    01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DΕ
    RTN4.
GN
    RTN4.
OS
    Mus musculus (Mouse).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX
    NCBI TaxID=10090;
RN
    [1]
RP
    SEQUENCE FROM N.A.
RC
    STRAIN=129/SvcJ7, and 129SvcJ7;
RA
    Oertle T., van der Putten H., Schwab M.E.;
    "Genomic Structure and Functional Characterization of the Promoter
RT
    Structures of Human and Mouse Nogo/Rtn-4.";
RT
RL
    Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RN
    [2]
RP
    SEQUENCE FROM N.A.
RC
    STRAIN=129/SvcJ7, and 129SvcJ7;
    Oertle T., Schwab M.E.;
RA
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
    SEOUENCE FROM N.A.
RC
    STRAIN=129/SvcJ7;
RA
    Van der Putten H.;
RL
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RN
RP
    SEQUENCE FROM N.A.
RC
    STRAIN=129SvcJ7;
    Van der Putten H., Mir A.;
RA
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
DR
    EMBL; AY102281; AAM73503.1; -.
DR
    EMBL; AY102286; AAM73508.1; -.
DR
    MGD; MGI:1915835; Rtn4.
DR
    GO; GO:0005783; C:endoplasmic reticulum; IDA.
DR
    GO; GO:0007399; P:neurogenesis; IDA.
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
    SEQUENCE
              356 AA; 38403 MW; 4366C03BA9630B56 CRC64;
SQ
 Query Match
                         62.8%; Score 443; DB 11; Length 356;
 Best Local Similarity 98.9%; Pred. No. 6.5e-37;
                             0; Mismatches 1; Indels
 Matches
          92; Conservative
                                                              0; Gaps
                                                                          0:
Qу
          49 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 108
             Db
         169 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 228
         109 AKSDEGHPFRAYLESEVAISEELVOKYSNSALG 141
QУ
              Dh
         229 QKSDEGHPFRAYLESEVAISEELVQKYSNSALG 261
```

```
RESULT 8
Q8BHF5
ID
                PRELIMINARY;
                                  PRT;
                                        375 AA.
    Q8BHF5
AC
    Q8BHF5;
DT
    01-MAR-2003 (TrEMBLrel. 23, Created)
DT
    01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE
    RTN4.
GN
    RTN4.
OS
    Mus musculus (Mouse).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX
    NCBI TaxID=10090;
RN
    [1]
RP
    SEQUENCE FROM N.A.
RC
    STRAIN=129/SvcJ7, and 129SvcJ7;
RA
    Oertle T., van der Putten H., Schwab M.E.;
RT
    "Genomic Structure and Functional Characterization of the Promoter
    Structures of Human and Mouse Nogo/Rtn-4.";
RT
RL
    Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RN
    [2]
RP
    SEQUENCE FROM N.A.
    STRAIN=129/SvcJ7, and 129SvcJ7;
RC
    Oertle T., Schwab M.E.;
RA
RL
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RN
RP
    SEQUENCE FROM N.A.
    STRAIN=129/SvcJ7;
RC
RA
    Van der Putten H.;
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
    SEQUENCE FROM N.A.
RC
    STRAIN=129SvcJ7;
RA
    Van der Putten H., Mir A.;
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RT.
DR
    EMBL; AY102282; AAM73504.1; -.
    EMBL; AY102286; AAM73509.1; -.
DR
DR
    MGD; MGI:1915835; Rtn4.
    GO; GO:0005783; C:endoplasmic reticulum; IDA.
DR
    GO; GO:0007399; P:neurogenesis; IDA.
DR
DR
    InterPro; IPR003388; Reticulon.
    Pfam; PF02453; Reticulon; 1.
    PROSITE; PS50845; RETICULON; 1.
DR
               375 AA; 40300 MW; 23D9EB19BE671AE6 CRC64;
SO
    SEOUENCE
                         62.8%;
 Query Match
                                Score 443; DB 11; Length 375;
                         98.9%;
                               Pred. No. 6.9e-37;
 Best Local Similarity
 Matches
           92; Conservative
                               0; Mismatches
                                                1; Indels
                                                               0; Gaps
                                                                           0;
          49 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 108
Qу
             Db
         188 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 247
         109 AKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
Qу
```

```
RESULT 9
Q96B16
ID
    Q96B16
                 PRELIMINARY;
                                   PRT;
                                          392 AA.
AC
    Q96B16;
DT
     01-DEC-2001 (TrEMBLrel. 19, Created)
     01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DΤ
     01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DT
DE
    Hypothetical protein (RTN4).
GN
     RTN4.
    Homo sapiens (Human).
OS
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX
    NCBI TaxID=9606;
RN
     [1]
RP
     SEQUENCE FROM N.A.
RC
    TISSUE=Kidney;
RA
     Strausberg R.;
     Submitted (OCT-2001) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
     SEQUENCE FROM N.A.
     Oertle T., van der Putten H., Schwab M.E.;
RA
     "Genomic Structure and Functional Characterization of the Promoter
RT
RT
     Structures of Human and Mouse Nogo/Rtn-4.";
RL
     Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RN
RP
     SEQUENCE FROM N.A.
RA
     Oertle T., Schwab M.E.;
     Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
RN
RΡ
     SEQUENCE FROM N.A.
RA
     Van der Putten H.;
RL
     Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RN
RP
     SEQUENCE FROM N.A.
RX
    MEDLINE=22376540; PubMed=12488097;
     Oertle T., van der Putten H., Schwab M.E.;
RA
RT
     "Genomic Structure and Functional Characterization of the Promoter
     Structures of Human and Mouse Nogo/Rtn-4.";
RT
     J. Mol. Biol. 325:299-323(2003).
RL
     EMBL; BC016165; AAH16165.1; -.
DR
     EMBL; AY102285; AAM64242.1; -.
DR
     EMBL; AY102278; AAM64247.1; -.
DR
     GO; GO:0005783; C:endoplasmic reticulum; IEA.
DR
DR
     InterPro; IPR003388; Reticulon.
DR
     Pfam; PF02453; Reticulon; 1.
DR
     PROSITE; PS50845; RETICULON; 1.
KW
     Hypothetical protein.
SQ
     SEQUENCE
              392 AA; 42274 MW; D7B2AA5E839E58AD CRC64;
  Query Match
                          62.8%;
                                  Score 443; DB 4; Length 392;
                                 Pred. No. 7.3e-37;
  Best Local Similarity
                          98.9%;
  Matches
           92; Conservative
                                 0; Mismatches 1; Indels
                                                                 0; Gaps
                                                                              0;
```

```
Db
         205 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 264
Qу
         109 AKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
              Db
         265 QKSDEGHPFRAYLESEVAISEELVQKYSNSALG 297
RESULT 10
Q8K3G8
ID
               PRELIMINARY;
    Q8K3G8
                                PRT; 1163 AA.
AC
    Q8K3G8;
DT
    01-OCT-2002 (TrEMBLrel. 22, Created)
DT
    01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE
    Nogo-A.
GN
    RTN4.
OS
    Mus musculus (Mouse).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
OX
    NCBI TaxID=10090;
RN
    [1]
RP
    SEQUENCE FROM N.A.
RC
    STRAIN=BALB/c;
RA
    Jin W., Long M., Li R., Ju G.;
RT
    "Cloning and expression of the mouse Nogo-A protein.";
    Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
RL
DR
    EMBL; AY114152; AAM77068.1; -.
DR
    MGD; MGI:1915835; Rtn4.
DR
    GO; GO:0005783; C:endoplasmic reticulum; IDA.
DR
    GO; GO:0007399; P:neurogenesis; IDA.
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
    PROSITE; PS50845; RETICULON; 1.
DR
              1163 AA; 126691 MW; 6B5F362799417EA4 CRC64;
SO
    SEQUENCE
 Query Match
                        61.9%;
                               Score 436.5; DB 11; Length 1163;
 Best Local Similarity
                       95.9%; Pred. No. 1.1e-35;
           93; Conservative
                             0; Mismatches
                                              3;
                                                  Indels
                                                           1; Gaps
                                                                      1;
Qy
          46 KDKVVDLLYWRDIKKTGVV-FGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGV 104
              972 KTSVVDLLYWRDIKKTGVVYFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGV 1031
Db
Qу
         105 IQAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
             Db
        1032 IQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 1068
RESULT 11
Q8K3G7
ΙD
    08K3G7
               PRELIMINARY;
                                PRT;
                                      357 AA.
AC
    08K3G7:
    01-OCT-2002 (TrEMBLrel. 22, Created)
DΨ
    01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DΕ
    Nogo-B.
```

```
GN
     RTN4.
OS
    Mus musculus (Mouse).
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX
    NCBI TaxID=10090;
RN
     [1]
RP
     SEQUENCE FROM N.A.
RC
     STRAIN=BALB/c;
RA
     Jin W., Li R., Long M., Shen J., Ju G.;
     "Cloning and expression of the mouse Nogo-B protein.";
RT
RL
     Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases.
    EMBL; AY114153; AAM77069.1; -.
DR
DR
    MGD; MGI:1915835; Rtn4.
DR
    GO; GO:0005783; C:endoplasmic reticulum; IDA.
    GO; GO:0007399; P:neurogenesis; IDA.
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
SO
    SEQUENCE
               357 AA; 38566 MW; 73BB3D17DFDBDF15 CRC64;
 Query Match
                         61.3%; Score 432.5; DB 11; Length 357;
  Best Local Similarity
                         97.9%; Pred. No. 7.7e-36;
 Matches
           92; Conservative
                              0; Mismatches
                                                1; Indels
                                                               1; Gaps
          49 VVDLLYWRDIKKTGVV-FGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 107
Qу
             Db
         169 VVDLLYWRDIKKTGVVYFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIOA 228
         108 IAKSDEGHPFRAYLESEVAISEELVOKYSNSALG 141
Qy
             Db
         229 IQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 262
RESULT 12
Q7YRW9
ID
    Q7YRW9
                PRELIMINARY;
                                 PRT;
                                        184 AA.
    Q7YRW9;
DT
    01-OCT-2003 (TrEMBLrel. 25, Created)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
DE
    RTN4w (Fragment).
GN
    RTN4.
OS
    Bos taurus (Bovine).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovoidea;
OC
    Bovidae; Bovinae; Bos.
OX
    NCBI_TaxID=9913;
RN
    [1]
RP
    SEQUENCE FROM N.A.
RX
    MEDLINE=22715887; PubMed=12832288;
    Oertle T., Klinger M., Stuermer C.A., Schwab M.E.;
RA
RT
    "A reticular rhapsody: phylogenic evolution and nomenclature of the
RT
    RTN/Nogo gene family.";
RL
    FASEB J. 17:1238-1247(2003).
    EMBL; AY164744; AAP47319.1; -.
DR
FT
    NON TER
                  1
                         1
    SEQUENCE
SQ
               184 AA; 20671 MW; DE990E03BBAF84A1 CRC64;
```

```
Query Match
                        59.1%; Score 417; DB 6; Length 184;
                        96.6%; Pred. No. 1.4e-34;
 Best Local Similarity
          86; Conservative 0; Mismatches
                                               3; Indels
                                                                        0;
          53 LYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIAKSD 112
Qy
             Db
           1 LYWRDIKKTGVVFGXXLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIQKSD 60
         113 EGHPFRAYLESEVAISEELVQKYSNSALG 141
Qу
             Db
          61 EGHPFRAYLESEVAISEELVQKYSNSALG 89
RESULT 13
Q9GM33
               PRELIMINARY;
                                PRT;
ΙD
    Q9GM33
                                       179 AA.
AC
    Q9GM33;
DT
    01-MAR-2001 (TrEMBLrel. 16, Created)
    01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
DE
    Hypothetical protein.
    Macaca fascicularis (Crab eating macaque) (Cynomolgus monkey).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
OC
    Mammalia; Eutheria; Primates; Catarrhini; Cercopithecidae;
OC
    Cercopithecinae; Macaca.
    NCBI TaxID=9541;
OX
RN
    SEOUENCE FROM N.A.
RP
RC
    TISSUE=Brain;
RA
    Osada N., Hida M., Kusuda J., Tanuma R., Iseki K., Hirai M., Terao K.,
RA
    Suzuki Y., Sugano S., Hashimoto K.;
RT
    "Isolation of full-length cDNA clones from macaque brain cDNA
RT
    libraries.";
    Submitted (OCT-2000) to the EMBL/GenBank/DDBJ databases.
RL
DR
    EMBL; AB049853; BAB16739.1; -.
    GO; GO:0005783; C:endoplasmic reticulum; IEA.
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
DR
    PROSITE; PS50845; RETICULON; 1.
KW
    Hypothetical protein.
    SEQUENCE 179 AA; 19949 MW; 5F8CD4383FEE9E02 CRC64;
SQ
 Query Match
                        54.8%; Score 386; DB 6; Length 179;
 Best Local Similarity
                        96.4%; Pred. No. 2e-31;
 Matches
         81; Conservative
                              2; Mismatches
                                               1; Indels
                                                            0; Gaps
                                                                        0;
          58 IKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIAKSDEGHPF 117
Qу
             Db
           1 MKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYRGVIQAIQKSDEGHPF 60
         118 RAYLESEVAISEELVQKYSNSALG 141
Qу
             1:11:11:11:11:11:11:11:11:11:11:11
Db
          61 RAYLESEVAISEELVQKYSNSALG 84
```

```
O7T222
ID
     Q7T222
                PRELIMINARY;
                                  PRT;
                                         214 AA.
AC
     O7T222;
     01-OCT-2003 (TrEMBLrel. 25, Created)
DT
     01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT
DT
     01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE
     RTN4-M.
GN
     RTN4.
OS
     Carassius auratus (Goldfish).
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
OC
     Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
OC
     Cyprinidae; Carassius.
OX
     NCBI_TaxID=7957;
RN
     [1]
RP
     SEQUENCE FROM N.A.
RX
     MEDLINE=22715887; PubMed=12832288;
RA
     Oertle T., Klinger M., Stuermer C.A., Schwab M.E.;
RT
     "A reticular rhapsody: phylogenic evolution and nomenclature of the
RT
     RTN/Nogo gene family.";
     FASEB J. 17:1238-1247(2003).
RL
DR
     EMBL; AY164754; AAP47329.1; -.
SQ
     SEQUENCE
               214 AA; 24063 MW; E9B603B043159DD9 CRC64;
  Query Match
                         54.5%; Score 384; DB 13; Length 214;
 Best Local Similarity
                         71.4%; Pred. No. 3.9e-31;
 Matches 70; Conservative 20; Mismatches
                                                 8; Indels
                                                               0; Gaps
                                                                           0;
Qу
          43 KHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYK 102
             Db
          21 KHWKEQVVDLLYWRDLQRTGVVFGASLLLLLSLSVCSIISVISYVALALLSVTISFRIYK 80
         103 GVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSNSAL 140
Qу
             1::||: ||::|||::||
Db
          81 GILQAVQKSEDGHPFKMYLDKDIGISSELVQKYSDTAL 118
RESULT 15
Q9BQ59
ΙD
    Q9BQ59
                PRELIMINARY;
                                  PRT;
                                        199 AA.
AC
     Q9BQ59;
DТ
     01-JUN-2001 (TrEMBLrel. 17, Created)
DT
     01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE
    Similar to reticulon 1.
OS
    Homo sapiens (Human).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX
    NCBI TaxID=9606;
RN
    [1]
RP
    SEQUENCE FROM N.A.
RC
    TISSUE=Lung;
RA
    Strausberg R.;
    Submitted (FEB-2001) to the EMBL/GenBank/DDBJ databases.
RL
DR
    EMBL; BC003003; AAH03003.1; -.
DR
    EMBL; BC000314; AAH00314.1; -.
DR
    GO; GO:0005783; C:endoplasmic reticulum; IEA.
    GO; GO:0000786; C:nucleosome; IEA.
DR
```

```
DR
    GO; GO:0005634; C:nucleus; IEA.
    GO; GO:0003677; F:DNA binding; IEA.
DR
    GO; GO:0007001; P:chromosome organization and biogenesis (sen. . .; IEA.
DR
    GO; GO:0006334; P:nucleosome assembly; IEA.
DR
DR
    InterPro; IPR001951; Histone H4.
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS00047; HISTONE H4; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
             199 AA; 22642 MW; 7CFA44CC568DF6D8 CRC64;
SQ
    SEQUENCE
 Query Match
                       49.4%; Score 348; DB 4; Length 199;
 Best Local Similarity
                       64.0%; Pred. No. 1.7e-27;
 Matches
          64; Conservative 18; Mismatches
                                           18; Indels
                                                          0; Gaps
                                                                     0;
         38 MDGQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 97
Qу
                 Db
          1 MDCVWSNWKSQAIDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATIS 60
         98 FRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSN 137
Qу
            Db
         61 FRIYKSVLQAVQKTDEGHPFKAYLELEITLSQEQIQKYTD 100
```

Search completed: September 29, 2004, 18:19:49 Job time: 12.0927 secs

GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

September 29, 2004, 18:04:48; Search time 2.02133 Seconds Run on:

(without alignments)

3632.211 Million cell updates/sec

Title:

Sequence:

US-09-830-972-32

Perfect score: 705

1 QASGEAGVSCLRENFAVYSV......ESEVAISEELVQKYSNSALG 141

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched:

141681 seqs, 52070155 residues

Total number of hits satisfying chosen parameters:

141681

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

SwissProt 42:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

						~	
-			8				
K	esult No.	Score	Query Match	Length	DB	ID	Description
	1	495	70.2	199	1	RTN4 MOUSE	Q99p72 mus musculu
	2	447	63.4	1163	1	RTN4 RAT	Q9jk11 rattus norv
	3	447	63.4	1192	1	RTN4 HUMAN	Q9nqc3 homo sapien
	4	337	47.8	776	1	RTN1 HUMAN	Q16799 homo sapien
	5	337	47.8	777	1	RTN1 RAT	Q64548 rattus norv
	6	309	43.8	236	1	RTN3 HUMAN	095197 homo sapien
	7	308	43.7	237	1	RTN3 MOUSE	Q9es97 mus musculu
	8	214	30.4	545	1	RTN2 HUMAN	075298 homo sapien
	9	197	27.9	471	1	RTN2 MOUSE	070622 mus musculu
	10	77.5	11.0	243	1	T2RD MOUSE	Q9jka2 mus musculu
	11	77.5	11.0	261	1	PHSC_ECOLI	P77409 escherichia
	12	75.5	10.7	246	1	T2R8 MOUSE	Q9jka0 mus musculu
	13	75.5	10.7	545	1	G6PI_HELPY	O25781 helicobacte
	14	74.5	10.6	545	1	G6PI_HELPJ	Q9zk49 helicobacte
	15	74	10.5	268	1	YC73_HAEIN	P44150 haemophilus
	16	72	10.2	614	1	s6ac_rabit	P48055 oryctolagus
	17	72	10.2	3511	1	MY15_MOUSE	Q9qzz4 mus musculu

```
18
        71
              10.1
                       346 1 3BHS VACCC
                                                            P21097 v 3 beta-hy
19
        71
              10.1
                       346 1
                               3BHS VACCV
                                                          P26670 v 3 beta-hy
20
        70
               9.9
                       960 1
                               GBR1 MOUSE
                                                          Q9wv18 mus musculu
21
        70
              9.9
                       961 1
                               GBR1 HUMAN
                                                          Q9ubs5 homo sapien
                       991 1
                               GBR1 RAT
22
        70
             9.9
                                                          Q9z0u4 rattus norv
                       315 1
23
        69
               9.8
                               LXD1 PHOLE
                                                          P21309 photobacter
                                      P. Q1. P43.
JCUM Q9evhC
THPO 074377
NA P29111 b. 028244 ar. P34183 cael P43754 haemc Q96r17 homo s Q00669 drosoph O59831 schizosa P08158 emericell. Q58107 methanococ. Q9jym1 neisseria m P43439 enterococcu O34996 bacillus su
24
        69
               9.8
                       398 1
                               PGK STRPN
                                                          Q97s89 streptococc
25
        69
              9.8
                       468 1
                               YDBM CAEEL
26
      68.5
            9.7
                       238 1
                               T2RA MOUSE
27
      68.5
            9.7
                       311 1 HTRB HAEIN
28
      68.5
                      325 1 VP35 VARV
               9.7
                      184 1 YDB5_SCHPO
29
      68
               9.6
30
        68
               9.6
                    1447 1 DCC_HUMAN
                               VP35_VACCC
LEU1_BUCUM
                      324 1
31
      67.5
             9.6
32
      67.5
             9.6
                       503 1
33
      67.5
             9.6
                      877 1
                               SULH SCHPO
34
        67
             9.5
                      175 1
                               OLE2 BRANA
                      453 1
35
        67
             9.5
                               SYS ARCFU
                      525 1
756 1
36
        67
              9.5
                               SYH_CAEEL
                               RIRT HAEIN
37
        67
             9.5
38
      66.5
             9.4
                   3174 1 CHAC HUMAN
39
             9.4
      66
                   253 1 ADH_DROAD
40
        66
             9.4
                      537 1 YCUB SCHPO
41
       66 9.4
                      548 1 AMDS EMENI
42
      65.5
             9.3
                      182 1 Y696 METJA
                      398 1 ACK1_NEIMB
664 1 NTPI_ENTHR
880 1 DPO1_BACSU
      65.5 9.3
      65.5 9.3
65.5 9.3
43
44
45
      65.5 9.3
```

ALIGNMENTS

```
RESULT 1
RTN4 MOUSE
                STANDARD;
ID
     RTN4 MOUSE
                                   PRT;
                                          199 AA.
     Q99P72; Q9CTE3;
AC
     28-FEB-2003 (Rel. 41, Created)
     28-FEB-2003 (Rel. 41, Last sequence update)
     28-FEB-2003 (Rel. 41, Last annotation update)
DT
DΕ
     Reticulon 4 (Neurite outgrowth inhibitor) (Nogo protein).
GN
    RTN4 OR NOGO.
OS
    Mus musculus (Mouse).
OC
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX
    NCBI TaxID=10090;
RN
     [1]
RP
     SEQUENCE FROM N.A.
RC
     STRAIN=3T3-L1; TISSUE=Adipocyte;
     Coulson A.C., Craggs P.D., Morris N.J.;
RA
RT
     "Mouse vp20/RTN4C cDNA.";
     Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases.
RN
RP
     SEQUENCE OF 170-199 FROM N.A.
RC
     STRAIN=C57BL/6J; TISSUE=Embryo;
     MEDLINE=21085660; PubMed=11217851;
RX
RA
     Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
```

```
RA
     Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
RA
     Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,
     Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
RA
RA
     Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
RA
     Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
RA
     Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,
     Schriml L.M., Staubli F., Suzuki R., Tomita M., Wagner L., Washio T.,
RA
RA
     Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
RA
     Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
RA
     Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
RA
     Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,
RA
     Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
RA
     Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
RA
     Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
RA
     Suzuki H., Toyo-oka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
     Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohtsuki S.,
RA
RA
     Hayashizaki Y.;
RT
     "Functional annotation of a full-length mouse cDNA collection.";
RL
     Nature 409:685-690(2001).
     -!- FUNCTION: Potent neurite outgrowth inhibitor which may also help
CC
CC
        block the regeneration of the nervous central system in adults (By
CC
        similarity).
CC
    -!- SUBUNIT: Binds to RTN4R. Interacts with Bcl-xl and Bcl-2 (By
CC
        similarity).
CC
    -!- SUBCELLULAR LOCATION: Integral membrane protein. Anchored to the
CC
        membrane of the endoplasmic reticulum through 2 putative
        transmembrane domains (By similarity).
CC
CC
    -!- ALTERNATIVE PRODUCTS:
CC
        Event=Alternative splicing; Named isoforms=1;
CC
          Comment=A number of isoforms may be produced;
CC
CC
          IsoId=Q99P72-1; Sequence=Displayed;
CC
    -!- SIMILARITY: Contains 1 reticulon domain.
CC
     ______
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
    modified and this statement is not removed. Usage by and for commercial
CC
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
     DR
    EMBL; AF326337; AAK08076.1; -.
DR
    EMBL; AK003859; -; NOT ANNOTATED CDS.
DR
    MGD; MGI:1915835; Rtn4.
DR
    GO; GO:0005783; C:endoplasmic reticulum; IDA.
DR
    GO; GO:0030176; C:integral to endoplasmic reticulum membrane; ISS.
DR
    GO; GO:0005635; C:nuclear membrane; ISS.
DR
    GO; GO:0005515; F:protein binding; ISS.
DR
    GO; GO:0019987; P:negative regulation of anti-apoptosis; ISS.
DR
    GO; GO:0030517; P:negative regulation of axon extension; ISS.
DR
    GO; GO:0007399; P:neurogenesis; IDA.
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
KW
    Endoplasmic reticulum; Alternative splicing; Transmembrane.
FT
    DOMAIN
                  1
                       25 CYTOPLASMIC (Potential).
```

```
FΤ
     TRANSMEM
                 26
                        50
                                 POTENTIAL.
FT
     DOMAIN
                 51
                       137
                                 LUMENAL (Potential).
FT
     TRANSMEM
                138
                       162
                                 POTENTIAL.
FT
                163
                       199
     DOMAIN
                                 CYTOPLASMIC (Potential).
FT
     DOMAIN
                 12
                       199
                                 RETICULON.
SO
               199 AA; 22466 MW; 07BE5D580059ED9C CRC64;
     SEQUENCE
  Query Match
                         70.2%; Score 495; DB 1; Length 199;
  Best Local Similarity 97.1%; Pred. No. 2.6e-41;
  Matches 101; Conservative
                               0; Mismatches
                                                3; Indels
                                                               0; Gaps
                                                                           0;
           38 MDGQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 97
Qy
              11 114 114144441414144444
Db
            1 MDDQKKRWKDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTIS 60
Qу
           98 FRIYKGVIQAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
              Dh
           61 FRIYKGVIQAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 104
RESULT 2
RTN4 RAT
ID
                   STANDARD;
                                  PRT; 1163 AA.
AC
     Q9JK11; Q9JK10; Q9R0D9; Q9WUE9; Q9WUF0;
DΤ
     28-FEB-2003 (Rel. 41, Created)
     28-FEB-2003 (Rel. 41, Last sequence update)
DT
     10-OCT-2003 (Rel. 42, Last annotation update)
DT
     Reticulon 4 (Neurite outgrowth inhibitor) (Nogo protein) (Foocen)
DΕ
DΕ
     (Glut4 vesicle 20 kDa protein).
GN
    RTN4 OR NOGO.
OS
     Rattus norvegicus (Rat).
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OC
OX
    NCBI TaxID=10116;
RN
     [1]
     SEQUENCE FROM N.A. (ISOFORM 3), AND PARTIAL SEQUENCE.
RP
RC
     STRAIN=Sprague-Dawley; TISSUE=Adipocyte;
RX
    MEDLINE=99249816; PubMed=10231557;
RA
    Morris N.J., Ross S.A., Neveu J.M., Lane W.S., Lienhard G.E.;
RT
     "Cloning and characterization of a 22 kDa protein from rat adipocytes:
RT
     a new member of the reticulon family.";
RL
     Biochim. Biophys. Acta 1450:68-76(1999).
RN
RP
     SEQUENCE FROM N.A. (ISOFORMS 1; 2 AND 3).
RX
    MEDLINE=20129258; PubMed=10667796;
RA
    Chen M.S., Huber A.B., Van der Haar M.E., Frank M., Schnell L.,
RA
     Spillmann A.A., Christ F., Schwab M.E.;
RT
     "Nogo-A is a myelin-associated neurite outgrowth inhibitor and an
RT
     antigen for monoclonal antibody IN-1.";
RI.
    Nature 403:434-439(2000).
RN
RP
    SEQUENCE FROM N.A. (ISOFORMS 2 AND 4).
RC
    STRAIN=Wistar Kyoto; TISSUE=Vascular smooth muscle;
RA
    Ito T., Schwartz S.M.;
     "Cloning of a member of the reticulon gene family in rat: one of two
RT
RT
    minor splice variants.";
RL
    Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases.
```

```
RN
     [4]
RP
     FUNCTION.
RX
     MEDLINE=22033691; PubMed=12037567;
RA
     GrandPre T., Li S., Strittmatter S.M.;
RT
     "Nogo-66 receptor antagonist peptide promotes axonal regeneration.";
RL
     Nature 417:547-551(2002).
CC
     -!- FUNCTION: Potent neurite outgrowth inhibitor which may also help
CC
         block the regeneration of the nervous central system in adults (By
CC
         similarity).
     -!- SUBUNIT: Binds to RTN4R. Interacts with Bcl-xl and Bcl-2 (By
CC
CC
         similarity).
CC
     -!- SUBCELLULAR LOCATION: Integral membrane protein. Anchored to the
CC
         membrane of the endoplasmic reticulum through 2 putative
CC
         transmembrane domains (By similarity).
CC
     -!- ALTERNATIVE PRODUCTS:
         Event=Alternative splicing; Named isoforms=4;
CC
CC
         Name=1; Synonyms=Nogo-A, NI-220-250;
           IsoId=Q9JK11-1; Sequence=Displayed;
CC
CC
         Name=2; Synonyms=Nogo-B, Foocen-M1;
CC
           IsoId=Q9JK11-2; Sequence=VSP 005658;
CC
         Name=3; Synonyms=Nogo-C, VP20;
CC
           IsoId=Q9JK11-3; Sequence=VSP_005656, VSP_005657;
CC
         Name=4; Synonyms=Foocen-M2;
CC
           IsoId=Q9JK11-4; Sequence=VSP 005659;
     -!- TISSUE SPECIFICITY: Isoforms 1, 2 and 3 are present in optic
CC
CC
         nerve, spinal cord and cerebral cortex. Isoforms 1 and 2 are
CC
         present in dorsal root ganglion, sciatic nerve and PC12 cells
CC
         after longer exposure. Isoforms 2 and 3 are detected in kidney,
CC
         cartilage, skin, lung and spleen. Isoform 3 is expressed at high
CC
        level in skeletal muscle. In adult animals isoform 1 is expressed
CC
        mainly in the nervous system.
     -!- SIMILARITY: Contains 1 reticulon domain.
CC
CC
     CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
CC
     use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
     or send an email to license@isb-sib.ch).
CC
     ______
DR
     EMBL; AF051335; AAF01564.1; -.
DR
    EMBL; AJ242961; CAB71027.1; -.
DR
    EMBL; AJ242962; CAB71028.1; -.
DR
    EMBL; AJ242963; CAB71029.1; -.
DR
    EMBL; AF132045; AAD31019.1; -.
    EMBL; AF132046; AAD31020.1; -.
DR
    GO; GO:0030176; C:integral to endoplasmic reticulum membrane; IDA.
    GO; GO:0005635; C:nuclear membrane; ISS.
DR
DR
    GO; GO:0005515; F:protein binding; ISS.
DR
    GO; GO:0019987; P:negative regulation of anti-apoptosis; ISS.
    GO; GO:0030517; P:negative regulation of axon extension; ISS.
DR
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
ΚW
    Endoplasmic reticulum; Alternative splicing; Transmembrane.
    DOMAIN 1 989 CYTOPLASMIC (Potential).
FT
```

```
FT
     TRANSMEM
                990
                       1010
                                  POTENTIAL.
FT
     DOMAIN
                1011
                       1104
                                 LUMENAL (Potential).
FT
     TRANSMEM
                1105
                       1125
                                 POTENTIAL.
FT
     DOMAIN
                1126
                      1163
                                 CYTOPLASMIC (Potential).
FT
     DOMAIN
                 976
                       1163
                                 RETICULON.
FT
     DOMAIN
                  33
                         46
                                 POLY-GLU.
FT
     DOMAIN
                  73
                         76
                                 POLY-ALA.
FT
     DOMAIN
                 140
                        145
                                 POLY-PRO.
FT
     VARSPLIC
                 1
                        964
                                 Missing (in isoform 3).
FT
                                 /FTId=VSP 005656.
FT
     VARSPLIC
                                 AVLSAELSKTS -> MDGQKKHWKDK (in isoform
                 965
                        975
FT
FT
                                 /FTId=VSP 005657.
FT
     VARSPLIC
                 173
                        975
                                 Missing (in isoform 2).
FT
                                 /FTId=VSP 005658.
FT
     VARSPLIC
                192
                       975
                                 Missing (in isoform 4).
FT
                                 /FTId=VSP 005659.
FT
     CONFLICT
               1130
                      1131
                                 MISSING (IN REF. 3; AAD31020).
SO
     SEQUENCE
               1163 AA; 126386 MW; 8CB894B09E94F0B6 CRC64;
  Query Match
                         63.4%;
                                 Score 447; DB 1; Length 1163;
  Best Local Similarity
                         96.9%; Pred. No. 8.2e-36;
            93; Conservative
                                0; Mismatches
                                               3; Indels
                                                               0; Gaps
                                                                           0;
           46 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 105
Qу
                Db
          973 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 1032
          106 QAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
Qу
              Db
         1033 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 1068
RESULT 3
RTN4 HUMAN
ID
     RTN4 HUMAN
                               PRT; 1192 AA.
                   STANDARD;
     Q9NQC3; 094962; Q9BXG5; Q9H212; Q9H3I3; Q9UQ42; Q9Y293; Q9Y2Y7;
AC
AC
     09Y5U6:
DT
     28-FEB-2003 (Rel. 41, Created)
     28-FEB-2003 (Rel. 41, Last sequence update)
DT
     15-MAR-2004 (Rel. 43, Last annotation update)
DT
    Reticulon 4 (Neurite outgrowth inhibitor) (Nogo protein) (Foocen)
DE
     (Neuroendocrine-specific protein) (NSP) (Neuroendocrine specific
DE
DΕ
     protein C homolog) (RTN-x) (Reticulon 5) (My043 protein).
GN
     RTN4 OR NOGO OR ASY OR KIAA0886.
OS
    Homo sapiens (Human).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC
OX
    NCBI TaxID=9606;
RN
    [1]
RP
    SEQUENCE FROM N.A. (ISOFORMS 1; 2 AND 3).
RX
    MEDLINE=20129242; PubMed=10667780;
    Prinjha R., Moore S.E., Vinson M., Blake S., Morrow R., Christie G.,
RA
    Michalovich D., Simmons D.L., Walsh F.S.;
RA
    "Inhibitor of neurite outgrowth in humans.";
RT
RL
    Nature 403:383-384(2000).
RN
    [2]
```

```
SEQUENCE FROM N.A. (ISOFORMS 1 AND 2).
RP
RC
     TISSUE=Brain;
RX
     MEDLINE=21010696; PubMed=11126360;
     Tagami S., Eguchi Y., Kinoshita M., Takeda M., Tsujimoto Y.;
RA
RT
     "A novel protein, RTN-XS, interacts with both Bcl-XL and Bcl-2 on
RТ
     endoplasmic reticulum and reduces their anti-apoptotic activity.";
RL
     Oncogene 19:5736-5746(2000).
RN
RP
     SEQUENCE FROM N.A. (ISOFORMS 1; 2 AND 3).
RX
     MEDLINE=20237542; PubMed=10773680;
RA
     Yang J., Yu L., Bi A.D., Zhao S.-Y.;
RT
     "Assignment of the human reticulon 4 gene (RTN4) to chromosome
RT
     2p14-->2p13 by radiation hybrid mapping.";
     Cytogenet. Cell Genet. 88:101-102(2000).
RL
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 4).
RA
     Jin W.-L., Ju G.;
RT
     "Developmentally-regulated alternative splicing in a novel Nogo-A.";
RL
     Submitted (NOV-2000) to the EMBL/GenBank/DDBJ databases.
RN
RP
     SEQUENCE FROM N.A. (ISOFORMS 2 AND 3).
RC
     TISSUE=Placenta, and Skeletal muscle;
RA
     Ito T., Schwartz S.M.;
RT
     "Cloning of a member of the reticulon gene family in human.";
     Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases.
RL
RN
RΡ
     SEQUENCE FROM N.A. (ISOFORM 2).
     TISSUE=Fibroblast;
RC
RA
     Yutsudo M.;
RT
     "Isolation of a cell death-inducing gene.";
     Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 3).
RC
     TISSUE=Pituitary;
     Song H., Peng Y., Zhou J., Huang Q., Dai M., Mao Y.M., Yu Y., Xu X.,
RA
RA
     Luo B., Hu R., Chen J.;
RT
     "Human neuroendocrine-specific protein C (NSP) homolog gene.";
     Submitted (JUL-1998) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 3).
     Gu J.R., Wan D.F., Zhao X.T., Zhou X.M., Jiang H.Q., Zhang P.P.,
RA
     Qin W.X., Huang Y., Qiu X.K., Qian L.F., He L.P., Li H.N., Yu Y.,
RA
RA
     Yu J., Han L.H.;
RT
     "Novel human cDNA clone with function of inhibiting cancer cell
RT
     growth.";
     Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
     SEQUENCE FROM N.A. (ISOFORM 1).
RC
     TISSUE=Brain;
RX
     MEDLINE=99156230; PubMed=10048485;
RA
     Nagase T., Ishikawa K.-I., Suyama M., Kikuno R., Hirosawa M.,
     Miyajima N., Tanaka A., Kotani H., Nomura N., Ohara O.;
RA
RT
     "Prediction of the coding sequences of unidentified human genes. XII.
RT
     The complete sequences of 100 new cDNA clones from brain which code
RT
     for large proteins in vitro.";
RL
     DNA Res. 5:355-364(1998).
RN
     [10]
```

```
SEQUENCE FROM N.A. (ISOFORMS 2 AND 3).
RP
RC
     TISSUE=Brain, Ovary, Pancreas, Placenta, and Skeletal muscle;
ŔХ
     MEDLINE=22388257; PubMed=12477932;
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
RA
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
     Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
     Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA
     Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA
RA
     Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT
     "Generation and initial analysis of more than 15,000 full-length
RT
     human and mouse cDNA sequences.";
RL
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN
     [11]
RΡ
     SEQUENCE FROM N.A. (ISOFORM 3).
RX
     MEDLINE=20499367; PubMed=11042152;
RA
     Zhang Q.-H., Ye M., Wu X.-Y., Ren S.-X., Zhao M., Zhao C.-J., Fu G.,
RA
     Shen Y., Fan H.-Y., Lu G., Zhong M., Xu X.-R., Han Z.-G., Zhang J.-W.,
RA
     Tao J., Huang Q.-H., Zhou J., Hu G.-X., Gu J., Chen S.-J., Chen Z.;
     "Cloning and functional analysis of cDNAs with open reading frames for
RT
     300 previously undefined genes expressed in CD34+ hematopoietic
RT
RT
     stem/progenitor cells.";
RL
     Genome Res. 10:1546-1560(2000).
RN
     [12]
RP
     SEQUENCE OF 482-1192 FROM N.A. (ISOFORM 1/4).
     TISSUE=Brain;
RC
RA
     Mao Y.M., Xie Y., Zheng Z.H.;
RL
     Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN
RP
     SEQUENCE OF 186-1192 FROM N.A. (ISOFORM 1).
RC
     TISSUE=Testis;
RA
     Sha J.H., Zhou Z.M., Li J.M.;
     Submitted (JAN-2001) to the EMBL/GenBank/DDBJ databases.
RL
RN
     [14]
RP
     TOPOLOGY.
RC
     TISSUE=Brain;
RX
    MEDLINE=20129259; PubMed=10667797;
     GrandPre T., Nakamura F., Vartanian T., Strittmatter S.M.;
RA
RT
     "Identification of the Nogo inhibitor of axon regeneration as a
RT
     Reticulon protein.";
RL
    Nature 403:439-444(2000).
RN
     [15]
RP
    FUNCTION.
RC
    TISSUE=Brain;
RX
    MEDLINE=21069055; PubMed=11201742;
RA
     Fournier A.E., Grandpre T., Strittmatter S.M.;
RT
     "Identification of a receptor mediating Nogo-66 inhibition of axonal
```

```
RT
     regeneration.";
RL
     Nature 409:341-346(2001).
RN
RP
     REVIEW.
RX
     MEDLINE=21888956; PubMed=11891768;
RA
     Ng C.E.L., Tang B.L.;
RT
     "Nogos and the Nogo-66 receptor: factors inhibiting CNS neuron
RT
     regeneration.";
RL
     J. Neurosci. Res. 67:559-565(2002).
     -!- FUNCTION: Potent neurite outgrowth inhibitor which may also help
CC
CC
         block the regeneration of the nervous central system in adults.
CC
         Isoform 2 reduces the anti-apoptotic activity of Bcl-xl and Bcl-2.
CC
         This is likely consecutive to their change in subcellular
CC
         location, from the mitochondria to the endoplasmic reticulum,
CC
         after binding and sequestration.
CC
     -!- SUBUNIT: Binds to RTN4R. Interacts with Bcl-xl and Bcl-2.
     -!- SUBCELLULAR LOCATION: Integral membrane protein. Endoplasmic
CC
CC
         reticulum. Anchored to the membrane of the endoplasmic reticulum
         through 2 putative transmembrane domains.
CC
CC
     -!- ALTERNATIVE PRODUCTS:
CC
         Event=Alternative splicing; Named isoforms=4;
CC
         Name=1; Synonyms=RTN 4A, Nogo-A, RTN-xL;
CC
           IsoId=Q9NQC3-1; Sequence=Displayed;
CC
         Name=2; Synonyms=RTN 4B, Nogo-B, RTN-xS, Foocen-M;
CC
           IsoId=Q9NQC3-2; Sequence=VSP 005655;
CC
         Name=3; Synonyms=RTN 4C, Nogo-C, Foocen-S;
CC
           IsoId=Q9NQC3-3; Sequence=VSP 005652, VSP 005653;
CC
         Name=4;
CC
           IsoId=Q9NQC3-4; Sequence=VSP 005654;
     -!- TISSUE SPECIFICITY: Isoform 1 \overline{i}s specifically expressed in brain
CC
CC
         and testis and weakly in heart and skeletal muscle. Isoform 2 is
CC
         widely expressed excepted for the liver. Isoform 3 is expressed in
         brain, skeletal muscle and adipocytes. Isoform 4 is testis-
CC
CC
         specific.
     -!- SIMILARITY: Contains 1 reticulon domain.
CC
CC
     -!- CAUTION: Ref.11 sequence differs from that shown due to
CC
         frameshifts in positions 1149 and 1156.
     ______
CC
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
     use by non-profit institutions as long as its content is in no way
    modified and this statement is not removed. Usage by and for commercial
CC
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
     or send an email to license@isb-sib.ch).
CC
DR
     EMBL; AJ251383; CAB99248.1; -.
DR
     EMBL; AJ251384; CAB99249.1; -.
DR
     EMBL; AJ251385; CAB99250.1; -.
DR
    EMBL; AB040462; BAB18927.1; -.
DR
    EMBL; AB040463; BAB18928.1; -.
    EMBL; AF148537; AAG12176.1; -.
DR
    EMBL; AF148538; AAG12177.1; -.
DR
    EMBL; AF087901; AAG12205.1; -.
DR
    EMBL; AF320999; AAG40878.1; -.
DR
DR
    EMBL; AF132047; AAD31021.1; -.
DR
    EMBL; AF132048; AAD31022.1; -.
```

```
DR
     EMBL; AB015639; BAA83712.1; -.
DR
     EMBL; AF077050; AAD27783.1; -.
DR
     EMBL; AF177332; AAG17976.1; -.
DR
     EMBL; AB020693; BAA74909.1; -.
DR
     EMBL; BC001035; AAH01035.1; -.
DR
     EMBL; BC007109; AAH07109.1; -.
DR
     EMBL; BC014366; AAH14366.1; -.
  Query Match
                          63.4%; Score 447; DB 1; Length 1192;
  Best Local Similarity
                          96.9%; Pred. No. 8.4e-36;
            93; Conservative
                                0; Mismatches
                                                  3; Indels
                                                                0;
                                                                    Gaps
                                                                            0;
           46 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 105
Qу
                 Db
         1002 KTSVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 1061
          106 QAIAKSDEGHPFRAYLESEVAISEELVQKYSNSALG 141
Qу
              Db
         1062 QAIQKSDEGHPFRAYLESEVAISEELVQKYSNSALG 1097
RESULT 4
RTN1 HUMAN
     RTN1 HUMAN
                   STANDARD:
                                  PRT;
                                         776 AA.
     Q16799; Q16800; Q16801;
AC
     16-OCT-2001 (Rel. 40, Created)
DТ
DΤ
     16-OCT-2001 (Rel. 40, Last sequence update)
DT
     10-OCT-2003 (Rel. 42, Last annotation update)
DE
     Reticulon 1 (Neuroendocrine-specific protein).
GN
     RTN1 OR NSP.
OS
     Homo sapiens (Human).
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC
OX
     NCBI TaxID=9606;
RN
     [1]
     SEQUENCE FROM N.A. (ISOFORMS RTN1-A; RTN1-B AND RTN1-C).
RP
RC
     TISSUE=Lung carcinoma;
RX
     MEDLINE=93293865; PubMed=7685762;
     Roebroek A.J.M., Van de Velde H.J.K., Van Bokhoven A., Broers J.L.V.,
RA
     Ramaekers F.C.S., Van de Ven W.J.M.;
RΑ
     "Cloning and expression of alternative transcripts of a novel
RT
RT
     neuroendocrine-specific gene and identification of its 135-kDa
RT
     translational product.";
RL
     J. Biol. Chem. 268:13439-13447(1993).
RN
     [2]
RΡ
     ALTERNATIVE SPLICING.
    MEDLINE=96429995; PubMed=8833145;
RX
RA
     Roebroek A.J.M., Ayoubi T.A.Y., Van de Velde H.J.K.,
     Schoenmakers E.F.P.M., Pauli I.G.L., Van de Ven W.J.M.;
RA
     "Genomic organization of the human NSP gene, prototype of a novel gene
RT
RT
     family encoding reticulons.";
    Genomics 32:191-199(1996).
RL
RN
    [3]
    TISSUE SPECIFICITY.
RP
RX
    MEDLINE=98228245; PubMed=9560466;
    Hens J., Nuydens R., Geerts H., Senden N.H., Van de Ven W.J.M.,
RA
    Roebroek A.J., van de Velde H.J.K., Ramaekers F.C., Broers J.L.;
RA
```

```
RT
     "Neuronal differentiation is accompanied by NSP-C expression.";
RL
     Cell Tissue Res. 292:229-237(1998).
CC
     -!- FUNCTION: May be involved in neuroendocrine secretion or in
CC
         membrane trafficking in neuroendocrine cells.
CC
     -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane.
CC
     -!- ALTERNATIVE PRODUCTS:
CC
         Event=Alternative splicing; Named isoforms=3;
CC
        Name=RTN1-A; Synonyms=NSP-A;
CC
          IsoId=Q16799-1; Sequence=Displayed;
CÇ
        Name=RTN1-B; Synonyms=NSP-B;
CC
          IsoId=Q16799-2; Sequence=VSP 005644;
CC
        Name=RTN1-C; Synonyms=NSP-C;
CC
          IsoId=Q16799-3; Sequence=VSP 005645, VSP 005646;
CC
     -!- TISSUE SPECIFICITY: EXPRESSED IN NEURAL AND NEUROENDOCRINE TISSUES
        AND CELL CULTURES DERIVED THEREFROM. EXPRESSION OF ISOFORM RTN1-C
CC
        IS STRONGLY CORRELATED WITH NEURONAL DIFFERENTIATION.
CC
CC
     -!- PTM: Isoforms RTN1-A and RTN1-B are phosphorylated.
CC
     -!- SIMILARITY: Contains 1 reticulon domain.
CC
     ______
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
     the European Bioinformatics Institute. There are no restrictions on its
CC
CC
     use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
     CC
DR
    EMBL; L10333; AAA59950.1; -.
DR
    EMBL; L10334; AAA59951.1; -.
DR
    EMBL; L10335; AAA59952.1; -.
    PIR; A46583; A46583.
    PIR; I60904; I60904.
DR
DR
    Genew; HGNC:10467; RTN1.
DR
    MIM; 600865; -.
DR
    GO; GO:0030176; C:integral to endoplasmic reticulum membrane; TAS.
DR
    GO; GO:0004871; F:signal transducer activity; NAS.
    GO; GO:0030182; P:neuron differentiation; TAS.
DR
DR
    GO; GO:0007165; P:signal transduction; NAS.
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
KW
    Endoplasmic reticulum; Alternative splicing; Transmembrane;
KW
    Phosphorylation.
FT
    TRANSMEM
               603
                      623
                               POTENTIAL.
FT
    TRANSMEM
               726
                     746
                               POTENTIAL.
FT
    DOMAIN
               589 776
                               RETICULON.
FT
                609
    DOMAIN
                      612
                               POLY-LEU.
FT
    VARSPLIC
              1
                      420
                               Missing (in isoform RTN1-B).
FT
                               /FTId=VSP 005644.
FT
                               Missing (in isoform RTN1-C).
    VARSPLIC
               1
                      568
FT
                               /FTId=VSP 005645.
FT
    VARSPLIC
               569
                      588
                               GPGPLGPGAPPPLLFLNKQK -> MQATADSTKMDCVWSNW
FT
                               KSQ (in isoform RTN1-C).
FT
                               /FTId=VSP 005646.
SQ
    SEQUENCE 776 AA; 83617 MW; CA5B6232353096FE CRC64;
 Query Match
                       47.8%; Score 337; DB 1; Length 776;
```

```
Best Local Similarity 67.4%; Pred. No. 3e-25;
  Matches
           62; Conservative 16; Mismatches 14; Indels 0; Gaps
                                                                            0;
Qу
           46 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 105
              Db
          586 KQKAIDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATISFRIYKSVL 645
          106 QAIAKSDEGHPFRAYLESEVAISEELVQKYSN 137
Qу
              11: 1:111111:111 1: :1:1 :111::
Db
          646 QAVQKTDEGHPFKAYLELEITLSQEQIQKYTD 677
RESULT 5
RTN1 RAT
     RTN1 RAT
ID
                   STANDARD; PRT; 777 AA.
     Q64548; Q64547;
     16-OCT-2001 (Rel. 40, Created)
     16-OCT-2001 (Rel. 40, Last sequence update)
DT
     10-OCT-2003 (Rel. 42, Last annotation update)
DT
     Reticulon 1 (Neuroendocrine-specific protein) (S-rex).
DΕ
GN
     RTN1 OR NSP.
OS
     Rattus norvegicus (Rat).
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OC
OX
     NCBI TaxID=10116;
RN
     [1]
     SEQUENCE FROM N.A. (ISOFORMS RTN1-B AND RTN1-S).
RP
     STRAIN=Wistar; TISSUE=Brain cortex;
RC
RX
     MEDLINE=96386034; PubMed=8793864;
     Baka I.D., Ninkina N.N., Pinon L.G.P., Adu J., Davies A.M.,
RA
     Georgiev G.P., Buchman V.L.;
     "Intracellular compartmentalization of two differentially spliced s-
RT
RT
     rex/NSP mRNAs in neurons.";
RL
     Mol. Cell. Neurosci. 7:289-303(1996).
CC
     -!- FUNCTION: May be involved in neuroendocrine secretion or in
CC
        membrane trafficking in neuroendocrine cells.
     -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane (By
CC
CC
        similarity).
CC
    -!- ALTERNATIVE PRODUCTS:
CC
        Event=Alternative splicing; Named isoforms=2;
CC
        Name=RTN1-B; Synonyms=S-RexB;
CC
          IsoId=Q64548-1; Sequence=Displayed;
CC
        Name=RTN1-S; Synonyms=S-RexS;
CC
          IsoId=Q64548-2; Sequence=VSP_005647, VSP_005648;
    -!- TISSUE SPECIFICITY: EXPRESSED PREDOMINANTLY IN CENTRAL AND
CC
        PERIPHERAL NERVOUS SYSTEM OF NEWBORN AND ADULT RATS. LOW LEVELS
CC
        HAVE BEEN ALSO DETECTED IN HEART, ADRENAL GLAND AND SPLEEN.
CC
        EXPRESSION OF ISOFORM RTN1-B IS RESTRICTED TO PARTICULAR NEURONAL
CC
        TYPES.
CC
    -!- DEVELOPMENTAL STAGE: DETECTED ON EMBRYONIC DAY E10 IN THE
CC
        HINDBRAIN AND IN E11 IN THE FOREBRAIN. DURING THE NEXT 3 EMBRYONIC
        DAYS THE LEVELS OF S-REXS INCREASES AND REMAINS STABLE AT E13 IN
CC
CC
        THE HINDBRAIN AND AT E14 IN THE FOREBRAIN. THE LEVELS OF S-REXB
CC
        DOES NOT CHANGE AS SIGNIFICANTLY DURING DEVELOPMENT OF THE
CC
        HINDBRAIN.
CC
    -!- SIMILARITY: Contains 1 reticulon domain.
```

```
This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
     use by non-profit institutions as long as its content is in no way
CC
     modified and this statement is not removed. Usage by and for commercial
CC
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
     or send an email to license@isb-sib.ch).
     _____
CC
DR
     EMBL; U17604; AAC53046.1; -.
DR
     EMBL; U17603; AAC53045.1; -.
DR
     InterPro; IPR003388; Reticulon.
     Pfam; PF02453; Reticulon; 1.
DR
     PROSITE; PS50845; RETICULON; 1.
DR
KW
     Endoplasmic reticulum; Alternative splicing; Transmembrane.
FΨ
     TRANSMEM
                604
                      624
                                POTENTIAL.
FT
     TRANSMEM
                727
                      747
                               POTENTIAL.
FT
     DOMAIN
               590
                    777
                               RETICULON.
                              POLY-LEU.
                610 613
FT
     DOMAIN
FT
     VARSPLIC
               1
                      569
                               Missing (in isoform RTN1-S).
FT
                               /FTId=VSP 005647.
\operatorname{FT}
     VARSPLIC 570 589
                                IPGPLGSDLVPPLPFFNKQK -> MQATADSTKMDCVWSNW
FT
                                KSQ (in isoform RTN1-S).
FT
                                /FTId=VSP 005648.
     SEQUENCE 777 AA; 83001 MW; AF7479C50F28D0AC CRC64;
SO
  Query Match
                        47.8%; Score 337; DB 1; Length 777;
  Best Local Similarity 67.4%; Pred. No. 3e-25;
           62; Conservative 16; Mismatches 14; Indels
                                                           0; Gaps
          46 KDKVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVI 105
Qу
             587 KQKAIDLLYWRDIKQTGIVFGSFLLLLFSLTQFSVVSVVAYLALAALSATISFRIYKSVL 646
Db
Qу
         106 QAIAKSDEGHPFRAYLESEVAISEELVQKYSN 137
             11: 1:111111:1111 1: :1:1 :111::
Db
         647 QAVQKTDEGHPFKAYLELEITLSQEQIQKYTD 678
RESULT 6
RTN3 HUMAN
    RTN3 HUMAN
                  STANDARD;
                               PRT; 236 AA.
AC
    095197;
    16-OCT-2001 (Rel. 40, Created)
DT
DT
    16-OCT-2001 (Rel. 40, Last sequence update)
DT
    10-OCT-2003 (Rel. 42, Last annotation update)
    Reticulon protein 3 (Neuroendocrine-specific protein-like 2) (NSP-like
DE
    protein II) (NSPLII).
GN
    RTN3 OR NSPL2.
OS
    Homo sapiens (Human).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC
OX
    NCBI TaxID=9606;
RN
RP
    SEQUENCE FROM N.A., AND TISSUE SPECIFICITY.
RC
    TISSUE=Retina;
RX
    MEDLINE=99265974; PubMed=10331947;
RA
    Moreira E.F., Jaworski C.J., Rodriguez I.R.;
```

```
"Cloning of a novel member of the reticulon gene family (RTN3): gene
 RT
RT
      structure and chromosomal localization to 11q13.";
RL
     Genomics 58:73-81(1999).
RN
RP
     SEQUENCE FROM N.A.
RA
     Huang X., Zhou Y., Du G., Yuan J., Qiang B.;
     "Cloning and expression analysis of a cDNA encoding a novel
RT
RT
     neuroendocrine-specific protein-like protein 1: NSPL1.";
RL
     Submitted (JAN-1999) to the EMBL/GenBank/DDBJ databases.
RN
     SEQUENCE FROM N.A.
RP
RC
     TISSUE=Brain, Eye, and Lymph;
RX
     MEDLINE=22388257; PubMed=12477932;
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
RA
     Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
     Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA
RA
     Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA
     Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT
     "Generation and initial analysis of more than 15,000 full-length
RT
     human and mouse cDNA sequences.";
RL
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
CC
     -!- SUBCELLULAR LOCATION: Integral membrane protein. Endoplasmic
CC
         reticulum (Potential).
     -!- TISSUE SPECIFICITY: WIDELY EXPRESSED WITH HIGHEST EXPRESSION IN
CC
CC
         BRAIN. THREE TIMES MORE ABUNDANT IN MACULA THAN IN PERIPHERAL
CC
         RETINA.
     -!- SIMILARITY: Contains 1 reticulon domain.
CC
CC
     ______
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
    the European Bioinformatics Institute. There are no restrictions on
CC
CC
     use by non-profit institutions as long as its content is in no way
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
CC
     or send an email to license@isb-sib.ch).
CC
DR
     EMBL; AF059524; AAC99319.1; -.
     EMBL; AF059529; AAD20951.1; -.
DR
DR
    EMBL; AF059525; AAD20951.1; JOINED.
DR
    EMBL; AF059526; AAD20951.1; JOINED.
DR
    EMBL; AF059527; AAD20951.1; JOINED.
DR
    EMBL; AF059528; AAD20951.1; JOINED.
DR
    EMBL; AF119297; AAD26810.1; -.
DR
    EMBL; BC000634; AAH00634.1; -.
DR
    EMBL; BC010556; AAH10556.1; -.
```

```
DR
     EMBL; BC011394; AAH11394.1; -.
DR
     EMBL; BC022993; AAH22993.1; -.
DR
     Genew; HGNC:10469; RTN3.
DR
     MIM; 604249; -.
DR
     GO; GO:0005615; C:extracellular space; TAS.
DR
     InterPro; IPR003388; Reticulon.
DR
     Pfam; PF02453; Reticulon; 1.
DR
     PROSITE; PS50845; RETICULON; 1.
KW
     Transmembrane; Endoplasmic reticulum.
FT
     TRANSMEM
                  68
                         88
                                  POTENTIAL.
FT
     TRANSMEM
                 177
                        197
                                  POTENTIAL.
FT
     DOMAIN
                  48
                        236
                                  RETICULON.
                236 AA; 25609 MW; DDC6A4544ABCDFB7 CRC64;
SQ
     SEQUENCE
  Query Match
                          43.8%; Score 309; DB 1; Length 236;
  Best Local Similarity
                          60.9%; Pred. No. 4.7e-23;
            56; Conservative 18; Mismatches
                                                 18; Indels
                                                                0; Gaps
                                                                             0;
Qу
           49 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 108
              Db
           48 VHDLIFWRDVKKTGFVFGTTLIMLLSLAAFSVISVVSYLILALLSVTISFRIYKSVIQAV 107
          109 AKSDEGHPFRAYLESEVAISEELVQKYSNSAL 140
Qу
               11:11/1:11: :: :1 1
                                      | |:|:
Db
          108 QKSEEGHPFKAYLDVDITLSSEAFHNYMNAAM 139
RESULT 7
RTN3 MOUSE
     RTN3 MOUSE
                    STANDARD;
                                   PRT;
                                         237 AA.
AC
     Q9ES97;
DT
     16-OCT-2001 (Rel. 40, Created)
     16-OCT-2001 (Rel. 40, Last sequence update)
DT
     15-MAR-2004 (Rel. 43, Last annotation update)
DT
     Reticulon protein 3.
DΕ
GN
     RTN3.
OS
    Mus musculus (Mouse).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX
    NCBI_TaxID=10090;
RN
     [1]
     SEQUENCE FROM N.A.
RP
RA
     Huang X., Zhou Y., Qiang H., Yuan J., Qiang B.;
    "Cloning and expression profile of a novel mouse cDNA encoding a human
RT
RT
     RTN3 homolog.";
     Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
    SEQUENCE FROM N.A.
RC
    TISSUE=Eve;
RX
    MEDLINE=22388257; PubMed=12477932;
    Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
    Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
    Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
    Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
RA
    Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
    Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
    Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
```

```
Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
RA
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
RA
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA
     Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA
     Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT
     "Generation and initial analysis of more than 15,000 full-length
RT
     human and mouse cDNA sequences.";
RL
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
CC
     -!- SUBCELLULAR LOCATION: Integral membrane protein. Endoplasmic
CC
         reticulum (Potential).
CC
     -!- SIMILARITY: Contains 1 reticulon domain.
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
     the European Bioinformatics Institute. There are no restrictions on its
     use by non-profit institutions as long as its content is in no way
CC
CC
     modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
     or send an email to license@isb-sib.ch).
CC
CC
     ______
DR
     EMBL; AF195940; AAG31360.1; -.
     EMBL; BC014697; AAH14697.1; -.
DR
     MGD; MGI:1339970; Rtn3.
DR
DR
     InterPro; IPR003388; Reticulon.
DR
     Pfam; PF02453; Reticulon; 1.
     PROSITE; PS50845; RETICULON; 1.
DR
     Transmembrane; Endoplasmic reticulum.
KW
FT
     TRANSMEM
                69
                       89
                                POTENTIAL.
FT
     TRANSMEM
                167
                       187
                                POTENTIAL.
FT
     DOMAIN
                49
                       237
                                RETICULON.
SO
     SEQUENCE
               237 AA; 25428 MW; EB60A0A7AC45F0DE CRC64;
  Query Match
                         43.7%; Score 308; DB 1; Length 237;
  Best Local Similarity
                        59.8%; Pred. No. 6e-23;
  Matches
          55; Conservative 19; Mismatches 18; Indels
                                                              0;
                                                                 Gaps
Qу
          49 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 108
             Db
          49 VHDLIFWRDVKKTGFVFGTTLIMLLSLAAFSVISVVSYLILALLSVTISFRVYKSVIQAV 108
Qу
         109 AKSDEGHPFRAYLESEVAISEELVQKYSNSAL 140
              ||:|||:||:||:
                                     | | |:|:
Db
         109 QKSEEGHPFKAYLDVDITLSSEAFHNYMNAAM 140
RESULT 8
RTN2 HUMAN
    RTN2 HUMAN
                   STANDARD;
                                 PRT;
                                        545 AA.
AC
    075298; 060509;
DT
    16-OCT-2001 (Rel. 40, Created)
DT
    16-OCT-2001 (Rel. 40, Last sequence update)
    10-OCT-2003 (Rel. 42, Last annotation update)
```

```
Reticulon protein 2 (Neuroendocrine-specific protein-like 1) (NSP-like
 DΕ
 DΕ
     protein 1) (NSPLI).
GN
     RTN2 OR NSPL1.
OS
     Homo sapiens (Human).
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX
     NCBI_TaxID=9606;
RN
     [1]
RP
     SEQUENCE FROM N.A., ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY.
RC
     TISSUE=Lung carcinoma;
     MEDLINE=98360096; PubMed=9693037;
RX
     Roebroek A.J.M., Contreras B., Pauli I.G.L., Van de Ven W.J.M.;
RA
     "cDNA cloning, genomic organization, and expression of the human RTN2
RT
     gene, a member of a gene family encoding reticulons.";
RT
     Genomics 51:98-106(1998).
RL
RN
RP
     SEQUENCE OF 108-545 FROM N.A. (ISOFORM RTN2-B).
RC
     TISSUE=Brain;
RX
     MEDLINE=98191726; PubMed=9530622;
RA
     Geisler J.G., Stubbs L.J., Wasserman W.W., Mucenski M.L.;
     "Molecular cloning of a novel mouse gene with predominant muscle and
RT
RT
     neural expression.";
RL
     Mamm. Genome 9:274-282(1998).
     -!- SUBCELLULAR LOCATION: Integral membrane protein. Endoplasmic
CC
CC
         reticulum (Potential).
CC
     -!- ALTERNATIVE PRODUCTS:
CC
         Event=Alternative splicing; Named isoforms=2;
CC
        Name=RTN2-A;
CC
          IsoId=075298-1; Sequence=Displayed;
CC
          Note=Isoform RTN2-C is produced by alternative initiation at
CC
          Met-341 of isoform RTN2-A;
CC
        Name=RTN2-B:
CC
          IsoId=075298-2; Sequence=VSP 005649;
CC
         Event=Alternative initiation;
CC
          Comment=2 isoforms, RTN2-A (shown here) and RTN2-C, are produced
CC
          by alternative initiation at Met-1 and Met-341;
     -!- TISSUE SPECIFICITY: ISOFORM RTN2-C IS HIGHLY EXPRESSED IN SKELETAL
CC
CC
        MUSCLE.
    -!- SIMILARITY: Contains 1 reticulon domain.
CC
    ______
CC
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
CC
    or send an email to license@isb-sib.ch).
     _____
CC
DR
    EMBL; AF004222; AAC32542.1; -.
DR
    EMBL; AF004223; AAC32543.1; -.
DR
    EMBL; AF004224; AAC32544.1; -.
DR
    EMBL; AF038540; AAC14910.1; -.
DR
    Genew; HGNC:10468; RTN2.
DR
    MIM; 603183; -.
DR
    GO; GO:0030176; C:integral to endoplasmic reticulum membrane; NAS.
DR
    GO; GO:0004871; F:signal transducer activity; NAS.
    GO; GO:0007165; P:signal transduction; NAS.
DR
```

```
DR
     InterPro; IPR003388; Reticulon.
DR
     Pfam; PF02453; Reticulon; 1.
DR
     PROSITE; PS50845; RETICULON; 1.
KW
     Endoplasmic reticulum; Alternative splicing; Transmembrane;
KW
     Alternative initiation.
FT
     CHAIN
                   1
                        545
                                  RETICULON PROTEIN 2, ISOFORM RTN2-A.
FT
     CHAIN
                 341
                        545
                                  RETICULON PROTEIN 2, ISOFORM RTN2-C.
FT
     INIT MET
                 341
                        341
                                  FOR ISOFORM RTN2-C.
FT
     TRANSMEM
                 368
                        388
                                  POTENTIAL.
FT
     TRANSMEM
                 463
                        483
                                  POTENTIAL.
FT
     DOMAIN
                 345
                        545
                                  RETICULON.
FT
     VARSPLIC
                 272
                        344
                                  Missing (in isoform RTN2-B).
FT
                                  /FTId=VSP 005649.
SO
     SEQUENCE
              545 AA; 59263 MW; 971FD2F909E1E9E6 CRC64;
  Query Match
                          30.4%; Score 214; DB 1; Length 545;
  Best Local Similarity 46.7%; Pred. No. 2.2e-13;
  Matches
           42; Conservative 21; Mismatches 27; Indels
                                                                            0;
           48 KVVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQA 107
Qу
              Db
          344 KVADLLYWKDTRTSGVVFTGLMVSLLCLLHFSIVSVAAHLALLLLCGTISLRVYRKVLQA 403
          108 IAKSDEGHPFRAYLESEVAISEELVQKYSN 137
Qу
              : : | :||:|||: :: :: | :: |:
Db
          404 VHRGDGANPFQAYLDVDLTLTREQTERLSH 433
RESULT 9
RTN2 MOUSE
ID
     RTN2 MOUSE
                   STANDARD;
                                 PRT;
                                         471 AA.
     070622; 070620;
DΤ
     16-OCT-2001 (Rel. 40, Created)
DT
     16-OCT-2001 (Rel. 40, Last sequence update)
     15-MAR-2004 (Rel. 43, Last annotation update)
DT
    Reticulon protein 2 (Neuroendocrine-specific protein-like 1) (NSP-like
DE
DE
     protein 1) (NSPLI).
    RTN2 OR NSPL1.
GN
    Mus musculus (Mouse).
OS
OC
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX
    NCBI TaxID=10090;
RN
     [1]
RP
     SEQUENCE FROM N.A. (ISOFORMS 1 AND 2), AND TISSUE SPECIFICITY.
     STRAIN=FVB/N, and 129/Sv; TISSUE=Cerebellum, and Skeletal muscle;
RC
RX
    MEDLINE=98191726; PubMed=9530622;
RA
     Geisler J.G., Stubbs L.J., Wasserman W.W., Mucenski M.L.;
     "Molecular cloning of a novel mouse gene with predominant muscle and
RT
RT
    neural expression.";
RL
    Mamm. Genome 9:274-282(1998).
RN
    [2]
    SEQUENCE FROM N.A. (ISOFORM 1).
RP
RC
    TISSUE=Retina:
RX
    MEDLINE=22388257; PubMed=12477932;
RA
    Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
    Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
    Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
```

```
RA
     Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
RA
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
RA
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA
     Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA
RA
     Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
     "Generation and initial analysis of more than 15,000 full-length
RT
RT
     human and mouse cDNA sequences.";
RL
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
CC
     -!- SUBCELLULAR LOCATION: Membrane-bound. Endoplasmic reticulum
CC
         (Potential).
CC
     -!- ALTERNATIVE PRODUCTS:
CÇ
         Event=Alternative splicing; Named isoforms=2;
CC
        Name=1; Synonyms=Brain;
CC
           IsoId=070622-1; Sequence=Displayed;
CC
        Name=2; Synonyms=Muscle;
CC
          IsoId=070622-2; Sequence=VSP_005650, VSP 005651;
CC
     -!- TISSUE SPECIFICITY: Expressed predominantly in neural and muscular
CC
        tissues.
CC
    -!- SIMILARITY: Contains 1 reticulon domain.
CC
     ______
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
CC
    use by non-profit institutions as long as its content is in no way
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
CC
    EMBL; AF038537; AAC14906.1; -.
DR
DR
    EMBL; AF038537; AAC14907.1; -.
DR
    EMBL; AF038538; AAC14908.1; -.
DR
    EMBL; AF038539; AAC14909.1; -.
DR
    EMBL; AF093624; AAD13195.1; -.
DR
    EMBL; BC031370; AAH31370.1; -.
DR
    MGD; MGI:107612; Rtn2.
DR
    InterPro; IPR003388; Reticulon.
DR
    Pfam; PF02453; Reticulon; 1.
DR
    PROSITE; PS50845; RETICULON; 1.
KW
    Endoplasmic reticulum; Alternative splicing; Transmembrane.
FT
    TRANSMEM
                295
                      315
                                POTENTIAL.
FT
    DOMAIN
                272
                      471
                                RETICULON.
FT
    VARSPLIC
                1
                      267
                                Missing (in isoform 2).
FT
                                /FTId=VSP 005650.
FT
    VARSPLIC
                268
                      271
                                PLLL -> MGSK (in isoform 2).
FT
                                /FTId=VSP 005651.
SQ
    SEQUENCE 471 AA; 51346 MW; 9BBD8F372CF63AD3 CRC64;
 Query Match
                        27.9%; Score 197; DB 1; Length 471;
```

```
Best Local Similarity 44.3%; Pred. No. 8.6e-12;
  Matches
            39; Conservative 20; Mismatches
                                                 29; Indels
                                                                 0; Gaps
Qу
           49 VVDLLYWRDIKKTGVVFGASLFLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAI 108
               Db
           272 VADLLYWKDTRTSGAVFTGLMASLLCLLHFSIVSVAAHLALLGLCATISLRVYRKVLQAV 331
          109 AKSDEGHPFRAYLESEVAISEELVQKYS 136
Qу
               : | :||:|||: :: :: | :: |
Db
          332 HRGDGTNPFQAYLDMDLTLTREQTERLS 359
RESULT 10
T2RD MOUSE
     T2RD MOUSE
                    STANDARD;
                                   PRT;
                                          243 AA.
AC
     Q9JKA2;
     10-OCT-2003 (Rel. 42, Created)
DT
     10-OCT-2003 (Rel. 42, Last sequence update)
     10-OCT-2003 (Rel. 42, Last annotation update)
DT
     Taste receptor type 2 member 13 (T2R13) (Taste receptor family {\tt B}
DF.
DE
     member 3) (TRB3) (Fragment).
GN
     TAS2R13.
OS
     Mus musculus (Mouse).
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
OX
     NCBI TaxID=10090;
RN
     [1]
RP
     SEQUENCE FROM N.A.
RC
     STRAIN=DBA/2J;
RX
     MEDLINE=20227309; PubMed=10766242;
RA
     Matsunami H., Montmayeur J.-P., Buck L.B.;
     "A family of candidate taste receptors in human and mouse.";
RT
     Nature 404:601-604(2000).
RL
RN
     [2]
RP
     REVIEW.
     MEDLINE=22135574; PubMed=12139982;
RX
RA
     Montmayeur J.-P., Matsunami H.;
     "Receptors for bitter and sweet taste.";
RT
RL
     Curr. Opin. Neurobiol. 12:366-371(2002).
RN
     [3]
RP
    REVIEW.
    MEDLINE=21634924; PubMed=11696554;
RX
    Margolskee R.F.;
    "Molecular mechanisms of bitter and sweet taste transduction.";
RT
RL
    J. Biol. Chem. 277:1-4(2002).
RN
    [4]
RP
    REVIEW.
RX
    MEDLINE=22469025; PubMed=12581520;
    Zhang Y., Hoon M.A., Chandrashekar J., Mueller K.L., Cook B., Wu D.,
RA
RA
     Zuker C.S., Ryba N.J.;
    "Coding of sweet, bitter, and umami tastes: different receptor cells
RT
    sharing similar signaling pathways.";
RT
RL
    Cell 112:293-301(2003).
    -!- FUNCTION: Receptor that may play a role in the perception of
CC
CC
        bitterness and is gustducin-linked. May play a role in sensing the
CC
        chemical composition of the gastrointestinal content. The activity
        of this receptor may stimulate alpha gustducin, mediate PLC-beta-2
CC
```

0;

```
CC
           activation and lead to the gating of TRPM5.
 CC
       -!- SUBCELLULAR LOCATION: Integral membrane protein.
 CC
       -!- TISSUE SPECIFICITY: Expressed in subsets of taste receptor cells
 CC
            of the tongue and palate epithelium and exclusively in gustducin-
 CC
            positive cells.
 CC
       -!- MISCELLANEOUS: Most taste cells may be activated by a limited
 CC
            number of bitter compounds; individual taste cells can
 CC
            discriminate among bitter stimuli.
       -!- SIMILARITY: Belongs to family T2R of G-protein coupled receptors.
 CC
       CC
 CC
       This SWISS-PROT entry is copyright. It is produced through a collaboration
       between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC
       the European Bioinformatics Institute. There are no restrictions on its
 CC
       use by non-profit institutions as long as its content is in no way
 CC
       modified and this statement is not removed. Usage by and for commercial
 CC
       entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
       or send an email to license@isb-sib.ch).
       _________
CC
DR
       EMBL; AF247733; AAF64510.1; -.
       MGD; MGI:1890148; Tas2r13.
DR
DR
       InterPro; IPR007960; TAS2R.
DR
       Pfam; PF05296; TAS2R; 1.
KW
       Receptor; G-protein coupled receptor; Transmembrane.
      NON TER
                      1
                                1

        DOMAIN
        <1</td>
        12
        CYTOPLASMIC (POTENTIAL).

        TRANSMEM
        13
        33
        2 (POTENTIAL).

        DOMAIN
        34
        54
        EXTRACELLULAR (POTENTIAL).

        TRANSMEM
        55
        75
        3 (POTENTIAL).

        DOMAIN
        76
        99
        CYTOPLASMIC (POTENTIAL).

        TRANSMEM
        100
        120
        4 (POTENTIAL).

        DOMAIN
        121
        150
        EXTRACELLULAR (POTENTIAL).

        TRANSMEM
        151
        171
        5 (POTENTIAL).

        DOMAIN
        172
        195
        CYTOPLASMIC (POTENTIAL).

        TRANSMEM
        196
        216
        6 (POTENTIAL).

        DOMAIN
        217
        222
        EXTRACELLULAR (POTENTIAL).

        TRANSMEM
        223
        >243
        7 (POTENTIAL).

FT
      DOMAIN
                       <1
                               12
                                           CYTOPLASMIC (POTENTIAL).
FT
FT
FT
FT
FT
FT
FT
FТ
FT
FT
FT TRANSMEM 223 >243
                                          7 (POTENTIAL).
FT CARBOHYD 128 128
FT NON_TER 243 243
                                         N-LINKED (GLCNAC. . .) (POTENTIAL).
SQ SEQUENCE 243 AA; 28110 MW; D8AD14AF95B9E0B2 CRC64;
  Query Match
                                11.0%; Score 77.5; DB 1; Length 243;
  Best Local Similarity 27.1%; Pred. No. 2;
  Matches 32; Conservative 18; Mismatches 47; Indels 21; Gaps 5;
Qу
              17 VYSVSVGMHNLLLLEGRSWQEMDGQKKH---WKDKVVDLLYWRDIKKTGVVFGASLFLLL 73
                 Db
              37 LYSALMTTRKVLIIFNNSWTVIN----HFNIWLATCLSIFYFLKIAN----FSNSIFLSL 88
              74 SLTVFSIVSVTAYIALALLSV-----TISFRIYKGVIQAIAKSDEG-HPFRAYL 121
Qу
                     | ::||| ::| || || || :|| :|| || :||
Db
              89 RWRVKTVVSVTLMMSLLLLFVNVLVINTFIVISVDVYKVNTSYSSHSDNNLHISRIFL 146
RESULT 11
PHSC ECOLI
ID PHSC ECOLI
                        STANDARD; PRT; 261 AA.
AC P77409;
```

```
DT
      01-NOV-1997 (Rel. 35, Created)
DT
      01-NOV-1997 (Rel. 35, Last sequence update)
DT
      16-OCT-2001 (Rel. 40, Last annotation update)
DΕ
      PhsC protein homolog.
GN
     YDHU OR B1670.
OS
     Escherichia coli.
     Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
\mathsf{OC}
OC
     Enterobacteriaceae; Escherichia.
OX
     NCBI TaxID=562;
RN
     SEQUENCE FROM N.A.
RP
RC
     STRAIN=K12 / MG1655;
     MEDLINE=97426617; PubMed=9278503;
RX
     Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,
RA
     Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,
RA
     Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J.,
RA
RA
     Mau B., Shao Y.;
RT
     "The complete genome sequence of Escherichia coli K-12.";
RL
     Science 277:1453-1474(1997).
RN
     [2]
RP
     SEQUENCE FROM N.A.
RC
     STRAIN=K12 / MG1655;
RX
     MEDLINE=97175536; PubMed=9023191;
     Hensel M., Shea J.E., Baeumler A.J., Gleeson C., Blattner F.R.,
RA
RA
     Holden D.W.;
     "Analysis of the boundaries of Salmonella pathogenicity island 2 and
RT
RT
     the corresponding chromosomal region of Escherichia coli K-12.";
     J. Bacteriol. 179:1105-1111(1997).
RL
RN
     [3]
     SEQUENCE FROM N.A.
RP
RC
     STRAIN=K12;
     MEDLINE=97251357; PubMed=9097039;
RX
     Aiba H., Baba T., Fujita K., Hayashi K., Inada T., Isono K.,
RA
     Itoh T., Kasai H., Kashimoto K., Kimura S., Kitakawa M.,
RA
     Kitagawa M., Makino K., Miki T., Mizobuchi K., Mori H., Mori T.,
RA
     Motomura K., Nakade S., Nakamura Y., Nashimoto H., Nishio Y.,
RA
     Oshima T., Saito N., Sampei G., Seki Y., Sivasundaram S.,
RA
     Tagami H., Takeda J., Takemoto K., Takeuchi Y., Wada C.,
RA
     Yamamoto Y., Horiuchi T.;
RA
     "A 570-kb DNA sequence of the Escherichia coli K-12 genome
RT
     corresponding to the 28.0-40.1 min region on the linkage map.";
RT
RL
     DNA Res. 3:363-377(1996).
    -!- SUBCELLULAR LOCATION: Integral membrane protein. Inner membrane
CC
CC
         (Potential).
CC
     -!- SIMILARITY: TO S.TYPHIMURIUM PHSC.
CC
     _____
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
CC
DR
    EMBL; AE000262; AAC74740.1; -.
DR
    EMBL; U68703; AAB47946.1; -.
    EMBL; D90810; BAA15442.1; -.
DR
```

```
DR
     PIR; F64924; F64924.
DR
     EcoGene; EG13955; ydhU.
DR
     InterPro; IPR000516; Ni hydr CytB.
DR
     Pfam; PF01292; Ni hydr_CYTB; 1.
KW
     Transmembrane; Inner membrane; Complete proteome.
FT
     TRANSMEM
                  25
                        45
                                 POTENTIAL.
FT
     TRANSMEM
                  81
                        101
                                 POTENTIAL.
FT
     TRANSMEM
                 108
                        128
                                 POTENTIAL.
FT
     TRANSMEM
                182
                       202
                                 POTENTIAL.
FT
     TRANSMEM
                224
                       244
                                 POTENTIAL.
     SEQUENCE 261 AA; 29583 MW; 65CF1A45691A0AF3 CRC64;
SQ
  Query Match
                         11.0%; Score 77.5; DB 1; Length 261;
  Best Local Similarity 27.6%; Pred. No. 2.2;
  Matches
           29; Conservative 16; Mismatches
                                                 43; Indels
                                                             17; Gaps
                                                                           4;
Qу
           22 VGMHNLLLLEGRSWQEMD-GQKKHWKDKVVDLLYWRDIKKTGVVFGASLFLLL----SLT 76
              Db
           44 LGLHALLRARGVKKSATDHGEKIYLYSKAVRLWHWSN-----ALLFVLLLASGLIN 94
Qу
           77 VFSIVSVTAYIALALLSVTISFRI---YKGVIQAIAKSDEGHPFR 118
               1::| || :| : | : | : | | | | | | | |
Db
           95 HFAMVGATAVKSLVAVHEVCGFLLLACWLGFVLINAVGDNGHHYR 139
RESULT 12
T2R8 MOUSE
     T2R8 MOUSE
                   STANDARD;
                                  PRT;
                                         246 AA.
     Q9JKA0;
AC
DT
     10-OCT-2003 (Rel. 42, Created)
DT
     10-OCT-2003 (Rel. 42, Last sequence update)
     10-OCT-2003 (Rel. 42, Last annotation update)
     Taste receptor type 2 member 8 (T2R8) (Taste receptor family B member
DE
     5) (TRB5) (Fragment).
GN
     TAS2R8.
     Mus musculus (Mouse).
OS
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
OX
    NCBI TaxID=10090;
RN
     [1]
RP
    SEQUENCE FROM N.A.
RC
     STRAIN=C57BL/6J;
    MEDLINE=20227309; PubMed=10766242;
RX
RA
    Matsunami H., Montmayeur J.-P., Buck L.B.;
RT
    "A family of candidate taste receptors in human and mouse.";
    Nature 404:601-604(2000).
RL
RN
    [2]
RP
    REVIEW.
RX
    MEDLINE=22135574; PubMed=12139982;
    Montmayeur J.-P., Matsunami H.;
RT
    "Receptors for bitter and sweet taste.";
RL
    Curr. Opin. Neurobiol. 12:366-371(2002).
RN
    [3]
RP
    REVIEW.
RX
    MEDLINE=21634924; PubMed=11696554;
RA
    Margolskee R.F.;
RT
    "Molecular mechanisms of bitter and sweet taste transduction.";
```

```
J. Biol. Chem. 277:1-4(2002).
RL
RN
     [4]
RP
     REVIEW.
RX
     MEDLINE=22469025; PubMed=12581520;
RA
     Zhang Y., Hoon M.A., Chandrashekar J., Mueller K.L., Cook B., Wu D.,
RA
     Zuker C.S., Ryba N.J.;
RT
     "Coding of sweet, bitter, and umami tastes: different receptor cells
RT
     sharing similar signaling pathways.";
RL
     Cell 112:293-301(2003).
     -!- FUNCTION: Receptor that may play a role in the perception of
CC
CC
         bitterness and is gustducin-linked. May play a role in sensing the
CC
         chemical composition of the gastrointestinal content. The activity
CC
         of this receptor may stimulate alpha gustducin, mediate PLC-beta-2
CC
         activation and lead to the gating of TRPM5.
CC
     -!- SUBCELLULAR LOCATION: Integral membrane protein.
CC
     -!- TISSUE SPECIFICITY: Expressed in subsets of taste receptor cells
CC
        of the tongue and palate epithelium and exclusively in gustducin-
CC
        positive cells. Expressed in 15% taste bud cells in circumvallate
CC
        and foliate papillae but only in 2% in fungiform papillae.
CC
     -!- MISCELLANEOUS: Most taste cells may be activated by a limited
CC
        number of bitter compounds; individual taste cells can
CC
        discriminate among bitter stimuli.
CC
     -!- SIMILARITY: Belongs to family T2R of G-protein coupled receptors.
     CC
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
    modified and this statement is not removed. Usage by and for commercial
CC
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
    or send an email to license@isb-sib.ch).
CC
    ______
CC
DR
    EMBL; AF247735; AAF64512.1; -.
DR
    MGD; MGI:1890259; Tas2r8.
    InterPro; IPR007960; TAS2R.
DR
DR
    Pfam; PF05296; TAS2R; 1.
KW
    Receptor; G-protein coupled receptor; Transmembrane.
FT
    NON TER
                1
                       1
FT
    DOMAIN
                 1
                       15
                               CYTOPLASMIC (POTENTIAL).
FT
    TRANSMEM
                16
                      36
                               2 (POTENTIAL).
               37 59
60 80
81 102
103 123
FT
    DOMAIN
                               EXTRACELLULAR (POTENTIAL).
FT
    TRANSMEM
                               3 (POTENTIAL).
FT
    DOMAIN
                               CYTOPLASMIC (POTENTIAL).
FT
    TRANSMEM
                               4 (POTENTIAL).
FT
   DOMAIN
               124 153
                               EXTRACELLULAR (POTENTIAL).
FT
    TRANSMEM
               154
                     174
                               5 (POTENTIAL).
FT
    DOMAIN
               175
                     198
                               CYTOPLASMIC (POTENTIAL).
FT
    TRANSMEM
               199
                      219
                               6 (POTENTIAL).
FT
    DOMAIN
               220
                     225
                               EXTRACELLULAR (POTENTIAL).
FT
    TRANSMEM
              226 246
                               7 (POTENTIAL).
FT
    NON TER
               246
                     246
              246 AA; 28430 MW; 8B8F96F8A62E4474 CRC64;
SQ
    SEQUENCE
 Query Match
                       10.7%; Score 75.5; DB 1; Length 246;
 Best Local Similarity 27.1%; Pred. No. 3.3;
 Matches 32; Conservative 18; Mismatches 47; Indels 21; Gaps
```

```
Qу
           17 VYSVSVGMHNLLLLEGRSWQEMDGQKKH---WKDKVVDLLYWRDIKKTGVVFGASLFLLL 73
              Db
           40 LYSALMTTRKVLIIFNNSWTVIN----HFNIWLATCLSIFYFLMIAN----FSNSIFLSL 91
           74 SLTVFSIVSVTAYIALALLSV-----TISFRIYKGVIQAIAKSDEG-HPFRAYL 121
Qу
                 1::||| ::| || |
                                            | | | : | |
                                                         : 11
Db
           92 RWRVKTVVSVTLLMSLLLLFVNVLVINTFIVISVDVYKVNTSYSSHSDNNIHISRIFL 149
RESULT 13
G6PI HELPY
     G6PI HELPY
                    STANDARD;
                                   PRT;
                                         545 AA.
AC
     025781;
     15-JUL-1998 (Rel. 36, Created)
DT
DT
     15-JUL-1998 (Rel. 36, Last sequence update)
     28-FEB-2003 (Rel. 41, Last annotation update)
     Glucose-6-phosphate isomerase (EC 5.3.1.9) (GPI) (Phosphoglucose
DE
     isomerase) (PGI) (Phosphohexose isomerase) (PHI).
     PGI OR HP1166.
GN
     Helicobacter pylori (Campylobacter pylori).
OS
     Bacteria; Proteobacteria; Epsilonproteobacteria; Campylobacterales;
OC
     Helicobacteraceae; Helicobacter.
OC
OX
     NCBI TaxID=210;
RN
     [1]
RP
     SEQUENCE FROM N.A.
     STRAIN=26695 / ATCC 700392;
RC
RX
     MEDLINE=97394467; PubMed=9252185;
     Tomb J.-F., White O., Kerlavage A.R., Clayton R.A., Sutton G.G.,
RA
RA
     Fleischmann R.D., Ketchum K.A., Klenk H.-P., Gill S., Dougherty B.A.,
RA
     Nelson K., Quackenbush J., Zhou L., Kirkness E.F., Peterson S.,
     Loftus B., Richardson D., Dodson R., Khalak H.G., Glodek A.,
     McKenney K., FitzGerald L.M., Lee N., Adams M.D., Hickey E.K.,
RA
     Berg D.E., Gocayne J.D., Utterback T.R., Peterson J.D., Kelley J.M.,
RA
     Cotton M.D., Weidman J.M., Fujii C., Bowman C., Watthey L., Wallin E.,
RA
     Hayes W.S., Borodovsky M., Karp P.D., Smith H.O., Fraser C.M.,
RA
     Venter J.C.;
     "The complete genome sequence of the gastric pathogen Helicobacter
RT
RT
     pylori.";
RL
    Nature 388:539-547(1997).
     -!- CATALYTIC ACTIVITY: D-glucose 6-phosphate = D-fructose 6-
CC
CC
         phosphate.
CC
     -!- PATHWAY: Involved in glycolysis and in gluconeogenesis.
CC
     -!- SUBCELLULAR LOCATION: Cytoplasmic (By similarity).
CC
    -!- SIMILARITY: Belongs to the GPI family.
CC
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
     the European Bioinformatics Institute. There are no restrictions on its
CC
CC
    use by non-profit institutions as long as its content is in no way
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
CC
DR
    EMBL; AE000622; AAD08211.1; -.
DR
    PIR; F64665; F64665.
DR
    HSSP; Q9N1E2; 1HOX.
DR
    TIGR; HP1166; -.
```

```
DR
     HAMAP; MF 00473; -; 1.
DR
     InterPro; IPR001672; G6P Isomerase.
DR
     Pfam; PF00342; PGI; 1.
DR
     PRINTS; PR00662; G6PISOMERASE.
DR
     PROSITE; PS00765; P GLUCOSE_ISOMERASE_1; 1.
DR
     PROSITE; PS00174; P_GLUCOSE_ISOMERASE_2; 1.
KW
     Isomerase; Gluconeogenesis; Glycolysis; Complete proteome.
FT
     ACT SITE
                 382
                        382
                                  BY SIMILARITY.
FT
     ACT SITE
                 510
                        510
                                  BY SIMILARITY.
              545 AA; 62487 MW; BDC68D1625190236 CRC64;
SQ
     SEQUENCE
  Query Match
                          10.7%; Score 75.5; DB 1; Length 545;
  Best Local Similarity
                          25.3%; Pred. No. 7.5;
           37; Conservative 20; Mismatches
  Matches
                                                  44; Indels
                                                                45; Gaps
                                                                             6;
           23 GMHNLL-----LLEGRSWQEMDGQ---KKHWKDKVVDLLYWRDIKKTGVVFGASL 69
Qу
                               ::1:1::1 1: 1 11: 11: 1
Db
          411 GHHEILFSNVLAQAQAFMKGKSYEEALGELLFKGLDKDEAKDLAHHR-----VFFGNRP 464
Qу
           70 FLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIAKSD----- 112
                      | | :: | :||
                                   Db
          465 SNILLLEKISPSNIGALVALYEHKVFV----QGVIWDINSFDQWGVELGKELAVPILQE 519
          113 -EGHPFRAYLESEVAISEELVQKYSN 137
Qу
                    11:1
                             :: |:: | |
Db
          520 LEGHKSNAYFDSS---TKHLIELYKN 542
RESULT 14
G6PI HELPJ
ID
     G6PI HELPJ
                    STANDARD:
                                   PRT:
                                          545 AA.
AC
     Q9ZK49;
     16-OCT-2001 (Rel. 40, Created)
DT
DT
     16-OCT-2001 (Rel. 40, Last sequence update)
     28-FEB-2003 (Rel. 41, Last annotation update)
DT
DE
     Glucose-6-phosphate isomerase (EC 5.3.1.9) (GPI) (Phosphoglucose
DE
     isomerase) (PGI) (Phosphohexose isomerase) (PHI).
GN
     PGI OR JHP1093.
OS
     Helicobacter pylori J99 (Campylobacter pylori J99).
OC
     Bacteria; Proteobacteria; Epsilonproteobacteria; Campylobacterales;
OC
     Helicobacteraceae; Helicobacter.
OX
     NCBI TaxID=85963;
RN
     [1]
RP
     SEQUENCE FROM N.A.
RX
     MEDLINE=99120557; PubMed=9923682;
RA
     Alm R.A., Ling L.-S.L., Moir D.T., King B.L., Brown E.D., Doig P.C.,
     Smith D.R., Noonan B., Guild B.C., deJonge B.L., Carmel G.,
RA
     Tummino P.J., Caruso A., Uria-Nickelsen M., Mills D.M., Ives C.,
RA
     Gibson R., Merberg D., Mills S.D., Jiang Q., Taylor D.E., Vovis G.F.,
RA
RA
     Trust T.J.:
    "Genomic sequence comparison of two unrelated isolates of the human
RT
    gastric pathogen Helicobacter pylori.";
RT
    Nature 397:176-180(1999).
RL
    -!- CATALYTIC ACTIVITY: D-glucose 6-phosphate = D-fructose 6-
CC
CC
        phosphate.
CC
    -!- PATHWAY: Involved in glycolysis and in gluconeogenesis.
CC
    -!- SUBCELLULAR LOCATION: Cytoplasmic (By similarity).
```

```
CC
     -!- SIMILARITY: Belongs to the GPI family.
CC
     _______
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
     the European Bioinformatics Institute. There are no restrictions on its
     use by non-profit institutions as long as its content is in no way
CC
     modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
     or send an email to license@isb-sib.ch).
CC
     CC
     EMBL; AE001536; AAD06664.1; -.
DR
DR
     PIR; E71851; E71851.
     HSSP; Q9N1E2; 1HOX.
DR
    HAMAP; MF 00473; -; 1.
DR
     InterPro; IPR001672; G6P Isomerase.
DR
DR
     Pfam; PF00342; PGI; 1.
     PRINTS; PR00662; G6PISOMERASE.
    PROSITE; PS00765; P_GLUCOSE_ISOMERASE_1; 1.
DR
     PROSITE; PS00174; P_GLUCOSE_ISOMERASE_2; 1.
DR
KW
    Isomerase; Gluconeogenesis; Glycolysis; Complete proteome.
FT
    ACT SITE
             382
                    382 BY SIMILARITY.
510 BY SIMILARITY.
FT
    ACT SITE
               510
    SEQUENCE 545 AA; 62302 MW; 7DB544D95FD1D237 CRC64;
SQ
  Query Match
                        10.6%; Score 74.5; DB 1; Length 545;
  Best Local Similarity 25.3%; Pred. No. 9.4;
 Matches 37; Conservative 19; Mismatches 45; Indels 45; Gaps
                                                                      6:
          23 GMHNLL-----LLEGRSWQEMDGQ---KKHWKDKVVDLLYWRDIKKTGVVFGASL 69
Qу
                            ::|:|::| |: | ||: || :|
Db
         411 GHHEILFSNVLAQAQAFMKGKSYEEALGELLSKGLDKDEAKDLAHHR-----VFFGNRP 464
QУ
          70 FLLLSLTVFSIVSVTAYIALALLSVTISFRIYKGVIQAIAKSD----- 112
               Db
         465 SNILLLEKISPSNIGALVALYEHKVFV-----QGVIWDINSFDQWGVELGKELAVPILQE 519
Qу
         113 -EGHPFRAYLESEVAISEELVQKYSN 137
                  11:1
                         : |:: | |
Db
         520 LEGHKSNAYFDSS---TRHLIELYKN 542
RESULT 15
YC73 HAEIN
ΙD
    YC73 HAEIN
                 STANDARD; PRT; 268 AA.
    01-NOV-1995 (Rel. 32, Created)
    01-NOV-1995 (Rel. 32, Last sequence update)
28-FEB-2003 (Rel. 41, Last annotation update)
DE
    Hypothetical protein HI1273.
GN
    HI1273.
OS
    Haemophilus influenzae.
    Bacteria; Proteobacteria; Gammaproteobacteria; Pasteurellales;
OC
    Pasteurellaceae; Haemophilus.
OX
    NCBI TaxID=727;
RN
    [1]
RP
    SEQUENCE FROM N.A.
RC
    STRAIN=Rd / KW20 / ATCC 51907;
```

```
RX
    MEDLINE=95350630; PubMed=7542800;
RA
    Fleischmann R.D., Adams M.D., White O., Clayton R.A., Kirkness E.F.,
    Kerlavage A.R., Bult C.J., Tomb J.-F., Dougherty B.A., Merrick J.M.,
RA
    McKenney K., Sutton G., Fitzhugh W., Fields C.A., Gocayne J.D.,
RA
    Scott J.D., Shirley R., Liu L.-I., Glodek A., Kelley J.M.,
RA
    Weidman J.F., Phillips C.A., Spriggs T., Hedblom E., Cotton M.D.,
RA
RA
    Utterback T.R., Hanna M.C., Nguyen D.T., Saudek D.M., Brandon R.C.,
RA
    Fine L.D., Fritchman J.L., Fuhrmann J.L., Geoghagen N.S.M.,
    Gnehm C.L., McDonald L.A., Small K.V., Fraser C.M., Smith H.O.,
RA
RA
    Venter J.C.;
RT
    "Whole-genome random sequencing and assembly of Haemophilus influenzae
RT
    Rd.";
RL
    Science 269:496-512(1995).
    ______
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
    or send an email to license@isb-sib.ch).
CC
CC
    ______
DR
    EMBL; U32807; AAC22921.1; -.
DR
    PIR; F64024; F64024.
DR
    TIGR; HI1273; -.
DR
    InterPro; IPR000051; SAM bind.
    Hypothetical protein; Complete proteome.
KW
    SEQUENCE 268 AA; 30510 MW; E5B28DA7AADC4D0B CRC64;
SQ
 Query Match
                      10.5%; Score 74; DB 1; Length 268;
 Best Local Similarity 25.2%; Pred. No. 5;
         29; Conservative 15; Mismatches
                                          49; Indels
                                                        22; Gaps
                                                                   4;
          8 VSCLRENFAVYSVSVGMHNLLLLEGRSWQEMDGQKKHWKDKVVDLLYWRDIKKTGVVFGA 67
Qу
            Db
         94 LDCL----AQFKQKFGLHHLTTFH------KSWADN-----WDDVPQADVVLAS 132
         68 SLFLLLSL-TVFSIVSVTAYIALALLSVTISFRIYKGVIQAIAKSDEGHPFRAYL 121
QУ
              Db
        133 RSTLVDDLDDMIEKLCAKAKKRVFLTSVTQRHFLDEGVFEAIGREDIGFPTYIYL 187
```

Search completed: September 29, 2004, 18:14:57 Job time: 12.0213 secs